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Lentiviral vectors (LV) are often pseudotyped with the envelope G protein from 
vesicular stomatitis virus Indiana strain (VSVind.G). However, VSVind.G 
based continuous LV producer cell lines have not been reported; it has been 
assumed that VSVind.G is fusogenic and cytotoxic. To find alternative G 
proteins for LV production, we investigated other vesiculovirus G proteins 
(VesG) from VSV New Jersey strain (VSVnj), Cocal virus (COCV), Piry virus 
(PIRYV), VSV Alagoas virus (VSVala), and Maraba virus (MARAV). All these 
VesG envelopes were used in transient transfection to produce infectious 
particles that were robust during concentration and freeze-thawing. We then 
found, surprisingly, that VSVind.G and all the other VesG proteins could be 
constitutively expressed in 293T cells, and showed no cytotoxicity when 
compared to a retroviral Env protein. These VesG expressing cells could 
support LV production when other components were transiently supplied. 
However, we showed that VesG expressing cells do not show receptor 
interference hence LV can superinfect their producer cells, resulting in vector 
genome accumulation and possible toxicity. We attempted to knock-out the 
low- density lipoprotein receptor (LDLR) gene on producer cells, which was 
reported to be the primary cell entry receptor for VSVind.G. However, only a 
slight reduction in LV transduction was observed in LDLR-KO cells. Hence, 
other methods such as using anti-retroviral drugs to block superinfection may 





Lentiviral vectors (LVs) are usually pseudotyped with the G protein of vesicular 
stomatitis virus Indiana strain (VSVind.G) due to its high physical stability. 
However, this G protein has been believed to be toxic when expressed 
constitutively in cells owing to its high fusogenicity. Therefore, well-studied 
alternative G proteins can provide crucial insights related to their use in clinical 
grade LV production. In this study, I demonstrate that other tested 
vesiculovirus G proteins are as stable, both physically and thermally, as the 
gold standard VSVind.G. Also, I show that all tested G proteins, including 
VSVind.G, show similar cytotoxicity to that of the negative control. Also, I 
demonstrate that, against the commonly accepted concept that VSVind.G 
cannot be expressed in cells continuously, this G protein could be expressed 
stably in cells for up to five months. 
Moreover, these stable VSVind.G expressing cells supported LV production 
when were supplemented with other vector components transiently in this 
period. Similarly, other tested G proteins could also be stably expressed in 
cells for at least five months and generated transient LVs during this time. 
These G proteins can be employed to generate stable packaging cell lines for 
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1.1 Gene therapy- From concept to reality  
Gene therapy has the potential to treat a disease at its genetic roots, in both 
hereditary and acquired conditions [7]. Gene therapy can be simply defined as 
a treatment that involves the introduction of a new gene into a patient's cells 
in an attempt to cure a disease or improve a condition. Recent advances in 
molecular biology and the sequencing of the human genome helped to 
transform gene therapy from a revolutionary concept to an important tool in 
the treatment of genetic diseases [8].  
In the 20th century, it was already clear that some conditions are passed on 
from parents to offspring [9]. The idea of using viruses to deliver genes was 
first started in the mid-1970s when Varmus and Bishop reported that gamma-
retrovirus could obtain cellular genes naturally [10, 11]. In the late 1970s, 
recombinants of both non-integrating viruses (e.g. adenovirus, bovine 
papilloma, vaccinia and herpes simplex viruses) and integrating retroviruses 
were being studied by several laboratories [12].  
Although gene therapy was still controversial, by 1980s retrovirus-based gene 
transfer to mammalian cells was routinely performed [13-16]. In the early 
1990s, the first approved clinical trial was performed in patients with severe 
combined immunodeficiency (SCID) using gammaretrovirus based vectors. 
Temporary improvement of the immune system was observed in the patients, 
and although they still required enzyme replacement therapy, this can be 
considered as the first successful human gene therapy trial [16-18].  
In the mid-1990s, long-term expression of vectors based on adeno-associated 
virus (AAV) was demonstrated in mice which led to the first AAV gene therapy 
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clinical trial for haemophilia B in the late 1990s [19, 20]. While these early trials 
were relatively safe, AAVs were cleared as a result of pre-existing neutralising 
antibodies in the body [21].    
In early 2000, Cavazzana-Calvo and colleagues introduced the common 
interleukin receptor γ-chain (IL2RG) in the bone marrow of patients with X-
linked severe combined immunodeficiency (X-SCID) using a murine 
leukaemia virus (MLV)-based vector. Although this therapy restored the 
immune system function, several cases of leukaemia (including the death of 
one patient) that were induced due to the insertional mutagenesis caused by 
the vectors were reported [22]. Similar results were observed by Thrasher 
group (University College London, UK) in 2004 [23].  
The first effective gene therapy trial for cancer treatment was reported in 2006. 
In this trial, the T cells of the patients were engineered using a retroviral vector 
to express TCR against a melanoma antigen ex vivo. Cells were then re-
administrated into the patients. This treatment resulted in regression in 2 out 
of fifteen patients [24]. 
Currently, many human gene therapy clinical trials have proved to be effective. 
All the scientific efforts in the past decades, both successful and unsuccessful, 
helped to improve gene therapy through the development of better vectors 
regarding safety, and efficacy.      
1.2 Vectors used for gene delivery 
Vectors are vehicles that are used to transfer genetic materials into target cells 
and tissues. The ideal vector for gene delivery should be specific to target cells 
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efficiently, stable (e.g. thermostable at body temperature), safe, and to have 
high and long-term expression levels for as long as required.  
Naked DNA injection into tissues locally or into systemic circulation might 
seem to be the simplest way of gene delivery to the body, however, injected 
naked DNA can be rapidly degraded by nucleases or cleared by the immune 
system, which can limit the efficiency of gene transfer into target cells [25, 26]. 
Therefore, other methods were developed to increase the efficiency of gene 
delivery. These methods include viral and non-viral based gene delivery 
systems. Viral vectors are effective tools for gene transfer. However, there are 
limitations associated with their use including immunogenicity [27, 28], 
carcinogenesis [29], difficulty in production and scaling up [30, 31], and limited 
capacity for the transgene [32]. Non-viral delivery systems were developed as 
an alternative to virus-based delivery systems owing to several advantages 
such as lower immunogenicity and toxicity, larger carrying capacity, and 
simpler production and scale-up [33]. Non-viral methods are used for gene 
delivery in around 20% of all current clinical trials [34, 35] and are categorised 
into two types, physical and chemical. In physical methods, physical force is 
used to permeabilise the cellular membrane. The most common physical 
methods are microinjection, electroporation, ultrasound, and gene gun. 
Chemical methods, on the other hand, use carriers such as liposomes, cationic 
lipids, and polymers to deliver genetic material into target cells [36-38]. 
Nevertheless, despite all the advances so far, the ideal vector has yet to be 
constructed. 
On the other hand, viruses have evolved naturally to transfer their nucleic acid 
into target cells for replication. This feature makes viruses to be attractive as 
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gene delivery vehicles. Over the years they have been engineered to make 
suitable vehicles for gene transfer into humans. Specific viruses have been 
chosen based on their characteristics to develop viral vector systems. DNA 
viruses such as adenoviruses, adeno-associated viruses, and herpesviruses 
have been widely used in clinical trials [39].   
Amongst RNA viruses, retroviral vectors are the most commonly used due to 
their high gene transfer efficiency and expression of therapeutic genes. These 
vectors have a relatively large carrying capacity of ~9kb, can integrate into the 
host cell genome, and therefore, can induce long-term expression of the 
transgene in target cells [40]. Over the past decades, a number of patients 
with various immunodeficiencies have been treated using MLV-based 
gammaretroviral vectors to transduce autologous haematopoietic cells with 
the desired transgene [41-43] (Table 1-2). In recent years, lentiviral vectors 
that are derived from human immunodeficiency virus type 1 (HIV-1) have been 
utilised due to their unique ability to infect both dividing and non-dividing cells 
[44-46] (Table 1-3). This is a desirable characteristic in gene therapy 
applications that slowly-dividing cells such as haematopoietic stem cells or T 
lymphocytes are the gene delivery target. The focus of this thesis will be on 
HIV-1- based lentiviral vectors. 
1.3 Retroviruses  
The Rous sarcoma virus (RSV) was the first retrovirus to be discovered when 
it was isolated from tumours in chickens [47]. Other retroviruses then were 
isolated from a range of animals [48-50]. The first human retrovirus was 
isolated in the 1980s in human T-cell leukaemia virus type 1 (HTLV-1) affected 
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patients [51]. Shortly after, the human immunodeficiency virus (HIV) which is 
now known as the cause of acquired immune deficiency syndrome (AIDS), 
was discovered in 1984 [52, 53]. 
Retroviruses belong to the family of Retroviridae which consists of a large 
number of enveloped RNA viruses. This family is divided into two main sub-
families; Orthoretrovirinae and Spumaretrovirinae. Orthoretrovirinae is further 
divided into two groups: simple and complex viruses. Simple viruses are 
alpharetroviruses, betaretroviruses, and gammaretroviruses; complex viruses 
are deltaretroviruses, epsilonretroviruses, and lentiviruses. Spumaretrovirinae 
sub-family has one known genus, spumavirus (Table 1-1). 
The RNA genome of the Retroviridae family is positive sense, linear, single-
stranded, and 7-12 kb in size. The replication method of retroviruses is 
considered the hallmark of this family as they employ a reverse transcriptase 
enzyme, encoded by the viral pol gene, to transcribe the viral single-stranded 
RNA (ssRNA) into linear double-stranded DNA (dsDNA) which after entering 
the nucleus integrates into the target cell genome [54, 55].  Retroviruses are 
surrounded by an envelope consisting of a host cell-derived lipid bilayer and 
virus-encoded envelope glycoprotein.   
The genome of both simple and complex retroviruses contain three main 
coding domains: gag, which codes for the viral structure including capsid (CA), 
matrix (MA) and nucleocapsid (NC) proteins; pol, that codes for the viral 
enzymes necessary for replication such as reverse transcriptase (RT), 
protease (PR), and integrase (IN); and env, that codes for the viral envelope 
glycoprotein that consists of the transmembrane (TM) and surface (SU) 
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subunits [56]. Complex retroviruses such as lentiviruses contain additional 
open reading frames that code for regulatory genes, for example the regulatory 
genes tat and rev in HIV-1, which are essential for the viral genome expression 
and nuclear export, respectively, in addition to a set of accessory genes (e.g. 
HIV-1 vpu, vif, vpr and nef) that are essential for viral pathogenicity. The 
retrovirus genome has the long terminal repeat (LTR) at both 5’ and 3’ ends. 
Sequences within the viral LTR contain cis-acting regulatory sequences that 
regulate viral gene expression and genome replication [55].  
The RNA genome of HIV contains R and U5 sequences at the 5’ end, followed 
by a packaging signal (ψ) which is responsible for incorporating the RNA 
genome into viral particles [57].  Another R sequence is repeated at the 3’ end 
of the genome following U3. The R sequences on both ends of the viral 
genome have a pivotal role in reverse transcription (Figure 1-1A). What makes 
retroviruses unique is the reverse transcription and integration into the cell 
genome, which makes the retroviral infection permanent [54] as it is inherited 
by daughter cells.  
The attachment of retroviral surface glycoprotein to specific receptors on target 
cells induces conformational changes in the glycoprotein exposing the fusion 
domain which leads to the fusion of the viral membrane to that of the target 
cell. This membrane fusion results in the release of the viral core, including the 
RNA genome, into the cell’s cytoplasm. Reverse transcriptase then 
transcribes this RNA into DNA that enters the nucleus and integrates into the 
host cell genome via the viral integrase [54, 58]. With integration, the viral 
genome becomes part of the cellular genome and can employ the cellular 
systems such as RNA polymerase II and ribosomes to express the viral genes. 
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In simple retroviruses, from the integrated provirus two different mRNAs are 
synthesised; spliced mRNAs that encode the viral proteins, and un-spliced 
mRNAs that are destined for incorporation into progeny virions, and for gag/pol 
expression. After viral protein synthesis from the mRNAs by the cellular 
machinery in the cytoplasm, in most retroviruses, the viral proteins are 
transferred to the plasma membrane where viral particle assembly takes 
place. The envelope is acquired during the budding process where the viruses 
are released from the plasma membrane.  
As retroviruses efficiently deliver their genome into the host cell, they have 
been converted to vehicles for gene delivery. In addition to the ability to 
integrate into the target cell genome, the simple genetic organisation is the 
primary factor in choosing gammaretroviral vectors (GRVs) for delivering 
genetic materials [54]. Most gammaretroviral vectors have been developed 
based on MLV (murine leukaemia virus) for gene transfer applications where 
they have been used widely over the past decades [43, 56]. However, there 
are some adverse effects caused by gammaretroviral vector integration into 
the host cell genome; the integrase and LTRs of these vectors seem to 
promote preferential interaction with active host cell promoter and enhancer 
regions that are enriched for transcription factor binding sites [59]. Therefore, 
transcriptional activation of nearby proto-oncogenes by the vector has been 
occurring in some clinical trials (e.g. X-SCID) leading to myelodysplasia or 
lymphoid leukaemia [41, 60]. 
Moreover, GRVs enter the nucleus only when the cells are undergoing mitosis 
while the nuclear membrane degenerates. Therefore, they can only infect 
dividing cells [61, 62]. This can be a major limitation when the target cells are 
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non-dividing and/or slow-dividing cells such as haematopoietic stem cells 
(targeted in immunodeficiency disorders and hereditary anaemia clinical 
trials), quiescent lymphocytes (targeted in cancer clinical trials), hepatocytes, 
neurons, and muscle fibres.  
On the other hand, as lentiviruses use nuclear pores to enter the nucleus, they 
can infect both dividing and non-dividing cells [63]. This unique characteristic 
makes lentiviruses to be even more attractive to be used as viral vectors. 
Additionally, these vectors have been developed without the viral LTR 
enhancer elements (SIN or self-inactivating vectors) to reduce the chances of 
transcriptional activation of nearby proto-oncogenes.  Furthermore, the overall 
insertion site of lentiviral vectors (LVs) seems to be different from that of 
gamma-retroviral vectors, possibly due to the cellular factors associated with 
IN or the alterations of the LTR in LVs as well as the differences between the 
integrases of these two vectors [41, 59, 64]. Owing to these advantages, more 
studies have been conducted in an attempt to develop safer and more efficient 
























Betaretrovirus Mouse mammary 
tumour virus 
Gammaretrovirus MLV, FLV 
Complex 
Deltaretrovirus BLV, HTLV 
Epsilonretrovirus Walleye dermal 
sarcoma virus 
Lentivirus HIV, BIV, FIV 
Spumaretrovirinae  Spumavirus HFV, SFV 
Table 1-1. Retroviridae family classification.  
BIV: Bovine immunodeficiency virus; BLV: Bovine leukaemia virus; FIV: Feline 
immunodeficiency virus; FLV: Feline leukaemia virus; HFV: Human foamy virus; HIV: Human 
immunodeficiency virus; HTLV: Human T-lymphotropic virus; MLV: Murine leukaemia virus; 
RSV: Rous sarcoma virus; SFV: Simian foamy virus. 
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1.3.1 Gamma-retroviral vectors in clinical trials 
Stable integration into the host cell genome, ease of manipulation and 
production of therapeutic-containing vectors are some of the reasons behind 
retroviral vectors (RVs) becoming the most frequently used vectors for gene 
therapy applications [65]. Haematopoietic stem cells (HSCs) (CD34+ cells), 
usually autologous, are obtained from the patient, expanded and then 
transduced with therapeutic-containing RVs ex vivo before administration back 
into the patient. Allogeneic haematopoietic stem cell transplantation (HSCT) is 
considered to be the gold standard for treating primary immunodeficiencies 
(PID) [66-68]. This method not only minimises the risk of immunologic 
complications including graft-versus-host disease (GVHD) and graft rejection 
but also is more accessible to patients especially those without HLA-matched 
donors [69]. MLV-based gammaretroviral vectors (GRVs) have been used for 
the treatment of some PIDs including X-linked severe combined 
Immunodeficiency (SCID-X1), adenosine deaminase deficiency (ADA-SCID), 
X-linked Chronic Granulomatous Disorder (X-CGD), and Wiskott - Aldrich 
syndrome (WAS). Although some of these trials resulted in clinical benefits 
comparable to that of the allogeneic HSCT [67, 70, 71], the occurrence of 
insertional mutagenesis (IM) caused by GRV integration was one of the 
complications reported in these clinical trials. Consequently, studies have 
been done to improve all aspects of ex vivo transduction to minimise the risk 
of IM as well as to optimise HSC culture and transduction conditions [60, 72]. 
Furthermore, to eliminate the off-target effects and to guarantee adequate 
transgene expression, the use of specific promoters have been studied in the 
past few years [73].  
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Third generation self-inactivating (SIN) LVs have been developed in an 
attempt to eliminate the risk of IM caused by GRVs [69]. These SIN LVs have 
shown encouraging results in recent trials including adrenoleukodystrophy 
(ALD) [74], metachromatic leukodystrophy (MLD) [75], β-thalassemia [76], and 
WAS [77, 78]. 
Some selected gamma-retroviral vector-mediated gene therapy clinical trials 
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Lentiviruses are a subclass of retroviruses (Table 1-1).  They consist of two 
copies of positive-sense single-stranded RNA genome. They are 
characterised by a long incubation period (Lente means slow in Latin) in which 
the virus pathogenicity is at a low level. Lentiviruses include a number of 
viruses such as human immunodeficiency virus-1 (HIV-1), HIV-2 and simian 
immunodeficiency virus (SIV). Amongst these viruses, HIV-1, which causes 
acquired immunodeficiency syndrome or AIDS in humans, has been the 
interest of many researchers.  
1.4.1 HIV-1 life cycle 
HIV-1 wild-type genome contains nine open reading frames: gag, pol, env, rev, 
tat, vpr, vpu, vif, and nef (Figure 1-3A). The HIV-1 replication cycle [99] 
includes two stages: early and late. Early phase begins with viral 
attachment/entry to the cell and ends in proviral integration. The late phase 
includes viral gene expression, viral particle assembly, budding, release, and 
maturation [58]. 
 
Table 1-2. List of selected recent RV-mediated gene therapy clinical trials. 
HSCs: hematopoietic stem cells; PID: primary immunodeficiency; ADA-SCID: adenosine 
deaminase deficiency; SCID-X1: X-linked severe combined immunodeficiency; X-CGD: X-
linked chronic granulomatous disorder; WAS: Wiskott Aldrich syndrome; WASP: WAS protein; 
ALD: adrenoleukodystrophy; MLD: metachromatic leukodystrophy; IL2RG: interleukin-2 
receptor common gamma chain; ARSA: arylsulfatase-A; GRV: Gamma-retroviral vector; Env: 
envelope; MLV: murine leukaemia virus; GALV: gibbon ape leukaemia virus; NS: not specified. 
Gp+Am12, PG13, ψCRIP and Vamp are stable gammaretroviral packaging cell lines. HEK 
293T cells were used in transient production. 
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1.4.1.1 Cell attachment and viral entry 
Viral entry to the target cell is the first stage of the life cycle. This stage requires 
the attachment of the virus Env to the host cell receptor followed by the fusion 
of virus and host cell membranes [100, 101].  
Following the initial attachment to the cell surface, the envelope engages with 
the specific receptors to enter the cells. The CD4 membrane glycoprotein and 
a G-protein-coupled chemokine receptor act as cellular receptor and co-
receptor for HIV entry. The chemokine receptors include cysteine-cysteine 
chemokine receptor 5 (CCR5) [102] and chemokine (C-X-C motif) receptor 4 
(CXCR4) (Figure 1-2, step 1) [103]. CD4 is mainly expressed on helper T cells 
(Th) and engages with the antigens presented by the major histocompatibility 
complex class II (MHC II) inducing immune response against the specific 
antigen [104].  
The envelope glycoprotein of HIV is a homotrimer of non-covalently linked 
heterodimers composed of a receptor-binding surface unit (gp120) and a 
fusogenic transmembrane unit (gp41). In the early stage of replication cycle, 
attachment of gp120 to CD4 receptor leads to conformational changes in 
gp120 and gp41 subunits. Conformational changes in the gp120 lead to the 
attachment of this protein to a co-receptor, CCR5 or CXCR4 [105]. 
Conformational rearrangement in gp41 occurs due to folding at the hinge 
regions of the trimer resulting in an amino-terminal helical region (HR-N) and 
a carboxy-terminal helical region (HR-C) to form a six-helical bundle (6HB). 
This results in the exposure of the hydrophobic fusion peptide leading to its 
insertion into the target cell membrane (Figure 1-2, step 2) [106-108].  The HIV 
attachment and entry into the cells can happen through pH-independent 
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endosomal uptake [109]. Next, the virion core is released into the cytoplasm. 
This core, which is now called the reverse transcription complex (RTC), in 
simple viruses such as Molony MLV consists of the viral genome, RT, IN, and 
CA, however, the HIV RTC contains Nef and Vpr in addition [110].  
1.4.1.2 Reverse transcription 
Before 1970, the accepted concept of the information flow or the ‘central 
dogma’ described that the information in genes flows from DNA to protein 
through RNA; DNA is required for RNA transcription and RNA for protein 
synthesis. In 1970 reverse transcription was first reported by two independent 
groups [40, 111] which changed the concept of information flow in molecular 
biology.  
Retroviruses package two copies of ssRNA. These two copies are used in 
reverse transcription to make the viral dsDNA (Figure 1-2, step 3). In addition, 
the HIV RT generates the LTRs on both ends of the DNA genome which will 
aid in the integration process [112].  
To initiate reverse transcription [110], a transfer RNA Lys3 (tRNALys3) binds to 
the primer binding site (PBS) of the HIV genome which is located downstream 
of the unique 5 (U5) in RNA [113, 114]. This binding mediates the synthesis of 
the minus cDNA including the U5 and R of the 5’ end which is termed as strong 
stop cDNA (Figure 1-1A). RT then degrades the RNA associated with the 
newly synthesised cDNA via its RNase H function (Figure 1-1B) [115]. As the 
R sequence is present in both 5’ and 3’ ends of the genome, the strong stop 
cDNA jumps to the 3’ end to bind the R sequence. This jump is known as the 
first strand transfer which leads to the minus strand cDNA extension to the 5’ 
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end of the RNA genome (Figure 1-1C). Apart from the 3’ polypurine tract (PPT) 
and the central PPT (cPPT) which are resistant to RNase H degradation, the 
rest of the template RNA is digested by the RNase H function of RT (Figure 1-
1D). The purine-rich sequences then act as primers to extend the 
complementary strand, or the positive strand, of DNA (Figure 1-1E). Having 
multiple transcription initiation sites results in the faster synthesis of the 
positive strand DNA compared to that of the minus strand [116]. The second 
strand transfer occurs as the complementary PBS on both strands bind 
together which results in the development of a circular DNA (Figure 1-1F/G). 
Strand displacement synthesis follows which results in copying the LTR 
sequence on both ends of the viral DNA which produces a longer DNA 
genome compared to the viral RNA [117]. By completing the reverse 
transcription and DNA synthesis, RTC develops into the pre-integration 
complex (PIC) [118].  
RT is a complicated process with two template exchange. Moreover, RT is 
error-prone (approximately one substitution per 10,000 bases) as it lacks 
proofreading activity [119, 120]. These factors contribute to recombination and 
high diversity of the HIV genome which contributes to the challenges of 










Figure 1-1. Steps of Reverse Transcription.  
Schematic of HIV-1 reverse transcription illustrating the conversion of ssRNA viral genome 
into double stranded DNA. RNA is shown in black and DNA in grey. (A) Initiation of reverse 
transcription by RT following tRNA binding with the primer binding site downstream of U5. 
(B) Synthesis of the minus-strand starts from the U5 and R sequences in the 5’ end of the 
genome. The RNase H activity of RT degrades the viral RNA in the generated RNA-DNA 
complex (dotted line). (C) The first strand transfer: the minus strand is transferred to the 
identical R sequences at the 3’. (D) cDNA extension while viral RNA gets degraded except 
for RNase H resistant cPPT and PPT sequences. (E) cPPT and PPT sequences act as 
primers for the plus strand DNA synthesis. (F) The second strand transfer: the tRNA primer 
is cleaved by RNAse H domain and plus strand DNA elongated from the PPT sequence is 
transferred to the 3’ side of the minus strand DNA. DNA synthesis of the plus strand is 
resumed from the cPPT. (G) Following elongation of both strands of DNA, a double 







1.4.1.3 Viral uncoating 
HIV capsid encloses the viral RNA genome, viral proteins such as CA, NC, 
RT, IN, and Vpr. RT are present within the capsid [121]. The shape and 
stability of the capsid have a direct effect on RT efficiency and hence viral 
infectivity [122]. The loss of capsid prior to entry of the viral genome to the cell 
nucleus is known as uncoating [123, 124]. This process is essential for viral 
genome entry to the nucleus as the diameters of the nuclear pore is smaller 
than that of the viral capsid.  
Although uncoating is known to take place during the transition between RTC 
and pre-integration complex (PIC) [118], the exact time and location of 
uncoating are yet to be elucidated. A study demonstrated that some CA stays 
in association with the PIC in the nucleus [125]. In a different study, complete 
cores were observed at the nuclear pore complex (NPC) suggesting that 
uncoating occurs when RTC arrives at the NPC. This might be the viral 
strategy to protect its genome against the host immune system [126, 127]. 
1.4.1.4 Nuclear transport of the viral genome  
While GRVs require nuclear membrane breakdown during mitosis in order to 
enter the nucleus (hence infecting only dividing cells) [61], HIV PIC contains 
MA, IN, and Vpr in association with the viral genome [128] allowing the 
complex to access the host cell chromatin in non-dividing cells (Figure 1-2, 
step 4) [129].  
NPCs are vessels cross the nuclear membrane that allows selected molecules 
and proteins such as ribonucleoproteins to pass through to or from the nucleus 
[130]. While molecules smaller than 9 nm in diameters can pass through NPCs 
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through diffusion, as HIV PIC is considerably larger, other mechanisms of 
nuclear transport are in place [131].      
One mechanism is by the interaction of the remaining capsid in the PIC with 
some nuclear transport factors (e.g. NUP358, NUP153) in the NPCs [132]. 
The other mechanism of PIC nuclear transport is mediated via energy-
dependent transport machinery through the interaction of the IN of the PIC 
with members of an importin-α protein family that exist in the NPCs [133].  
1.4.1.5 Integration of viral DNA into the host genome 
Upon entering the nucleus, the proviral DNA integrates into the host cell 
genome to maintain stable infection (Figure 1-2, step 5). This integration is 
mediated by the viral IN [134, 135]. The retroviral IN structure was analysed 
through the crystal structure of prototype foamy virus IN revealing that IN 
exists in dimers in the integration complex. While each monomer plays a 
distinct role in this complex, contact of the viral LTR is allowed via an extended 
conformation of the inner monomer. In HIV, IN was shown to have a few 
distinct structural and functional domains: The N-terminal domain (NTD), the 
N-terminal extension domain, the core catalytic domain (CCD), and the C-
terminal domain (CTD) [136]. 
Structural analysis of integration intermediates revealed three steps in the 
integration process. The first step takes place prior to PIC entering the nucleus 
where two nucleotides are removed from both ends of the viral dsDNA (from 
the U3 of the upstream 5’ LTR and the U5 of the downstream of 3’ LTR). This 
process is known as 3’ end processing [137]. Upon nuclear entry of the PIC, 
the exposed oxygen of the hydroxyl group on the processed 3’ ends of each 
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strand attack and join phosphodiester bonds on the host cell DNA strand. This 
step is known as the strand transfer during which a few nucleotides (four for 
MLV, five for HIV) on each side of the provirus remain single-stranded. In the 
final step of integration which is known as the gap repair process, the DNA 
repair system of the host cell fills in the gaps flanking the integrated viral 
genome [138, 139]. 
Lentiviral integration in host cells depends upon the interaction between the 
viral IN and the host cell protein lens epithelium-derived growth factor 
(LEDGF/p75). LEDGF/p75 protein contains a nuclear localisation signal and 
chromatin binding elements on its N-terminal region while the C-terminal 
region attaches to the IN via the integrase-binding domain (IBD) [140]. It has 
been shown that the absence of LEDGF/p75 protein affects HIV integration 
[141] and reduces viral infectivity [142, 143].  
While the elucidation of the complete human genome helped with identifying 
retroviral integration sites [144, 145], advancement in next-generation 
sequencing enhanced the quantitative analysis of larger number of integration 
sites [135]. Various studies revealed that retroviral integration is not random 
[146]. For instance, at the chromosomal level, while MLV preferentially 
integrates near transcription start sites, HIV favours integrating within active 
transcriptional units [147, 148], which may promote efficient viral gene 
expression after integration. Accordingly, HIV-based vectors are considered 
safer vectors compared to MLV-based ones. Other retroviruses show different 
specificity to integrate into the host cell genome. For instance, avian sarcoma-
leukosis virus (ASLV) is less likely to integrate into gene-dense regions [148], 
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and mouse mammary tumour virus (MMTV) has shown the most random 
integration profile so far [149].  
1.4.1.6 Viral gene expression 
After integration, the late phase of HIV infection occurs in which the viral 
genome is transcribed. This process is controlled by the DNA regulatory 
elements in the viral LTR that employ the cellular RNA polymerase II complex.  
One of the first products to be transcribed is the transactivator protein (Tat). 
This protein then binds to the transactivation response (TAR) element at the 
5′ LTR on the HIV genome to stimulate transcription initiation of the viral 
genome. This mediates the recruitment of the cellular positive transcription 
elongation factor b (P-TEF-b) which includes proteins that are necessary for 
elongation (e.g. Cyclin-dependent kinases). This recruitment results in 
increased affinity of Tat protein to TAR which triggers hyper-phosphorylation 
of the C-terminal domain of RNA polymerase II stimulating efficient 
transcriptional elongation [150]. 
1.4.1.7 Viral RNA export from the nucleus 
In early stages of transcription, while unspliced transcripts are retained in the 
nucleus, fully spliced mRNAs coding for Tat, Rev, and Nef are exported to the 
cytoplasm via the nuclear export factor NXF1 (Figure 1-2, step 6) [151]. The 
nuclear export of unspliced transcripts in HIV is controlled by Rev.  Rev is 
imported to the nucleus via cellular importin β [152] where it binds to its 
associate cis-acting element the Rev-response element (RRE) within env on 
the mRNA transcripts [153]. This complex then interacts with cellular export 
proteins and GTP-bound form of the Ran GTPase to promote nuclear export 
of viral transcripts [154, 155].   
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1.4.1.8 Viral assembly, budding, and release  
Gag which is the main viral structural protein is synthesised in the cytoplasm 
from the full-length RNA as a polyprotein precursor, containing the domains 
for MA, CA, NC, p6, and two spacer peptides. This RNA then is translated into 
Gag and GagPol precursors. Gag-Pol which codes for the viral enzymes as 
well as the Gag proteins is synthesised by programmed ribosomal frameshift 
and its expressed level is at approximately 5% of that of Gag (Figure 1-2, step 
7) [156].  
After transport to the cytoplasm, HIV RNAs are either translated into viral 
proteins or packaged into the newly assembled particles [157]. Two copies of 
RNA are packaged into each virion. This allows the recombination during 
reverse transcription. Moreover, this might help the virus to carry on with 
reverse transcription even if one RNA copy is functional [157, 158]. After the 
RNA is dimerised, it is encapsidated by NC of Gag via the packaging signal 
(ψ) [159]. This complex then is anchored to the plasma membrane via MA. It 
has been shown that defective MA results in mistargeting the complex to the 
late endosomes [160].  
While Gag and Pol proteins are translated in the cytoplasm then transported 
to the cell membrane, Env is trafficked via the secretory pathway in the rough 
endoplasmic reticulum (RER) where it is glycosylated and trimerised. The 
cellular protease furin then cleaves Env into the surface unit (SU; gp120) and 
transmembrane unit (TM; gp41) and is delivered to the cell membrane via 
vesicular transport [161]. These glycoproteins are then transported to the cell 
membrane where the assembly of the virions takes place. Gag and Env are 
localised to common sites, the inner leaflet of the plasma membrane where 
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HIV-1 particles assemble. Env is recruited by Gag, either directly or via a 
cellular bridging protein, to be incorporated to the viral particle [162]. The N-
terminal of Gag is known as MA, which directly binds to Env.  The central 
domain of Gag is known as CA which creates the shell that encapsidates the 
viral core. Mutations in Gag’s MA has been reported to block Env incorporation 
highlighting the role of Env-MA interaction in viral assembly [163]. As the 
virions bud out, they acquire the lipid bilayer from the plasma membrane and 
the Env spikes.  
Progeny viruses are released from the infected cells through membrane 
splitting. This process is mediated by the cellular endosomal sorting 
complexes required for the transport (ESCRT) pathway which is involved in 
intracellular membrane fission processes required for particle release such as 
cytokinesis and budding of enveloped viruses away from the membrane [164]. 
This process is recruited by Gag after which non-infectious immature viral 
particles are released from the cells (Figure 1-2, step 8).  
1.4.1.9 Viral maturation 
For the viral particles to be infectious, they need to go through maturation 
(Figure 1-2, step 9).  This requires the protease protein which is encoded by 
the Gag-Pol precursor.   As soon as the viral particles are released from the 
cells, to trigger maturation, Gag and Gag-Pol polyproteins are cleaved into 










1.4.2 Restriction factors influencing HIV-1 infection 
Like other viruses, HIV-1 utilises various host cellular proteins for its replication 
in the host cells.  However, some cellular proteins, known as restriction factors, 
have evolved as part of the host defence mechanism to block the HIV-1 
lifecycle [167]. In turn, HIV-1 has evolved to evade the anti-viral defence 
mechanism, via accessory proteins such as Vif and Vpu, in order to infect and 
replicate in human cells [168]. As these factors tend to be species-specific, the 
anti-viral activity of these proteins is considered as a barrier preventing cross-
species transmission [168]. 
Some factors such as Fv4 in mice can prevent viral infection by blocking cell 
entry while some other proteins act as post-entry restriction factors. Fv4 is a 
Figure 1-2. Schematic of HIV-1 Life Cycle.  
The major steps of the human immunodeficiency virus type-1 life cycle are shown. Adapted 
from [4].  
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mutant form of retroviral provirus that expresses a mutant env. This Env 
prevents the spleen focus-forming virus (SFFV) from entering the cell by 
interacting with the viral receptor on the cell surface [169, 170]. This process 
is known as receptor interference.  
1.4.2.1 APOBEC3 
Apolipoprotein B mRNA editing enzyme catalytic polypeptide-like-3 
(APOBEC3) is a family of cytidine deaminases that includes APOBEC3B, 
APOBEC3DE, APOBEC3F, APOBEC3G (A3G), and APOBEC3H proteins 
that inhibit HIV-1 replication [171, 172].  A3G is one of the most studied HIV-1 
restriction factors and has been shown to be the most potent anti-HIV-1 in this 
family [167, 173]. During reverse transcription, this protein causes 
deamination of the DNA minus strand resulting in multiple hypermutations in 
the plus strand. This leads to the production of abnormal viral transcripts and 
thus degradation [167]. In the presence of Vif however, this protein prevents 
A3G to be packaged in the viral particle to retain viral infectivity [174]. 
1.4.2.2 TRIM5α  
TRIM5α belongs to the family of tripartite motif (TRIM)-containing protein 
[175]. This protein has been shown to bind to the viral capsid. It has been 
proposed that the interaction with the capsid can either mediate degradation 
or can induce an immune reaction against the virus. Either way, this interaction 





The sterile α motif domain – and histidine-aspartate domain-containing protein 
1 (SAMHD1) is found in myeloid cells and resting T cells [180-182]. It was 
believed that this protein functions as an anti-HIV-1 restriction factor by 
reducing the nucleotide pool and thus inhibiting reverse transcription [183]. 
Yet, recently it was reported that this protein degrades the viral RNA via its 
RNase activity [184]. Nevertheless, HIV accessory protein Vpx inhibits 
SAMHD1 anti-viral activity [180, 181]. 
1.4.2.4 MX2 
Myxovirus resistance 2 protein (MX2) is a restriction factor that is induced by 
IFN. This protein inhibits nuclear transport of the viral cDNA or prevents its 
integration into the genome through interaction with the viral capsid [185, 186]. 
HIV-1 however, averts MX2 anti-viral activity by reducing cellular cyclophilin A 
(CypA) which has a role in stabilising the HIV-1 capsid and hence facilitating 
viral infection [186, 187].   
1.4.2.5 Tetherin 
Tetherin which is also known as BST2 or CD317 is an IFN-inducible protein 
that is expressed on the cell surface of different cell types including myeloid 
and lymphoid cells [188]. It functions as an anti-HIV-1 restriction factor by 
blocking viral release from the infected cells [189]. HIV-1 accessory gene vpu 
(or nef in lentiviruses that do not express vpu) has been reported to antagonise 
tetherin's anti-viral function [190]. 
1.4.2.6 SERINC 
Serine incorporator (SERINC) family consists of multi-pass membrane 
transporters [191]. While there is still no evidence of direct interaction between 
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SERINC5 and viral envelope, it has been recently reported that SERINC5 
might destabilise the trimer conformation of the envelope, therefore, blocking 
fusion [167]. The absence of Nef antagonises the activity of SERINC5 by 
mediating its relocalisation from the plasma membrane to the reticulum 
compartment [192, 193].  
1.4.3 Development of HIV-1 derived lentiviral vectors  
Lentiviral vectors have been developed from various lentiviruses such as HIV-
2 [194], the simian [195], feline [196], bovine immunodeficiency [197] or the 
caprine arthritis-encephalitis virus [198], and equine infectious anaemia virus 
(EIAV) [199]  however, LVs derived from HIV-1 are most widely used for gene 
transfer applications.  
LVs are produced by cells that are transfected to express the necessary viral 
components including gag/pol, and env genes [200]. The first generation LV 
production plasmids included three plasmids: a plasmid coding for the 
packaging (gag/pol), accessory (vif, vpu, vpr, and nef), and regulatory (tat and 
rev) genes; a plasmid transferring the gene of interest, known as transfer 
vector, flanked by the LTRs and including the packaging signal (Ψ); a plasmid 
coding for env. In order to widen the tropism of these vectors, the endogenous 
HIV-1 envelope glycoprotein (gp41/120) is often replaced with that of the 
vesicular stomatitis virus Indiana strain (VSVind.G) [201]. This process is 
known as vector pseudotyping. Other envelope glycoproteins such the feline 
endogenous retrovirus RD114, Cocal virus, and the Gibbon Ape leukaemia 
virus (GALV) were also used to pseudotype LVs. Also, transduction of 
neuronal cells was accomplished by using LVs pseudotyped with Venezuelan 
Equine Encephalitis and Rabies virus. Moreover, efficient transduction of 
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CD34+ HSC was achieved by using chimeric envelopes such as RD114/LTR 
(contains the cytoplasmic domain of the MLV) and RDpro (contains the HIV-1 
cleavage site) [202].  Nevertheless, as so far VSVind.G pseudotyped LVs 
demonstrated higher titres compared to other envelope glycoproteins, 
VSVind.G is considered to be the gold standard for LV pseudotyping [203]. 
In the second generation of LVs, while utilising the three plasmid system, the 
safety was improved by eliminating the viral accessory genes (vif, vpu, vpr, 
and nef), from the packaging plasmid (Figure 1-3B) [204]. As the likelihood of 
generating replication competent viruses (RCV) remained a major concern for 
clinical application of these vectors [205], the third generation of LV production 
system was developed (Figure 1-3C). This system improved the biosafety of 
the vectors over 2nd generation system firstly by using self-inactivating (SIN) 
vectors in which the promoter and enhancer are deleted (e.g. deletion of a 
399bp DNA fragment including the TATA box which is necessary for 
transcription initiation) from the U3 in 3’LTR [206]. This deletion in the 3’LTR 
is transferred to the 5’LTR after the first round of infection.  Furthermore, tat is 
eliminated in this system and is replaced by a constitutive promoter, such as 
the Rous sarcoma virus [205] or the cytomegalovirus (CMV) [207] promoters 
(as used in the vector constructs pRRL and pCCL, respectively), is fused to 
the 5’LTR. Consequently, the expression of the transfer vector genome is no 
longer dependent on tat activation [208]. Moreover, the packaging plasmid is 
split into two plasmids; one encoding the rev gene and the other encoding a 
codon-optimised gag/pol gene [208-210]. These improvements had major 
roles in reducing the risk of developing RCV or insertional mutagenesis in 




    
  
Figure 1-3. Lentiviral vector packaging systems.  
(A) Lentiviral packaging system is based on the HIV-1 wild type genome which consists of nine 
open reading frames. To increase safety, this genome is edited and split across multiple 
plasmids. (B) Second generation system that contains a single packaging plasmid encoding 
the Gag, Pol, Rev, and Tat. The transfer plasmid contains the viral LTRs and psi (ψ) packaging 
signal. The envelope is encoded by a third, separate plasmid. (C) In third generation systems 
the packaging plasmid is further split into two plasmids, one encoding rev and one encoding 
gag and pol. In this system the transgene is encoded by a SIN vector containing a mutated 3’ 
LTR and a foreign promoter fused to the 5’ LTR. RRE: rev response element; LTR: long 






1.4.3.1 VSVind.G-pseudotyped lentiviral vectors 
Retroviruses have limited natural host range and cell tropism. For gene 
therapy, one might either want to limit or expand the range of cells susceptible 
to transduction by a gene therapy vector. So far, many vectors have been 
developed in which the endogenous viral envelope proteins have been 
replaced either by envelope proteins from other viruses or by chimeric 
proteins.  Viruses in which the envelope proteins have been replaced are 
referred to as pseudotyped viruses [211].  Depending on the envelope used 
for pseudotyping, some of the virus particle characteristics such as tropism 
and stability might be altered. Due to mentioned restrictions in using lentiviral 
vectors with the HIV-1 envelope such as lower particle stability as well as the 
limited cell tropism (the CD4 receptor is usually expressed in T-lymphocytes, 
monocytes, macrophages and dendritic cells, the primary target cells for 
primate immunodeficiency viruses in vivo  [212]), LVs are usually pseudotyped 
with VSV-G Indiana strain glycoprotein as it has an extremely broad tropism. 
Furthermore, VSVind-G seems to increase the vector particle stability that can 
provide purification advantage by allowing the vector concentration to a high 
titre using ultracentrifugation [213].  
Nevertheless, this pseudotyping has several drawbacks; first, VSVind.G is 
highly fusogenic, which can lead to syncytia formation and cell death at mildly 
basic pH levels, and highest levels of fusogenic activity have been seen at pH 
around 7.2 [214]. Syncytium formation by VSV G protein at neutral pH might 
be considered as an unusual characteristic as this protein triggers viral entry 
through pH-triggered fusion [215]. Nevertheless, VSV G protein was reported 
to be an atypical fusion protein that undergoes reversible conformational 
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changes [216]. Upon its transport to the plasma membrane via the secretory 
pathway, it goes through the acidic environment of the Golgi apparatus which 
triggers conformational changes. Therefore, G protein reaches the plasma 
membrane in a fusion-active form and thus is able to perform cell-cell fusion. 
The resulting syncytia are inevitably destined for apoptosis, as shown for other 
fusogenic viruses [217-219].  
1.4.4 Lentiviral vector production methods 
 The main LV production method is by delivering the packaging plasmid, 
envelope protein, and transfer vector into a cell line such as HEK 293T cells 
that is able to package all the viral components into a viral particle [220]. The 
size and quality of transgene, the employed method of transfection, and the 
target cells are amongst factors that can influence the efficiency of transfection 
[221].  
1.4.4.1 Transient production of lentiviral vectors 
Transient production of LVs is easy and less time consuming compared to 
stable cell line development. In addition, this method enables the expression 
of some cytotoxic viral proteins. Although transient method is the most efficient 
technique for research, the high cost and low adaptability of this method to 
large-scale Good Manufacturing Practice (GMP) vector production [222], 
potential contamination with transfection plasmids [223], batch-to-batch 
variability, and difficulty in optimisation of transfection conditions limit the use 
of transient method for clinical purposes. The yield of current methods which 
are set in cell factories (109-1011 TU), is sufficient to treat only a few numbers 
of patients [74, 76, 222].  
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Recent work optimising the different aspects of production such as cell type, 
culturing method (adherent vs suspension) and density, culture media 
supplementation (e.g. with or without serum), and plasmid delivery systems 
(e.g. calcium phosphate [224] or polyethyleneimine (PEI) [225]), has led to 
production of larger scale industrial batches of LVs [226].   
HEK 293 cells have been commonly used for vector production, lab-based 
protein production, and gene expression studies. These cells have been 
modified to different derivatives such as HEK 293T and HEK 293FT (traceable 
HEK 293T cells) [227].  HEK 293T cells express the SV40 (simian virus 40) T-
Antigen which is compatible with vectors carrying the SV40 origin of replication 
resulting in higher expression levels. Moreover, these cells have a high growth 
rate and transfection efficiency [228]. While these cells are heavily used for 
small-scale vector production, they are as desirable for larger scale 
applications. One method used for larger-scale LV production is the direct 
scale-up, which refers to expanding the small-scale production culture surface 
by adding production units such as Cell Factory™ (Nunk) and CellSTACK® 
systems (Corning) [229].  
Although using adherent cells for LV production is the common gold standard 
method, the optimal technique for industrial-scale vector production at the 
moment is using cell suspension in bioreactors. Therefore, HEK 293T cells 
have been recently adapted to grow in suspension culture. Serum or other 
animal-originated components are not required for maintaining these cells in 
culture. Thus, these cells are more suitable for clinical applications due to 
reduced risk of contamination. Moreover, these suspension cells can be 
readily expanded into different types of vessels (e.g. wave bags, shake flasks, 
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stainless steel bioreactors) which aids with the scaling up of the production. 
Recently, a HEK 293 clone, HEK 293SF-3F6, was established for suspension 
culture [230, 231]. Culturing this clone in serum-free media in 3 litres stirred 
tank bioreactors yielded in titre up to 108 transduction units (TU)/mL of LV 
[232]. 
Still, the optimisation of these large-scale production methods is needed for 
the development of an industrial-friendly method of LV production where lower 
amounts of DNA is used, and the cost of production is reduced. Consequently, 
development of stable producer cells seems to be a more affordable way of 
production of LVs to be used to treat various diseases [229].   
1.4.4.2 Stable production of lentiviral vectors 
Stable vector production can potentially overcome the limitations of the 
transient method such as batch-to-batch variability and cost of production, as 
well as can reduce the risk of DNA recombination and generating RCVs [233]. 
A packaging cell line (PCL) stably expresses gag-pol, rev, and/or env. When 
the transgene is provided, the PCL becomes a producer cell line. Even though 
a stable cell line should ideally be consistent in growth and to be able to 
produce large volumes of infectious LVs, PCLs developed so far not only 
achieved low titres of 105 -107 TU/mL, but also demonstrated less stability over 
generations due to the cytotoxic effects of some viral components [201, 234, 
235]. It has been reported that VSVind.G and some viral elements such as 
protease are toxic to cells when expressed continuously [201]. To overcome 
the toxicity of the envelope glycoprotein in stable cell line production, 
VSVind.G has been replaced with other envelope glycoproteins such as 
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RDpro which is derived from the feline endogenous virus envelope RD114, 
and GALV [236].  
1.4.4.2.1 Established packaging cell lines  
Several stable packaging cell lines have been developed over the past years 
[237-239]. The STAR packaging cell line was developed via a novel approach 
of transfecting HEK 293T cells with second-generation MLV vectors [240]. 
While titres were higher than 107 TU/mL, as non-SIN vectors were utilised, the 
clinical application of these cells was limited. RD2-MolPack is another 
packaging cell line that was developed that continuously expresses RD114-
RT (a chimeric RD114 containing the cytoplasmic domain of MLV [241]). This 
cell line was also developed using a non-SIN vector. Next, RD3-MolPack was 
then developed using a SIN vector instead. Nevertheless, in both cell lines, 
the titres were around 106 TU/mL which is not ideal for clinical use [239]. 
Recently, Humbert et al. reported a third-generation SIN LV producer cell line 
using Cocal G protein. These cells were adapted to grow in serum-free 
suspension culture and achieved concentrated titres of 108 IU/mL [237]. 
The Collins/Takeuchi group developed the WinPac packaging cell line that can 
support the continuous production of LV. A non-toxic gammaretroviral 
envelope from the feline endogenous virus RD114 with an altered cytoplasmic 
tail to allow LV incorporation, RDpro, was adopted [240]. Due to its lack of 
cytotoxicity, also as the receptor of this envelope is widely expressed on 
hematopoietic stem cells [242], RDpro was used in the STAR packaging cells 
[240] as well as WinPac-RD packaging cell line [238]. The WinPac (WP) cell 
line was developed by stably transfecting a codon-optimised gag-pol into HEK 
293FT cells using recombinant mediated cassette exchange (RMCE). In this 
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study, MLV vectors introduced recombinase recognition sites in actively 
transcriptional sites. Gag-pol genes were then introduced via RMCE into this 
active locus, and the rev and env genes were finally transfected into the cells 
stably. Although isolated single clones produced titres for several months, the 
titres of 106 TU/mL were sub-optimal for clinical purposes. Furthermore, due 
to the limited host tropism and reduced physical stability, compared to that of 
VSVind.G, which lead to suboptimal titres and virus recovery, the usage of the 
RDpro packaging cell line is limited.   
In 2010, Trobridge et al. published a paper in which lentiviral vectors were 
pseudotyped with the envelope G protein of Cocal virus (COCV). It has been 
reported that, in transient production systems, G protein of COCV (COCV.G) 
can efficiently pseudotype LVs producing relatively high titres (107 TU/mL).  
COCV.G LVs also demonstrated broad tropism as they could transduce a 
variety of cells of different origins including human, primate, and dog-
hematopoietic progenitor cells. Moreover, compared to VSVind.G-
pseudotyped LVs, COCV.G- pseudotyped LVs showed more resistance to 
inactivation by human and dog serum, which shows promise for in vivo 
applications [243]. Lastly, some preliminary data suggest that COCV.G might 
be less cytotoxic compared to VSVind.G when expressed continuously [244]. 
These favourable characteristics would facilitate affordable large-scale vector 
production if COCV.G also demonstrates high vector stability like VSVind.G. 
This would greatly improve the range of clinical applications of lentivectors and 
would help propel the field of LV-mediated gene therapy forward [238]. 
Consequently, our laboratory decided to replace the RDpro envelope in 
WinPac-RD packaging cell line with that of Cocal virus to generate WinPac-
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COCV.G cell line. From the WinPac-COCV.G transfected cells, single clones 
were isolated and vectors were produced by transiently transfecting them with 
SIN pHV plasmid which codes for GFP gene.  The titres of these vectors then 
were tested by measuring the percentage of GFP using flow cytometry. The 
initial results of the test were promising, as COCV.G seemed to show similar 
properties to its close phylogenetic relative VSVind.G [244]. 
Although it has been reported that the VSVind.G glycoprotein is cytotoxic, due 
to its advantages including high tropism, the stability of the viral particle, and 
higher vector titres, other strategies to express this glycoprotein in packaging 
cell lines were investigated. One of these strategies was the introduction of the 
inducible expression systems. Systems commonly use tetracycline or 
doxycycline [245-248] as inducible agents were developed to regulate the 
gene expression of cytotoxic viral components like VSVind.G. The Tet-off 
system was first introduced by Gossen and Bujard [249] where the expression 
of a Tet-inducible promoter was lessened when tetracycline was added into 
the system. In this system, a tetracycline-controlled transactivator protein and 
a tetracycline-responsive promoter element (TRE) are used to regulate the 
expression of the transgene. 
The tet-off system allows for the silencing of a gene as long as it remains in 
the system outside the expression period. In addition, the tetracycline has to 
be removed entirely from the system which might be easy in smaller scale 
cultures yet; it can be challenging in larger scale and suspension cell culture 
systems. Furthermore, as several days are needed for the production of the 
protein to reach its peak, as well as the risk of leakiness of expression in the 
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off-state, transcriptional instability was reported a few months after cultivating 
the cells [250]. 
A few years after the development of the tet-off system, the Tet-on system was 
introduced in which, instead of removal, the addition of tetracycline allows the 
expression of the gene.  In this system, the expression of the gene is switched 
on by tetracycline binding to the tetracycline transactivator and TRE [251, 252]. 
While this system is better for transient gene expression, the background 
activity of the inducible gene in the absence of the inducer agent is a limiting 
factor [253, 254]. Although this promoter has been through lots of modification, 
more improvement is needed to optimise the final product [255].  
1.4.5 Lentiviral vectors in clinical gene therapy 
While both GRVs and LVs have the advantage of integration into the host cell 
genome, LVs seem to be less mutagenic and hence safer vectors compared 
to GRVs, as they often do not show preferential integration near oncogenes 
or cell cycle genes [9, 256]. LVs have shown high efficacy in recent clinical 
trials for the treatment of HIV, cancer, and genetic diseases such as X-linked 
Adrenoleukodystrophy (X-ALD) and β-thalassaemia. The ability of LVs to 
stably infect non-dividing cells makes them better candidates compared to 
other integrating vectors [257]. 
1.4.5.1 Cancer immunotherapy 
Tumour cells have the ability to evade the immune system. Cancer 
immunotherapy includes antibody and cytokine therapies, cancer vaccines, 
and adoptive cell transfer [258]. These methods attempt to improve the 
targeting ability and cytotoxicity of the immune response in order to eliminate 
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tumour cells [257]. In anti-cancer vaccine design, effective delivery of tumour-
associated antigens (TAA) as well as avoiding tumour-induced immune 
tolerance are the major challenges [259].  
In cancer immunotherapy, ongoing CD8 T cell (cytotoxic T cell) immunity is 
required. Viral vectors have been shown to be very effective in inducing T cell 
response. Accordingly, LV-based vaccines seem to be suitable options due to 
their integration and therefore a prolonged expression of TAA which can be 
processed by the antigen-presenting cells (APCs), especially dendritic cells 
(DCs) as key T cell activators [260]. LV-based anti-cancer vaccines are also 
designed to target the tumour cells by specific antibodies incorporated in their 
envelope [9, 261]. 
To induce an anti-cancer immune response, autologous DCs are usually 
transduced with LVs carrying TAA [262] or co-stimulatory signals [263] ex vivo, 
then re-administrated into the patients [257].  LV-transduced DCs have been 
reported to induce expression of CD4+ T cells and a higher concentration of 
IFN-γ. Despite the potential advantages of this method, some challenges 
remain.  One is the low numbers of DCs in the peripheral blood. To overcome 
this issue, CD34+ blood or bone marrow DC precursors and CD14+ monocyte 
DC precursors have been stimulated by cytokines to differentiate into mature 
to DCs [264, 265]. Another obstacle is the short lifespan of antigen-carrying 
DCs [266]. This issue has been tackled by transducing DCs with LVs carrying 
survival genes such as c-FLIPS, c-FLIPL, and Bcl-XL resulting in prolonged 
DC survival time [267].  
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As production of mature DCs can be demanding, an alternative method of 
turning cancer cells themselves into APCs to stimulate the immune response 
has been developed. This method is based on the fact that cancer cells 
already express TAAs. Therefore, autologous cancer cells are transduced by 
co-stimulatory factors and cytokines which can induce Th1 and hence 
cytotoxic T lymphocyte (CTL) response against TAAs upon administration 
back to the patient [257].  
Moreover, B-cell lymphoma cells transduced with LVs expressing IL-12 (which 
is usually expressed by APCs in response to tumour antigens) have been 
tested in mouse models in comparison to systemic delivery of IL-12. Long-
term immunity and survival were reported in mice injected by modified cells 
[268]. Other LV-based cancer immunotherapies have been developed such as 
acute myeloid leukaemia (AML) cells transduced with CD80 and GM-CSF 
(inflammatory cytokine stimulating macrophage and DC infiltration) [269] or 
CD80 and IL-2 [270]. Both these cells induced an anti-tumour response. This 
method is believed to offer an improved immunotherapy response compared 
to that of the systemic delivery of IL-12 and IL-2 due to toxic effects [271].   
1.4.5.1.1 T-cell therapy 
In T-cell therapy, expressing engineered antigen-specific T-cell receptors 
(TCRs) or chimeric antigen receptors (CARs) aid in conveying cytotoxic T-cells 
against tumour-associated antigens [272, 273]. This approach has been used 
in treating several malignancies including neuroblastoma, 
lymphoma/leukaemia, colorectal cancer [98], melanoma, and synovial 
sarcoma. So far, no IM was reported despite the use of GRVs suggesting that 
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differentiated T-cells are resistant against malignant transformations [274, 
275].  
T cell therapy is based on selecting the autologous T cells that robustly 
express antigen-specific T cell receptors, activating and expanding them, then 
administrating them back to the patient. However, due to low numbers of Ag-
specific T cells and the challenges in their sufficient expansion, other 
strategies had to be developed. One of these strategies is based on the TCRs’ 
ability to be transferred from one T cell population to another [276]. 
Accordingly, a method has been developed in which TAA-specific TCR genes 
from highly active T cells are transferred to other isolated autologous T cells. 
LVs are the vector of choice for stable and efficient delivery of TCR cDNA; 
especially bicistronic LVs that express both the α and β genes of TCR [277]. 
Moreover, autologous T cells transduced with LV-TCRs targeting NY-ESO-1 
[278] and MART-1 [279] have been used in clinical trials for treating 
oesophageal cancer or metastatic melanoma, respectively.    
A possible disadvantage in using TCR is the risk of recombination between 
the introduced TCR with the endogenous one resulting in off-target 
genotoxicity [280]. This can be dealt with by using endonuclease to suppress 
the expression of the endogenous TRC. Zinc finger nucleases (ZFN)-edited T 
cells expressing LV-transferred TCRs against Wilms tumour-1 antigen have 
demonstrated higher purity and lower off-target effect compared to unedited T 
cells [281].   
In the past few years, chimeric antigen receptors or CARs against CD19+ have 
become very popular for treating different B cell malignancies. CARs consist 
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of an extracellular and intracellular domain. The extracellular domain contains 
a single-chain variable fragment (scFv) of the light and heavy chains of a TAA-
specific antibody that activates the immune system by directly recognising 
these tumour antigens. The intracellular region of CARs contains 1-3 domains 
that activate and enhance the cytotoxicity of T cells through increased cytokine 
secretion and proliferation [282, 283].  
Despite recent success using CARs against CD19+ B cell malignancies, they 
show some limitations. Since the extracellular scFv is of mouse origin, they 
can be immunogenic. Even antibodies derived from humanised mice have the 
potential of provoking the immune system as novel proteins resulting in their 
clearance from the body. This immune response can range from fever to organ 
failure and death and usually occurs due to uncontrolled overexpression of 
various cytokines which is known as cytokine storm or cytokine release 
syndrome (CRS). In addition, CARs are designed to recognise TAA 
independent of MHC, giving them an advantage over TCRs which are MHC-
dependant. This allows CARs only to identify extracellularly expressed 
antigens which limits the targets for this therapy.  
A possible approach to overcome CRS exploits suicide gene or cell-fate 
control system. In this system, a cDNA sequence such as an enzyme [e.g. 
herpes simplex virus-thymidine kinase (HSV-TK)], which can be activated 
upon administration of its associated prodrug (ganciclovir or GCV for HSV-
TK), is transduced into cells leading in the elimination of target cells [284, 285]. 
Moreover, universal CARs have been introduced recently. These T cells are 
engineered to have disrupted HLA-I [286], or to be devoid of TCR, β-2 m, and 
PD1 triple loci [287]. Anti-CD19 CAR-T cells were also recently developed by 
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TALENs which are less likely to develop GVHD. Tumour regression was 
reported after administration of genome-edited cells into two patients with 
refractory B cell acute leukaemia [288]. These universal CARs have been 
reported to demonstrate high anti-tumour activity while reduced allogeneic 
activity [289]. Nevertheless, as TAAs are usually self-antigens (e.g. CD19 
which is a marker on healthy B cells is overexpressed in B cell malignancies), 
on-target off-tumour response in T cell therapy is of concern. Consequently, 
further research to identify novel TAAs and to optimise CARs’ affinity is 
required in order to improve T cell treatment efficacy and off-target effects 
[284, 290, 291].  
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Table 1-3. List of selected recent LV-mediated gene therapy clinical trials. 
HSCs: hematopoietic stem cells; PID: primary immunodeficiency; WAS: Wiskott Aldrich 
syndrome; WASP: WAS protein; ALD: Adrenoleukodystrophy; MLD: metachromatic 
leukodystrophy; ARSA: arylsulfatase-A; LV: Lentiviral vector; Env: envelope; VSVind.G: 
vesicular stomatitis virus (Indiana strain). HEK 293T cells were used for transient vector 
production; X-SCID: X-linked severe combined immunodeficiency. 
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1.4.6 LV delivery for genome editing  
Genome editing technologies based on endonucleases have been the centre 
of attention in recent years as they have the advantage of genome modification 
over the viral vector which can only mediate gene addition [300]. 
Endonucleases mediate double-strand break (DSB) resulting in recombination 
in mammalian cells through non-homologous end-joining (NHEJ) and 
homology-directed repair (HDR) systems. At the site of DSB, NHEJ can 
inactivate a gene by creating insertion or deletion mutations while HDR, in the 
presence of a donor DNA, can modify specific sequences to correct a mutation 
or to insert a new sequence in a site-specific fashion [301]. 
Genome editing systems offer the possibility to tackle the problems of viral 
vector gene transfer such as genotoxicity due to integration and activation of 
proto-oncogenes. In addition, this method is desirable for the treatment of 
diseases with dominant detrimental mutations [300]. Moreover, the regulation 
of the modified gene expression is improved as its expression is controlled by 
the endogenous promoter [302].   
Zinc finger nucleases (ZFN) [303] or meganucleases [304] were amongst the 
early genome editing molecules to be used. Transcription activator-like 
effectors or TALES are bacterial DNA binding domains that were used to 
create TALE nucleases (TALENs) which can be engineered to target DNA 
sequence of interest. Although these nucleases opened new doors to genome 
manipulation, the design of specific nuclease for each DNA target is required 
which can limit their use [305-307].  
63 
 
More recently, the clustered regulatory interspaced short palindromic repeats 
(CRISPR)-associated 9 (Cas9) gene-editing system has become popular as it 
simplified the process of site-specific gene editing. The CRISPR-Cas9 
nucleases are based on a prokaryotic adaptive immune system by which they 
silence the nucleic acids of the invading viruses and plasmids [308]. This 
system uses a guide-RNA (gRNA) to target the specific target sequence and 
a Cas nuclease to cut [257, 308].  
As TALENs and CRISPR-Cas9 systems can target specific DNA sequences, 
they have been heavily studied and used in basic research applications in 
recent years [309, 310]. LVs delivering the CRISPR system used in mouse 
embryonic stem cells for site-directed mutagenesis showed higher gene 
suppression efficiency compared to RNAi [311]. Targeted gene suppression 
or activation using LVs delivering CRISPR was also achieved in human cells 
where the CRISPR-Cas transgene maintained stable expression for two 
weeks [312].  
Genome editing as a therapeutic agent has made its way into the clinic. For 
instance, ZFN against CCR5 has been engineered to block HIV infection in T-
cells and HSCs [313, 314]. Several CRISPR-Cas nuclease clinical trials 
targeting PD1 expression had also been recently approved in China [300]. 
Despite all the advances in this field, further preclinical studies are required for 
safer and more feasible designs, to minimise off-target cutting and mutations 
due to homologous DNA sequences. Also, the immunogenicity of nucleases 




The Rhabdoviridae family (the Greek word “rhabdos” meaning rod or wand) is 
one of the most ecologically diverse families of enveloped, bullet-shaped RNA 
viruses. This family includes two main prototype viruses: vesicular stomatitis 
virus (VSV) which belongs to the genera of vesiculoviruses, and rabies virus 
(RABV) which belongs to lyssaviruses. While the primary hosts of lyssaviruses 
are bats by which these viruses are transmitted, vesiculoviruses are usually 
transferred via insects to a wide host range of mammals. For many decades, 
VSV and RABV have been studied extensively as model systems for 
investigating the molecular mechanisms of rhabdovirus life cycle, infectivity, 
and antigenic properties [315]. 
1.5.1 Vesiculoviruses 
Vesiculoviruses consist of 16 viruses classified based on their host range, 
serological properties, and genome organisation [316, 317]. Vesicular 
stomatitis virus (VSV) was the first vesiculovirus to be described and is the 
most studied virus. VSV includes four serotypes: VSV Indiana (VSVind), VSV 
New Jersey (VSVnj), VSV Alagoas (VSVala), and Cocal virus (COCV).  Two 
other major vesiculoviruses are Chandipura virus (CHAV) and Piry virus 
(PIRYV).  
VSV causes vesicular disease (initially known as ‘sore mouth/ tongue’) in farm 
animals such as horses, pigs, and cattle [214]. They were first seen in livestock 
in the USA and South America. Both VSVind and VSVnj are endemic 
especially in central and South America. VSV’s natural hosts are their insect 
vectors as well as cattle, horses, pigs, and other mammals [318-320]. VSV 
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infection in human, however, can result in flu-like symptoms. PIRYV was first 
isolated in northern Brazil, and only five cases of non-fatal lab-related human 
infection have been reported so far. CHAV was first known as the cause of 
febrile disease and recently has been related to outbreaks of fatal encephalitis 
which is becoming a health concern in India [321, 322]. 
1.5.1.1 Genome organisation of vesiculoviruses 
Vesiculovirus’ genome is composed of a non-segmented, single-strand, 
negative-sense RNA encoding five structural proteins; nucleoprotein (N), 
phosphoprotein (P), matrix protein (M), glycoprotein (G) and large protein or 
the viral polymerase (L).  The RNA genome combines with N, P, and the viral 
polymerase to form the helical ribonucleoprotein (RNP) complex [215, 323]. 
This complex is connected to the envelope via the matrix protein (M), which 
binds to both the N protein and the inner leaflet of the lipid-bilayer membrane 
[324]. The matrix protein partly regulates the replication of VSV. This protein 
codes for the RNA polymerase as well as aids in viral budding. The matrix 
protein also has a pivotal role in the virus early infection by blocking the 
expression of antiviral genes (e.g. IFN), which aids the virus to replicate freely. 
The VSV envelope is a single-spanning transmembrane glycoprotein with 
receptor-binding and fusion activities. It contains a small transmembrane and 
C-terminal regions while 90% of G protein is its N-terminal region that protrude 
of the viral envelope [1, 325-327]. 
Full-length genome analysis of VSVind, VSVnj, and COCV structural proteins 
indicates that while these viruses are genetically closely related to each other, 
they all are serologically different [328, 329]. N, M, and L are the most 
conserved proteins while G and P are more variable [330]. 
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1.5.1.2 Vesiculovirus glycoprotein 
In enveloped viruses, the envelope glycoproteins play an essential role in viral 
attachment to the host cell receptor, fusion and viral infectivity [326]. VSVind 
(the prototype of vesiculoviruses) contains one glycosylated protein, G protein 
(VSVind.G) [214, 331]. The mature VSVind.G protein is a 65-kDa type I 
transmembrane protein (single-pass trans-membrane protein, N-terminal is 
exposed to the exterior of the cell while the C-terminal is located on the 
cytoplasmic side) containing 511 amino acids that oligomerises into a 
homotrimer during transport to the cell surface, where the trimer is then 
assembled into the viral particle [325]. 
While the glycoprotein of VSVind, VSVnj, and CHAV are well studied, there is 
little known about other vesiculovirus G proteins (VesGs) such as Maraba virus 
G protein (MARAV.G), COCV.G, VSVala.G, or PIRYV.G. Sequence analysis 
of VSVind.G indicates that this protein shares some characteristics with both 
class I and class II membrane-associated glycoproteins, however, due to 
reversibility of its conformational changes, this G protein is classified in a 
separate group of fusion proteins, class III [306, 332]. The structure of these 
classes of proteins consists of long extracellular ends, a hydrophobic 
transmembrane section, and a C-terminal domain within the cell membrane 
[317, 333].  
While CHAV.G and PIRYV.G share a similar number of amino acid residues 
(530 and 529, respectively), the G protein in other VesGs ranges around 511-
517 amino acid residues long [334-338] (Figure 1-4). Nevertheless, a high 
degree of homology on the amino acid level suggests high functional and 
structural similarities amongst these seven VesGs [323, 327, 333, 339, 340].  
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Amino acid alignment of the G protein of MARAV.G and COCV.G shows the 
highest homology to VSVind.G of around 78% and 72%, respectively.  
VSVala.G and VSVnj.G follow with 64% and 50% homology, respectively while 
PIRYV.G shows the lowest levels of homology (of around 40%) to VSVind.G 
(Figure 1-5A). Moreover, the phylogenetic analysis of the amino acid 
sequences of these G proteins highlights that MARAV and COCV are closely 
related to VSVind while PIRYV and CHAV are close to each other and distant 





Figure 1-4. Multiple amino acid sequence alignment of the G proteins of Vesiculoviruses. 
Dashed lines represent gaps introduced to maximise matching of amino acid residues. 
Blue shading indicates percent identity; dark blue: 80-100%, medium blue: 60-80% light 
blue: 40-60%, and no colour indicating <40% identity. The sequences were aligned using 
Clustal Omega online multiple sequence alignment tool (EMBL-EPI) and the alignments 












Figure 1-5. Phylogenetic relationship of vesiculoviruses based on G protein amino acid 
sequences.  
(A) The percent amino acid identities of the G proteins compared to VSVind.G are 
summarised in the table. (B) G proteins of the major vesiculoviruses, as well as the G 
protein of the rabies virus (another prototype rhabdovirus, utilised as the base for the 
phylogenetic tree), were included in the analysis. The amino acid sequences were aligned 
using Clustal Omega online multiple sequence alignment tool (EMBL-EPI). The 
evolutionary analyses were conducted in MEGA7 [3]. The evolutionary history was inferred 
by using the maximum likelihood method based on the Jones-Taylor-Thornton matrix-
based model [5]. The tree with the highest likelihood is shown with the bootstrap confidence 
values (out of 100) indicated at the nodes. The tree is drawn to scale, with branch lengths 
measured in the number of substitutions per site, depicted in the linear scale. CJSV: 
Carajas virus, ISFV: Isfahan virus. Vesiculoviruses that this thesis focuses on are 





Although the signal peptide shows different lengths amongst the seven 
vesiculoviruses, it shares similar characteristics in the four VSV serotypes; a 
charged residue near the N-terminal end, a hydrophobic central area, and a 
less hydrophobic C-terminal end [341, 342].  The signal peptide is 21 residues 
long in PIRYV.G and CHAV.G while it is 16 residues in VSVind.G, VSVnj.G, 
and MARAVA.G, and 17 residues in COCV.G [333, 338].  
Crystal structure of VSVind.G indicates four distinct domains (Figure 1-6C): 
Domain I (DI) which is called the lateral domain is rich in β-sheets. Domain II 
(DII) or the trimerisation domain consists of α-helices that are involved in the 
trimeric pre-fusion formation of the protein. This domain is further divided into 
three sections: the N-heptad repeat (NHR), the middle-heptad repeat (MHR), 
and the C-heptad repeat (CHR). Domain III (DIII) contains the pleckstrin 
homology domain (PHD) which consists of 2 α-helices and two β-sheets. This 
domain is inserted into domain II, and as it is the most exposed domain in the 
pre-fusion conformation, it has been suggested that might play a role in 
receptor recognition. Domain IV (DIV) is inserted into domain III and contains 
six β-sheets with highly preserved amino acid residues. Two hydrophobic 
fusion loops in this domain interact with the target cell membrane stabilising 
the structure of the G protein [1]. During conformational changes from pre- to 
post-fusion (Figure 1-6A/B), while domains I, III, and IV retain tertiary structure, 
their relative orientation is rearranged due to refolding of domain II [1, 2, 332]. 
These structural reformation has been suggested to move the fusion domain 
from the viral surface towards the target cell membrane.  
The low-pH conformation of CHAV.G has been recently revealed its high 
structural similarity to the post-fusion structure of VSVind.G within the central, 
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fusion, and PHD domains [2, 327, 343, 344]. Although the central and fusion 
domains are almost indistinguishable, PHD seems to be more diverse.  
Overall, PHD is the most diverse domain in VesGs, and it has been suggested 





Figure 1-6. Structure and domain organisation of VSVind.G. 
Mature VSVind.G protein (AA 17-429) generated by thermolysin-mediated limited 
proteolysis of virions [1, 2] in (A) prefusion and (B) postfusion structures. 3D structures 
were retrieved from RCSB Protein Data Bank, visualised, and coloured using JalView 
software. (C) Domain architecture of VSVind.G’s amino acid structure in a linear diagram.  
The C-terminus is not shown in the structure, indicated here in grey. Domain boundaries 
are numbered according to the G protein precursor which includes the signal peptide. 
Domains are indicated in colours: Lateral domain DI: red; Trimerisation domain DII: blue; 






1.5.1.3 Receptor-mediated viral entry 
VSV.G protein is responsible for entry to the target cell [332]. This includes 
attachment to the receptor on the cell surface followed by pH-dependant fusion 
to the endosomal membrane. After attachment to a cell receptor, VSV particles 
go through endocytosis in a clathrin-based manner [346].  
Current studies suggest that low-density lipoprotein receptor (LDLR) and its 
family members are the receptors for VSVind.G cell entry [347]. It has also 
been suggested that LDLR serves as the primary receptor for VSV and VSV.G 
pseudotyped LV infection, while other LDLR family members act as alternative 
receptors. This is based on a study where the VSVind infection was reduced 
in a dose-dependent manner by soluble LDLR (sLDLR). This infection was 
fully blocked when receptor-associated protein (RAP), which blocks all other 
LDLR family members except for LDLR itself), was added [348]. Similar data 
have been reported for COCV infection [244]. However, the receptor usage of 
other vesiculoviruses is yet to be known [349].  
1.5.1.3.1 The low-density lipoprotein receptor family 
The LDLR family is a class of single-transmembrane glycoproteins that are 
known as cell-surface receptors [350]. The LDLR family members are widely 
expressed on different cell types and variety of species which explains the 
broad tropism of VSVind and VSVind.G based vectors. In mammals, this 
family consists of different receptors: the LDLR itself, apolipoprotein E receptor 
2 (APOER2), very low-density lipoprotein receptor (VLDLR), the LDLR-related 
protein (LRP), LRP1B, megalin (LRP2), LRP3, LRP4, LRP5, and LRP6 [351].  
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The extracellular domains are structurally conserved amongst these 
receptors. This domain contains ligand binding repeats and epidermal growth 
factor (EGF) precursor homology domains which bind to and internalise the 
ligand, respectively. After endocytosis, these sites are involved in the pH-
dependent release of the ligand. The cytoplasmic tails are involved in 
regulation of ligand-internalisation through clathrin-mediated endocytosis 
[352-356]. 
Other than acting as an entry point for some viruses, the LDLR family 
members are involved in a range of cellular activities such as binding to 
signalling molecules and carrying various components like vitamins, toxins, 
and antibiotics. VLDL receptor interacts with the serine protease urokinase-
type plasminogen activator (uPA) to modulate proteolysis processes [357]. In 
addition, it is an entry port for the hepatitis C virus, independent of CD81 [358, 
359].  On the other hand, LRP and megalin are known as scavenger receptors 
as they bind to more than 20 ligands due to having 31 and 36 ligand 
recognition sites, respectively [360, 361].   
1.5.1.3.2 The low-density lipoprotein receptor  
The LDL receptor was first identified in association with the genetic disease 
familial hypercholesterolemia (FH) in which the receptor is dysfunctional due 
to mutations in the LDLR gene [362]. The primary role of the LDLR is to 
transport cholesterol-carrying lipoproteins to cells. The main lipoprotein ligand 
is LDLR which carries approximately 70% of the plasma cholesterol. LDLR 
molecules usually cluster on the cell surface in clathrin-coated pits. After 
binding to the ligand, this complex is endocytosed. Upon interaction with the 
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low pH of the endosome, the ligand is released, and LDLR is recycled back to 
the cell surface [350].  
The mature LDLR is a type I transmembrane protein consisting of 839 amino 
acids [363-366]. The ectodomain of LDLR contains two main regions: the 
ligand-binding domain (LBD) which consists of seven cysteine-rich repeats 
(CR1-CR7), each of about 40 amino acid residues (Figure 1-7). Each CR 
contains six cysteine residues that form three disulfide bridges, and an acidic 
residues cluster that coordinates the Ca2+ ion [349]. The ligand-binding domain 
is followed by the epidermal growth factor precursor homology (EGFPH) 
domain which has a role in the pH-dependant release of LDL in the endosome. 
The EGFPH contains two EGF-like repeats followed by six repeats of YWTD 
(β-propeller) which includes tyrosine, tryptophan, threonine, and aspartic acid 
residues, followed by another EGF-like repeat [367, 368]. Right after this 
domain, there is a serine/threonine-rich sequence that gets highly glycosylated 
which is then followed by the transmembrane and the cytosolic end of the 
protein enriched in O-linked oligosaccharides [364, 369-371].  
It has been shown that calcium ions have a crucial role in the binding of LDLR 
to LDL as the removal of these ions blocked the LDLR-LDL interaction [372]. 
These ions are necessary for the disulfide bonds between the conserved 
cysteine residues in the CR repeats as well as for the structure and binding 
ability of these residues [373, 374]. LDLR is highly flexible in binding various 
ligands. This characteristic has been linked to the lack of inter-domain 
connectivity between its CR repeats which results in an independent ligand-
binding structure in the receptor allowing the ligand-binding repeats to adjust 
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their position to be able to bind to various ligands in a variety of shapes and 
diameters [375].  
Electron microscopy and crystal structure studies suggest two different pH-
dependent structural conformations for LDLR. In neutral pH, this receptor has 
an elongated structure which is considered to be the binding-active or the open 
structure of LDLR. However, in acidic pH, this receptor adopts a closed 
conformation as the CR4 and CR5 interact with the β-propeller of the EGFPH 
domain resulting in ligand release [376]. The receptor is then recycled back to 
the cell surface. 
1.5.1.3.3 LDLR as the main receptor for VSVind.G cellular entry 
In the endosome, the acidic pH triggers conformational changes in G protein 
resulting in viral membrane fusion to that of the endosome releasing the viral 
genome into the cell cytoplasm. LDLR and other members of the LDLR family 
have been reported to be the primary receptors for VSVind.G [347, 349, 377]. 
VSV infection was successfully inhibited in a dose-dependent manner via 
soluble LDLR molecules and was entirely blocked by the addition of RAP 
[347]. 
It has been shown that CR2 and CR3 domains directly bind to VSV G protein 
in neutral pH (Figure 1-7). Binding was not detected in pH 6, suggesting that 
this interaction occurs only in the pre-fusion structure of VSV. Also, mAbs 
against the LDLR-CR3 were shown to block VSV infection [347, 349]. 
Moreover, VSV infection was blocked after incubation with soluble forms of 
CR2 and CR3 [349]. 
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Crystal structures of soluble G protein interaction with soluble CR2 and CR3 
indicate that VSVind.G interacts with both domains using the same recognition 
epitope [349]. The binding site on the G is organised by sections from residues 
8 to 10 and 350 to 354 in the lateral domain, 180 to 184 in the PHD domain, 
and 47 to 50 in the S2 segment. These sections undergo reorganisation in the 
post-fusion state hence losing the ability to interact with these binding sites [2]. 
Some of these residues seem to play a critical role in this interaction. For 
instance, the basic residues H8 and K47 are positioned closer to the acidic 
residues on the CR domains. K47 also binds to the amide groups of Q71 on 
CR2 via H-bond and forms a salt bridge with the acidic group of D110 on CR3.  
R354 also binds to the C=O groups of the main chain in both CRs. 
Furthermore, the mutated forms of K47 and R354 blocked the interaction 





Figure 1-7. Interactions between VSVind.G and CR2-CR3 domains of LDLR.  
Diagram demonstrates the bound structure of VSVind.G to both CR2 (right) and CR3 (left) on 
LDLR at neutral pH while both proteins are anchored to the viral and cell membranes, 
respectively. EGFL domain: epidermal growth factor-like domain.  
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1.5.1.4 pH sensing 
The envelope of enveloped viruses is derived from the phospholipid bilayers 
of the host cells [378]. For the viruses to deliver their genetic material to the 
target cell, they need to overcome the physical barrier of the phospholipid 
bilayers; the electrostatic repulsion of the polar groups of the phospholipids 
between the cell and the envelope. This is achieved through the viral 
glycoproteins in the viral envelope [106, 379, 380].  Upon exposure to the 
mildly acidic pH of the endosome, the viral glycoprotein goes through 
conformational changes that induce pore formation allowing proton 
penetration. This virion acidification reduces the affinity of the viral M protein 
to the viral ribonucleoprotein releasing it into the cytosol to initiate a successful 
infection [381]. 
Crystallography studies report three distinct conformational states in the 
glycoproteins; the prefusion state (Figure 1-4A), the extended intermediate 
state, and the postfusion state (Figure 1-4B). Structural analysis of the G 
protein indicates conformational changes take place due to side-chain 
protonation on Asp, Glu, and His. Three histidine residues H76, H178, and 
H423 have been shown to act as pH sensors on the pre-fusion structure of 
VSVind.G [2, 332, 382].  These residues have been shown to be conserved 
amongst all seven vesiculoviruses studied in this project yet, their role in pH 
sensing has not been confirmed in other G proteins [2, 332].  
In contrast, in the post-fusion state of VSVind.G, deprotonation of four acidic 
residues D268, D274, D393, and D395 have been reported to act as pH 
sensors for the transition back to the prefusion state [383].  While D274, D393, 
and D395 are conserved amongst all VesGs, it appears that vesiculoviruses 
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other than VSVind.G, recruit alternative residues as pH sensors.  For instance, 
it has been reported that in CHAV.G, deprotonation of D269, E234, and H209 
destabilises the post-fusion structure triggering the transition back to pre-
fusion structure [327].  
VSVind.G is a class III glycoprotein and is responsible for both receptor 
recognition and membrane fusion. This glycoprotein undergoes reversible 
conformational changes. It has been demonstrated that while acidic pH 
inactivates the viral infectivity, the infectivity was recovered when the pH was 
changed to the neutral range [384].  
The prefusion form of the VSVind.G is compact where many interactions exist 
between all four domains. Histidine residues act as pH sensors in the prefusion 
state [382, 385-387]. Two distinct pH-dependant residue interaction has been 
identified in the G protein, the Histidine/Cationic (HisCat) pairing where 
histidine (His) exists in cluster forms when pairing with other cationic residues 
such as lysine (Lys), arginine (Arg), or His. These clusters are mainly localised 
in the interfaces between DIV and DI and DII (Figure 1-4C). Various studies 
have investigated these clusters for pH sensing. His132/Lys15 and 
His162/His407 have been identified to mediate the pH-dependant 
conformational rearrangements in VSVind.G [388]. The second residue 
interaction is Anion-Anion (AniAni) pairing.  The AniAni pairing refers to the 
interaction between two anionic residues such as aspartate (Asp) and 
glutamate (Glu). At neutral pH, these two amino acids are negatively charged 
due to their acidic side chains. Upon pH acidification and therefore protonation, 
they form hydrogen bonds which stabilise the postfusion form of the molecule 
[389, 390].  All AniAni pairings are formed in DII at the trimer interface [339]. 
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In neutral pH, DI usually exists in the interior while DIII occupies the base of 
the molecule. DII however, is mainly unstructured in the neutral pH. Upon 
contact with the acidic pH of the endosome, DI moves to the exterior side while 
DII folds into a six α-helical structure which is highly stable [2]. The NHR and 
MHR of DII create the postfusion trimer by forming the three-helix core of the 
molecule enveloping the CHR section. DIII then folds beside DII while DIV 
extends towards the target cell membrane. While HisCat pairs are reduced, 
the number of AniAni interactions are increased in the postfusion formation 
[339, 390]. However, His residues that were involved in HisCat pairing in the 
prefusion state can form salt bridges with D145 of DIV in acidic pH stabilising 
the postfusion conformation. All these mechanisms that result in pH-
dependent stabilising of the G protein conformational changes, in both pre and 
postfusion states, are suggested to be the reason behind reversibility of the 




1.5.1.5 Fusogenic activity 
In the acidic pH of the endosome, the G protein undergoes conformational 
changes from the prefusion state to postfusion reformation where the fusion 
loops are exposed to merge the viral membrane to that of the endosome [2, 
106, 332, 339, 391, 392].  It has been reported that the highest levels of 
VSVind infectivity occur around the physiological pH (pH 7.2) and that these 
titres drop by 30-folds when pH is reduced to 7.0 and drop even further when 
pH value is at 6.8 [214, 327, 393].  
To investigate which part of the G protein is responsible for the viral fusogenic 
activity, after incubation of wild-type (WT) VSVind virus in acidic pH and 
comparing the amino acid sequence to that of the neutral pH, four mutations 
were identified in low-pH adapted VSVind virus: F18L, Q301R, K462R, and 
H65R. Three out of four changes in the above mutations are to arginine 
residues, suggesting that positive charges might play a role in pH-induced 
conformational changes of the G protein [214].  
Similar studies on VSVnj.G and CHAV.G reported that both these G proteins 
have lower pH threshold compared to VSVind.G [214, 327]. Moreover, cell-to-
cell fusion assays at mildly acidic pH demonstrated that while VSVind 
infectivity was completely stopped, VSVnj and CHAV were still able to replicate 
in infected cells causing them to fuse together, a process known as syncytia 
formation. This lower pH threshold and higher stability of VSVnj and CHAV in 
slightly acidic pH have been suggested to be related to higher pathogenicity 
and more severe outbreaks compared to VSVind, in animals and humans, 
respectively [214, 327]. Amino acid sequence alignment reveals that VSVnj.G 
contains the K462R amino acid exchange and CHAV.G contains the F18L. 
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Interestingly, while no similar data is reported for PIRYV.G, the G protein also 
contains the K462R amino acid replacement which suggests that PIRYV.G 
could also have lower pH threshold compared to VSVind.G.    
Martinez and Wertz also compared the G proteins of VSV Indiana and New 
Jersey strains. They reported that while VSVnj.G was still infectious in mildly 
acidic pH (6.8), the infectivity of VSVind.G was severely reduced.  Moreover, 
VSVnj.G was shown to have a lower pH threshold compared to VSVind.G as 
its infection was inhibited in the presence of ammonium chloride.  These 
biological differences between VSVind.G and VSVnj.G were linked to the 
higher pathogenicity of New Jersey serotyped compared to Indiana serotype. 
Sequence analysis of VSVind.G after repeated culture in pH 6.8 revealed a 
single amino acid substitution (F18L) to be responsible for adaptation to pH 
6.8. Repeated cultures of VSVind.G in lower acidic pH (6.6 and 6.4) exposed 
additional amino acid substitutions. Moreover, VSVind.G infectivity could be 
recovered after incubation at neutral pH indicating the reversibility of the 




1.5.1.6 Cell tropism of vesicular stomatitis virus 
VSV is small, replicates rapidly, can easily be manipulated, and has broad cell 
tropism, most human cell types and organisms as distant as Drosophila or 
zebrafish [394-396]. These advantages make this virus a popular model for 
basic research applications and studies such as vaccine development and 
pseudotyping other viruses. Although vaccine vectors have been originally 
developed based on human DNA viruses, in recent years the use of RNA 
viruses, especially animal RNA viruses like VSV, has been considered. The 
lack of a pre-existing neutralising antibody is one of the advantages the animal 
viruses have over the human viruses. Moreover, RNA viruses have rapid 
growth compared to DNA viruses which could be beneficial in vaccine 
development and dose amplification [397].  
The glycoprotein of VSVind (VSVind.G) is the most widely used envelope as 
a model in many studies [194, 211]. Besides broad tropism, VSVind.G 
pseudotyped viral particles demonstrate high physical stability and can 
produce high titres under ultracentrifugation. Nonetheless, VSVind envelope 
is highly sensitive to human serum limits their potential for in vivo applications 
[213]. In addition, VSVind.G is reported to be cytotoxic [201]. Accordingly, 
studies investigating alternative G proteins have been conducted to replace 
VSVind.G [237, 238].   
1.5.1.7 VSV as a vaccine vector and an oncolytic virus  
VSV can be engineered to stimulate the immune system against disease such 
as influenza and AIDS [397]. Studies have demonstrated that without the need 
of injection, mucosal vaccination of a live modified VSV has a protective effect 
against infection: intranasal administration of the live attenuated recombinant 
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VSV expressing hemagglutinin of influenza or the measles virus, protected the 
rodent subjects after a challenge with influenza [398] or measles viruses [399], 
respectively.  
The fact that many tumours are either non-responsive to IFN treatment or can 
develop resistance to the immune system [400] led to studies investigating the 
ability of viruses to infect tumour cells selectively.  This was based on the 
hypothesis that tumour cells infected by the virus can be cleared by the IFN 
that is expressed against the virus infection [401]. VSV can be modified to 
target cancer cells [397]. A recombinant strain of VSVind has been reported 
to show oncolytic ability where it infected and killed cancer cells in both in vitro 
and in vivo studies, while did not affect normal cells. While this oncolysis effect 
was improved massively in the presence of IFN [401-403], VSV was able to 
infect malignant primary cells with defective IFN response [404]. The efficiency 
of VSV against different malignancies [405] as well as recombinant VSV 
coding for the IFN-β gene against hepatocellular carcinomas [406] has been 
reported. These strains of IFN-inducing VSVs are not only efficient in 
promoting oncolysis, but they might also be utilised as vaccine vectors [397]. 
Investigations have been performed to alter the broad tropism of VSV to target 
specific cells. For this, a single-chain variable fragment (scFv) antibody against 
the human major histocompatibility complex class I (MHC-1) was linked to the 
N-terminus of VSV.G. Although LVs pseudotyped with this chimeric VSV.G 
specifically bound to the MHC-1, their infectivity was reduced due to the loss 
of fusogenic ability of the altered VSV.G [407]. 
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VSV is neurotropic and can cause lethal CNS infections in rodents and non-
human primates [408] and encephalitis in humans [409]. While post intranasal 
(i.n.) injection of WT VSV into non-human primates, no trace of the virus in the 
brain or the spinal cord was found, intrathalmic (i.t.) injection caused severe 
neurological disease [408, 410]. Although the mechanisms of this 
neurotropism are not clear, they need to be addressed for VSV to be safe for 
gene therapy and clinical applications [409]. 
Improved knowledge of the molecular biology and epidemiology of VSV in 
recent years, enabled scientists to work on engineering new strains of this 
virus that would be able to function not only as a safe vaccine but also as a 
killer of malignant cells.  Nevertheless, extensive work is needed to investigate 
the safety and the optimal way of delivery of this virus to human. Moreover, 
comprehensive investigations are required to study the interaction between 
the virus and the human immune system as well as the impact of virus 





1.6 Aims of the thesis 
VSVind.G is commonly used to pseudotype LVs. LVs pseudotyped with this G 
protein exhibit high physical stability. This characteristic enables vector 
concentration via ultracentrifugation yielding high vector titres. Nevertheless, 
when this protein was expressed continuously in cells, cytotoxicity due to high 
fusogenic activity as well as superinfection was reported. These have 
detrimental effects on the cell’s integrity and eventually vector titres. 
Accordingly, the work presented in this thesis aimed to explore the adaptation 
of genus Vesiculovirus envelopes, including VSVind.G, COCV.G, VSVnj.G, 
PIRYV.G, CHAV.G, VSVala.G, and MARAV.G, for lentiviral vector-based 
gene delivery.  
In the first part of this project, these G proteins were tested for functional 
lentiviral vector generation as well as for their physical and thermal stability in 
comparison to VSVind.G, to assess their suitability for high titre vector 
production. 
Chapter 4 of this thesis explored vesiculovirus G proteins’ cytotoxicity via 
comparing the fusogenicity amongst these G proteins including VSVind.G. 
Adaptation of all these G proteins to be stably expressed in cells was also 
examined.  
The final part of this project explores the occurrence of superinfection in other 
vesiculovirus G proteins as well as their receptor usage. Furthermore, the 















Materials and Methods 
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2.1 Cell culture 
2.1.1 HEK 293T cells 
The human embryonic kidney (HEK) 293T cells are widely used in cell biology 
experiments and are used throughout this project. These cells are derived from 
the original 293 cells that were first isolated from the kidney of an aborted 
human embryo in 1973 [411]. HEK 293T cells stably express the SV40 large 
T antigen which allows them to be transfected with high efficiency and grow in 
much higher rate than their parental cell line making them a good candidate 
for LV production [411, 412].   
These cells were maintained in Dulbecco's Modified Eagle Medium (DMEM) 
(Sigma-Aldrich) supplemented with 10% heat-inactivated Foetal Calf Serum 
(Gibco), 2mM L-Glutamine (Gibco), 100 units/ml Penicillin and 100μg/ml 
Streptomycin (Gibco).  All cells were kept in cell culture incubators at 37ºC and 
5% CO2. 
2.1.2 TE671 cells 
TE671 are human rhabdomyosarcoma cells.  In this project, they were mainly 
used for the pH-sensitivity assay as they showed robustness, especially when 
incubated at atmospheric CO2, compared to HEK 293T cells. These cells were 
also maintained in DMEM supplemented with 10% heat-inactivated Foetal Calf 
Serum, 2mM L-Glutamine, 100 units/ml Penicillin and 100μg/ml Streptomycin. 
All cells were kept in cell culture incubators at 37ºC and 5% CO2. 
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2.1.3 WinPac cells 
WinPac (WP) is a lentiviral vector packaging cell line derived from HEK 293FT 
cells. HEK 293FT cells are a traceable variant derived from HEK 293 cells 
[412]. The WinPac cells were produced by transfecting a codon optimised 
gag/pol cassette via recombinase-mediated cassette exchange (RMCE) as 
well as stable transfection of a plasmid encoding HIV rev protein. Stable 
transfection of these cells with plasmids encoding RDpro and COCV-G 
envelope proteins generated WinPac-RD and WinPac-CVG cell lines, 
respectively [238, 244]. 
WinPac cell lines were cultured in DMEM containing Glutamax (Gibco) 
supplemented with 100U/mL Penicillin/Streptomycin (Sigma-Aldrich), and 
10% heat-inactivated Foetal Calf Serum (Gibco) at 37°C and 5% CO2.  When 
indicated, antibiotics (Invivogen) were added to the culture medium.  




Table 2-1. Antibiotics used in mammalian cell lines. 
  











Inhibition of protein 
synthesis 
100 Rev 
Phleomycin DNA cleavage 30 Envelope 
Blasticidin 





2.2 Gene transfer to mammalian cells 
2.2.1 Transfection of Cells for G Protein Expression 
To express VesG on HEK293T cell surface, these were seeded one day prior 
to transfection at 3x106 cell per 10cm plate density. These cells were 
transfected by lipofection using FuGENE6 (Promega).  5μg/plate of G protein-
encoding plasmid was mixed with 20μl/plate of dH2O. When co-transfecting 
with pHV-Luc, 2.5μg/10cm plate of each plasmid was added. This DNA 
mixture was then added to a solution of OptiMEM (Gibco) and FuGENE6 (1:5 
μg of DNA: μl of FuGENE6), incubated at room temperature for 20-30 minutes 
and then added to each 10cm plate of HEK293T cells dropwise.  48 hours 
later, cells were harvested to be used in different assays. 
2.2.1.1 Plasmid details 
VesG envelopes were cloned into the high-expression plasmid backbone 
pMD2, driven by a CMV promoter (Figure 3-1A). Amino acid sequences for 
VSVnj.G (UniProt Accession Number: P04882), PIRYV.G (UniProt Accession 
Number: Q85213), MARAV.G (UniProt Accession Number: F8SPF4), 
VSVala.G (UniProt Accession Number: B3FRL4) were retrieved from UniProt. 
Codon-optimised genes were ordered from GENEWIZ (NJ, USA) and 
subcloned into the backbone. 
2.2.2 Transient lentiviral vector production and concentration 
Three-plasmid co-transfection of 293Ts was used to make lentiviral vectors. 
2x107 HEK 293T cells were seeded per 15cm plate a day prior to transfection.  
Cells were then transfected using FuGENE6 with the following plasmids: 2.5μg 
p8.91 (Gag-Pol and Rev expression plasmid), 2.5μg of envelope expression 
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plasmids, and 3.75μg of SIN pHV-GFP [green fluorescent protein (GFP)] 
expressing vector plasmid (Table 2-2). 
24 hours post-transfection, the medium is replaced with fresh complete 
DMEM.  48 hours post-transfection, the vector-containing media is collected 
for 2-3 days in 24-hour periods. Following collection, the supernatant was 
filtered through Whatman Puradisc 0.45μm cellulose acetate filters (SLS) and 
concentrated ~100X using ultracentrifugation [Beckmann Optima LK-90 
ultracentrifuge, SW-28 swinging bucket rotor (radius 16.1cm)] at 22,000 rpm 
(87,119 g) for 2 hours at 4°C. The vectors are resuspended in cold DMEM and 
incubated on ice for 1 hour before aliquoting and storage at -80°C. 
2.3 Plasmid amplification 
2.3.1 Transformation of competent cells with plasmid DNA 
5-alpha high-efficiency competent E.coli (NEB) was thawed on ice. 1-5µl of 
100ng of plasmid DNA/ligation mix was added to 50µl of competent cells, 
incubated on ice for 30 mins and heat shocked at 42°C for 30 seconds.  The 
cells were then incubated on ice for 5 minutes before adding 950µl of SOC 
medium (provided by the manufacturer). The mixture was incubated at 37°C 
for 60 minutes in a shaker at 250 rpm. Following incubation, 100µl of the 
mixture was spread on LB (Luria-Bertani) agar plates containing 100µg/ml 
ampicillin (Sigma-Aldrich). The plates were incubated at 37°C overnight to 
allow colony formation.   
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2.3.2 Colony screening by PCR 
Ampicillin-resistant colonies were screened for the correct construct using 
Polymerase chain reaction (PCR). GoTaq HotStart Green Master Mix 
(Promega) was prepared in a final volume of 25μl per reaction. Colonies were 
picked with a pipette tip, streaked on an agar plate containing 100μg/ml 
ampicillin (Sigma-Aldrich), and then transferred to PCR mastermix.  PCR 
cycling conditions were as follows: 98°C for 5 minutes; 25-35 cycles 
(denaturation at 98°C for 30 seconds; annealing for 30 seconds at 65°C; and 
elongation at 72°C for 30 seconds/kb of the insert); 72°C for 7 minutes. Melting 
temperatures were calculated using the NEB Tm Calculator: 
(http://tmcalculator.neb.com/#!/). 
2.3.3 Plasmid purification 
Mini and midi-preps were used for plasmid DNA purification. Single positive 
colonies were picked from LB agar plates and transferred to 5ml (for mini-








pMD2.1A-4A & 1B-4B.G 
Self-made G protein 
pRDpro-LF 




Sean B. Knight 
(Collins/Takeuchi Group) 
GFP expression with SIN 
LTR 
p8.91 Plasmid Factory Gag-Pol and Rev 
Table 2-2.  List of plasmids used. 
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preps) or 100ml (for midi-preps) of LB broth containing 100µg/ml ampicillin. 
Cultures were grown overnight at 37°C, shaking at 250 rpm.   
All plasmids were purified from bacterial cultures using the QIAGEN Plasmid 
Mini or Midi-prep kits (QIAGEN) according to the manufacturer’s instructions. 
In this system, LB cultures were pelleted by centrifugation at 4,000 rpm for 30 
minutes.  Bacteria were resuspended in Buffer P1 and exposed to a detergent 
in high pH conditions with the addition of Buffer P2 which causes denaturation 
of plasmid and genomic DNA as well as proteins. While the hydrogen bonds 
of the base pairs are completely disrupted, the circular structure of the plasmid 
prevents two DNA strands from separating in the short duration of exposure 
to these conditions. The addition of Buffer N3 neutralises the aforementioned 
conditions and enables the reformation of the base pairings in the plasmid 
DNA. The addition of Buffer N3 also helps co-precipitation of genomic DNA 
and proteins leaving plasmid DNA in the supernatant. Then plasmids are 
bound to an anion-exchange resin provided by the kit, washed with Buffer PB 
and PE once each, and finally eluted via Buffer EB under low salt conditions. 
After elution, DNA concentrations were determined using a NanoDrop 
(Spectrophotometer, ND-1000). 
2.4 Cloning 
2.4.1 Polymerase chain reaction (PCR) 
Phusion PCR Kit (NEB) was used to perform PCR reactions. Phusion 
polymerase was provided in an inactive form requiring activation before the 
polymerase reaction. This was achieved by incubating the reaction tubes at 
98°C for 5 minutes after the samples were mixed with the freshly prepared 
94 
 
master mix and Phusion polymerase. Since the enzyme was inactive at room 
temperature any endonuclease activity that would degrade primers were 
avoided as well as making it possible for the reaction to be set up at room 
temperatures.  The reactions were carried out in a PCR thermal cycler (Applied 
Biosystems, GenAmp PCR system 2700). 
2.4.2 Overlap extension PCR 
As in most PCR reactions, two flanking primers, one for each end, are used 
per sequence.  To link two DNA molecules, special primers are used at the 
ends that are to be joined.  For each molecule, the first of two PCRs creates a 
linear insert such that it has a 5' overhang complementary to the end of the 
other molecule. Following annealing when replication occurs, these 
extensions allow the strands of the PCR product to act as a pair of oversized 
primers and the two sequences will be fused. Once both DNA molecules are 
extended, a second PCR is carried out with only the flanking primers to amplify 




Figure 2-1. Overlap extension PCR. 
Schematic of overlapping extension PCR. Four primers were designed for the creation of 
each chimeric protein: flanking primers (a and d) and overlapping primers (b and c) which 
contain sequences from both templates. Primers b and c create overlapping sequences at 
each end after the first step PCR. In the second step PCR, the overlapping sequences, 
which are complementary to each other, bind together then the rest of the sequence is 
generated. The newly synthesised sequence is then amplified via a and d flanking primers. 
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2.4.3 Gel electrophoresis, DNA extraction, and purification 
Agarose gel electrophoresis was used to separate different sizes of DNA, to 
analyse PCR and colony screen PCR products as well as to separate and 
purify restriction endonuclease reaction fragments. 1% agarose gels were 
prepared by dissolving agarose (Sigma-Aldrich) in Tris/Borate/EDTA (TBE) 
Buffer.  Depending on the final volume of the solution the mixture was heated 
up in a microwave for 1.5-2 minutes shaking approximately every 30 seconds 
until the agarose was fully dissolved. The solution was then cooled before 
adding 0.1µl/mL SyberSafe DNA gel stain (Invitrogen). Gels were set in 
various casting trays using different sizes of combs depending on need and 
were left to set at room temperature for 30-45 minutes. 
To separate DNA fragments the set gels were placed in electrophoresis tanks 
containing TBE buffer in orientation in which wells closest and parallel to the 
cathode. A 1 kb GeneRuler DNA ladder (Thermo-Fisher Scientific) was added 
to 1 of the wells while samples, positive and negative controls containing DNA 
loading dye (Thermo-Fisher Scientific) to the other wells. The gels were run 
using a constant voltage of 100mW for an hour. Lastly, the DNA bands were 
visualised using a UV transilluminator (UltraBright Blue, Maestrogen), and 
necessary bands were extracted using a scalpel (Swann-Morton). 
The extracted DNA fragments were purified using the QIAquick Gel Extraction 
Kit (QIAGEN) according to the provided protocol. In short, pieces of gel 
extracted using a scalpel were dissolved at 60°C in Buffer QG and then 
centrifuged through an anion exchange resin to which DNA binds to under high 
salt and in acidic pH conditions created by the buffer. After a wash with Buffer 
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PE with ethanol, the DNA fragments were eluted with Buffer EB under low salt 
and high pH conditions. 
2.4.4 DNA digestion 
Various restriction endonucleases were used in the production of several 
plasmid constructs. All endonucleases were obtained from New England 
Biolabs. In a sample reaction, 1µg of the DNA sample was digested with ten 
units of enzyme/µg DNA, 1X of the buffer with bovine serum albumin (BSA) 
(according to manufacturer’s instructions) and nuclease-free water (MEB) with 
the final reaction volume of 50µl. The reaction mix was incubated at 37°C for 
10 minutes and was stopped by the DNA loading dye provided by the 
manufacturer. 
2.4.5 DNA ligation 
The quick ligation kits used were obtained from NEB and Thermo-Fisher 
Scientific and T4 DNA ligase was used according to the manufacturer’s 
instructions for cloning DNA plasmids. In a typical reaction, 50µg of backbone 
was mixed with the DNA insert in 1:3 molar ratio in a final concentration of 1X. 
Ligase buffer (supplied by the manufacturer) made up to a final volume of 10 
µl with nuclease-free water. The reaction was incubated at room temperature 
for 5 minutes and chilled on ice until transformation or stored at -20°C. 
2.5 Flow cytometry 
Fluorescence-activated cell sorting (FACS) analysis was used to determine 
the G protein or GFP expression, on the cell membrane and titrate lentiviral 
vectors, respectively.  FACS is a specialised type of flow cytometry in which 
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cells are carried by liquid flow in a way so that they pass through laser light 
beams one cell at a time for sensing. Then a detector measures the forward-
scattered light (FSC) and side scattered light (SSC), as well as dye-specific 
fluorescence signals. FSC is proportional to the cell size while SSC is a 
measure of cell granularity. All flow cytometry experiments were carried out 
using FACSCanto II (BD Biosciences) machine and FACS Diva analysis 
software (BD Biosciences). 
To analyse the data, FlowJo single cell analysis software (BD Biosciences) 
was utilised. This analysis was based on the negative HEK293T cells, which 
were gated for single cell population based on FSC and SSC data to eliminate 
any dead cells and debris. These gated cells represent the working population 
for the assay analysis. 
2.5.1 Titration of lentiviral vectors 
Vector titres were determined via flow cytometry analysis of GFP expression 
in vector-transduced HEK 293T cells. Titres are reported as TU/ml indicating 
how many cells can be transduced with a given volume of the vector.  3x105 
of HEK 293T cells/well of 12-well plate are seeded in 1mL medium containing 
8µg/mL polybrene (Sigma-Aldrich). Cells are challenged with a serial dilution 
of vectors 3-4 hours after seeding. GFP expression (5-30%) is measured using 
flow cytometry and the formula below: 
Titre (transfection unit/mL) = number of cells seeded*%GFP of positive 




2.5.2 Extracellular antibody staining  
HEK 293T cells were transfected based on section 2.2.1. 48 hours after, cells 
were harvested, washed twice with phosphate-buffered saline (PBS), and 
plated in U-bottom 96-well plates (Thermo-Fisher Scientific).  Cells were then 
incubated with extracellular antibodies in 1% bovine serum albumin (BSA) 
(Sigma-Aldrich) in PBS (Sigma-Aldrich) in a total reaction volume of 200μl for 
30 minutes at 4ºC. After washing twice with PBS to remove unbound 
antibodies, the cells were incubated for another 30 minutes at 4ºC with their 
respective fluorophore-conjugated secondary antibodies in 1% BSA in PBS in 
a total reaction volume of 200μl. Cells were then washed twice, fixed in 1% 
paraformaldehyde (PFA) (Sigma-Aldrich) in PBS, and analysed by flow 
cytometry. 
2.5.3 Intracellular antibody staining 
HEK 293T cells were transfected based on section 2.2.1. 48 hours after, cells 
were harvested, washed twice with phosphate-buffered saline (PBS), and 
plated in U-bottom 96-well plates (Thermo-Fisher Scientific). Cells were then 
fixed with 1% paraformaldehyde (PFA) in PBS for 20 minutes at room 
temperature.  After washing twice with PBS, cells were permeabilised by 
incubation in 0.05% saponin (Sigma-Aldrich) in PBS for 10 minutes at room 
temperature. The cells were then washed twice in PBS and blocked with 1% 
bovine serum albumin (BSA) in PBS for 60 minutes at room temperature. 
These cells were then stained with an optimised dilution of the primary 
antibody in 1% BSA in PBS for 60 minutes at room temperature in a total 
reaction volume of 200μl.  After washing twice with PBS to remove unbound 
antibodies, the cells were incubated with the respective secondary antibody in 
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the same buffer composition for another hour at room temperature. Following 
two washes with PBS, stained cells were analysed by flow cytometry. 
2.6 CRISPR-Cas9 gene editing system 
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a 
nuclease system utilised to mediate DNA cleavage (Figure 2-2A). To improve 
genome editing in mammalian cells, a codon-optimised Cas9 (CRISPR-
associated) gene in association with a specific single guide RNA (gRNA) has 
been adapted to be delivered to cells using lentivectors. To create individual 
lentiCRISPR targeting a gene (in this study the LDLR gene) three gRNAs were 
designed, based on the human LDLR gene sequence (Ensembl genome 
browser). These gRNAs were 20 nucleotides each and were flanked on their 
3’ end by the NGG PAM sequence (Protospacer adjacent motif) which is 
essential in target binding [411]. While two of the designed gRNA could not be 
sub-cloned into the plasmid backbone, the three oligo, which targeted the 
beginning of the open reading frame, was sub-cloned successfully. This oligo 
was phosphorylated (Table 2.3) and then annealed: 37 ºC for 30 minutes, 95 
ºC for 5 minutes, then ramped down to 25 ºC. 
The lentiCRISPR plasmid (AddGene) contains two expression cassettes, one 
for the chimeric gRNA and one for the Cas9 nuclease (Figure 5-5A) [413]. This 
vector was digested by BsmBI restriction enzyme (NEB) (see section 2.4.4 for 
DNA digestion). After gel purification of the digested backbone (see section 
2.4.3), 1:200 oligos diluted in ddH2O, were ligated into the backbone (Table 
2-4) at room temperature. Competent cells were then transformed by this 
plasmid (see section 2.3.1). To produce LVs, HEK 293T cells were co-
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transfected transiently with lentiCRISPR, packaging, and VSVind.G plasmids 
(see section 2.2.2). Transfected cells were selected with blasticidin for 10 days 
then were lysed and checked for LDLR gene expression via western blot 













Figure 2-2. CRISPR-Cas9 gene editing system schematic. 
(A) CRISPR-Cas9 schematic exhibiting complex formation and target binding via 
sequence-specific gRNA. The Cas9 cleaves both strands of DNA. The cellular repair 
system attempts to repair the cleaved DNA where it can introduce mutation in the sequence 








Table 2-3. Phosphorylation and annealing reaction of the oligos. 
 
Reagent Amount per reaction (μl) 
Diluted oligo  1  
Digested plasmid (50 ng) X 
2X Quick Ligase Buffer 
(NEB) 
5 
Quick Ligase (NEB) 1 
ddH2O Up to 11  
Table 2-4. Ligation reaction. 
 











Table 2-5. Guide RNA sequences used for against the LDLR gene.   
Reagent Amount per reaction (μl) 
Oligo 1 (100 μM) 1  
Oligo 2 (100 μM) 1 
10X T4 Ligation Buffer 
(NEB) 
1 




2.7 SDS-PAGE and immunoblotting  
HEK 293T cells (LDLR-wild-type and LDLR-KO; G protein expressing in 10cm 
plates were washed with PBS, dissociated with trypsin (Sigma-Aldrich). After 
spinning and removing the media, the cell pellets were lysed with 0.40 ml per 
plate of lysis buffer [(25mM Tris-HCl pH7.5, 150mM NaCl, 1% v/v Triton X-
100) supplemented with Roche cOmplete™ protease inhibitor cocktail (Sigma-
Aldrich)]. The lysates were centrifuged (17,000xg, 20 minutes) and the 
supernatants containing the cellular proteins were collected. Protein 
concentrations were determined using a Pierce BCA Protein assay reagent kit 
(Thermo-Fisher Scientific) using BSA as the standard. After normalisation of 
protein concentrations, samples were boiled at 95ºC for 5 minutes in 5X 
Laemmli buffer [0.5M Tris-HCl pH6.8, 10% glycerol, 2% sodium dodecyl 
sulfate (SDS), 0.2mg/ml Bromophenol blue, 5% β-Mercaptoethanol, and 0.1M 
dithiothreitol (DTT)] and were resolved by electrophoresis in a 4% (wt/vol) 
SDS-polyacrylamide staking gel, followed by 10% (wt/vol) resolving gel for 1.5-
2 hours at 120 volts. Proteins were then transferred onto a nitrocellulose 
membrane (GE Healthcare), blocked with 5% (wt/vol) skimmed milk in PBS-T 
(washing buffer; PBS with 0.1% (v/v) Tween20), and incubated with the 
indicated antibodies in the blocking buffer. Secondary antibodies conjugated 
to horse radish peroxidase were visualised by ECL™ Prime Western Blotting 




2.8 Luminescence Assay 
After trypsinisation, transfected cells were washed with PBS and plated on 
white 96-well plates (Thermo-Fisher Scientific) in triplicates at a volume of 50-
100μl/well following resuspension in PBS. Bright-Glo™ luciferase assay 
system (Promega) was utilised to quantify relative protein expression levels. 
For this, isovolume of the Bright-Glo substrate was added onto the cell 
suspensions, incubated at room temperature for 5 minutes and luminescence 
was measured using MicroBeta2 2450 Microplate Counter (PerkinElmer). 
2.9 Quantitative real-time PCR (qRT-PCR) 
To investigate for the presence/levels of expression of various genes qRT-
PCR was utilised. For all qPCR reactions, QuantiTect SYBR Green PCR Kit 
(QIAGEN) was employed. The SYBR Green dye is an asymmetrical cyanine 
dye used as a nucleic acid stain in molecular biology. The dye preferentially 
binds to double-stranded DNA, resulting in a DNA-dye complex that absorbs 
blue light and emits green light. As the specific DNA sequence is amplified by 
the polymerase (e.g. Taq DNA polymerase) the amount of double-stranded 
DNA thus bound SYBR Green amount and the fluorescence of the sample 
increase. The number of PCR cycles taken to reach a threshold fluorescence 
(Ct) gives a measure of how much specific DNA sequence was present in the 
sample at the beginning of the qPCR program. Meanwhile, the presence of 
ROX, a passive reference dye, compensates for non-PCR-related variations 
in fluorescence detection. As fluorescence from ROX dye does not change 
during the qPCR, PCR-related fluorescent signals can be normalised using 
the ROX signal. Furthermore, to control for non-specific DNA amplification, 
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which is a potential drawback of SYBR Green-based detection, a melting curve 
is run, whereby the thermocycler detects the melting point of the PCR product. 
Detection of a single melting point is indicative of a single PCR product. 
Total RNA was isolated from cells using the RNeasy kit according to 
manufacturer’s protocol (QIAGEN). Using the extracted RNAs, cDNA was 
synthesised using the First Strand cDNA Synthesis Kit (Thermo-Fisher 
Scientific) according to the manufacturer’s information. Fold-expression level 
differences compared to the utilised house-keeping gene (β-actin) were 
calculated using the Ct values obtained.  Beta-actin gene was used as 
endogenous gene control.  
To convert the Ct value into a useful measure of DNA amount, absolute 
quantification was used throughout this thesis. Therefore, standards 
containing known quantities of the DNA sequence of interest were included in 
the qPCR, and Ct values from these were used to calculate a standard curve. 
Calculations for standards made for qPCR using HIV leader primers to detect 
reverse-transcribed LV provirus copies. The size of the plasmid was used to 
calculate the molecular weight of the molecule which was then used to 
calculate the weight of 1010 plasmid copies in nanograms (ng). 1010 plasmid 
copies/2 μl aliquot of the plasmid was prepared in nuclease-free water which 
was then serially diluted to obtain 108, 107, 106, 105, 104, 103, 102, 101 
plasmids/2μl. Linear regression was later utilised to calculate the number of 
copies of the DNA sequence of interest in the reactions containing genomic 
DNA according to the standard curve. 
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A master mix was prepared according to the manufacturer’s protocol.  23μl of 
the master mix was added into each well of a 96-well qPCR plate (Agilent). 
Next, 2μl of the standard, sample or water per reaction was added to 
corresponding wells to a final volume of 25μl per each well. qPCR plates were 
sealed with an optically clear adhesive tape (Thermo-Fischer Scientific) and 
centrifuged briefly. A Stratagene Mx3005P qPCR System (Agilent) was used 
to run qPCR reactions and the data were analysed using the MxPro Software 
(Agilent). 
2.10 Microscopy 
2.10.1 Bright field microscopy 
Wide-field light microscopy (Leica Microsystems) was used to visualise cells 
after Giemsa staining. HEK 293T cells were transfected with various VesG. 
One hour post incubation in various pH values, cells were washed with PBS, 
fixed in 100% methanol for 10 minutes, stained with Giemsa stain for 30-60 
minutes, and washed with tap water. Stained samples were then visualised 
using wide-field light microscopy via 10X or 20X objective lens. 
2.10.2 Confocal microscopy 
HEK 293T cells were transfected with various VesG. One hour post incubation 
in various pH values, cells were washed with PBS, fixed in 100% methanol for 
10 minutes, and stained with WGA (green) and SYTO® 61 (red) for cytoplasm 
and nuclei, respectively. Stained samples were visualised using SP8 X 
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Mouse  Dr Pule (UCL) 1:500 
Table 2-6. List of primary antibodies used. 
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Vector Primer name Sequence 
Tail-VesG 
VSV-flanking RS GAATTCTTACTTTCCAAGTCGGTTCATCTC 
PIRY-flanking FW ATCAACACGTGTCTAGAGCCACCATGGATC 
NJ-flanking FW ATCAACACGTGTCTAGAGCCACCATGCTG 
COCV-flanking FW ATCAACACGTGGCCACCATGAAT 
PIRY-inner FW CCAGGGATGGTTCAGTAGTTGGAAAAGC 
PIRY-inner RS GCTTTTCCAACTACTGAACCATCCCTGGATC 
NJ-inner FW GAGGGCTGGTTCAGTAGTTGGAAAAGC 
NJ-inner RS GCTTTTCCAACTACTGAACCAGCCCTCCAC 
COCV-inner FW GAAGGTTGGTTTAGTAGTTGGAAAAGCTCT 
COCV-inner RS CCAACTACTAAACCAACCTTCGATAAGCTC 
 
Table 2-9. Primers used for cloning the Tail-VesG.  
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Indiana virus (VSVind) – 
San Juan strain 
P03522 M35219 
Maraba virus (MARAV) F8SPF4 HQ660076 
Cocal virus (COCV) O56677 AF045556 
Vesicular stomatitis 
Alagoas virus (VSVala) 
B3FRL4 ACB47442 
Vesicular stomatitis New 
Jersey virus (VSVnj) – 
Ogden strain 
P04882 V01214 
Piry virus (PIRYV) Q85213 D26175 


































Figure 2-3. Gel electrophoresis displaying various steps of constructs cloning.  
(A) Gel electrophoresis showing cloning various genes for the pMD.2A plasmid backbone 
and, (B) various Vesiculovirus G proteins.  
Figure 2-4. Gel electrophoresis displaying various steps of cloning the chimeric G protein 
via overlap extension PCR.  
Gel electrophoresis showing cloning various segments of each chimerae (upper panel) and 
the final step of PCR ligating the two overlapping segments to create each of the chimeric 














Physical stability of 
transiently produced LVs 
pseudotyped with various 
vesiculovirus G protein 
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3.1 Overview   
Lentiviral vectors (LVs) are important tools for gene delivery into cells for gene 
therapy purposes. As LVs use in clinical gene therapy requires highly 
concentrated and high-purity vectors produced by large-scale preparations, 
the stability of LVs during production, concentration, and transduction is a vital 
practical consideration [227, 414]. Overall stability of the vector, mediated by 
its envelope glycoprotein, is dependent on several factors including 
temperature, pH, freeze-thaw frequency, and incubation and production 
conditions (i.e. growth media, CO2 levels).   
However, the stability of HIV-1 based vectors has not been well-characterised 
[415]. Previous studies have demonstrated that when incubated at 37°C half-
life of retroviral vectors lies between 3.5-7 hours dependent on the envelope 
utilised [416-418]. The envelope glycoprotein of vesicular stomatitis virus 
Indiana strain (VSVind.G) is the most commonly used envelope to pseudotype 
LVs as it provides the vector particles with high physical stability enabling 
vector concentration to higher titres using high-speed ultracentrifugation [201, 
419].  
Stability of the prototype VSVind virus has been investigated from a health and 
safety perspective. The wild-type virus was remarkably stable in long-term 
incubation at 4°C demonstrating minimal loss of infection after over a month;  
however, upon incubation at 37°C complete degradation of the virus and loss 
of infectivity was observed within 21 days [420]. However, a similar inactivation 
pattern was not observed when short-term incubation (i.e. up to 30 mins) on 
viral inactivation was tested. No significant decrease in viral infectivity was 
113 
 
detected when the virus was incubated in the temperature range of 20-46°C, 
but it was rapidly (i.e. in less than four mins) degraded when incubated at 
temperatures above 50°C. All in all, the data acquired from this study 
corroborated previous studies performed on rabies virus and other 
rhabdoviruses (e.g. mokolo virus, spring viremia of carp virus, and pike fry 
rhabdovirus) [421]. Therefore, it can be inferred that thermal stability 
characteristics are shared amongst the rhabdovirus subfamily.  
Through directed evolution studies, several key amino acid residues have 
been identified which confer VSVind.G thermostability [422]. Following several 
rounds of plaque rescue, several advantageous mutations including K66T, 
T368A, and E380K were identified which enhanced the G protein’s existing 
thermostability. This increased thermostability may be the result of formation 
of new disulfide bond and electrostatic interactions [423]. Furthermore, an 
increased thermostability may lead to better physical stability and improved 
vector recovery following freeze-thaw cycles. All in all, the generation or usage 
of more stable envelope G proteins will aid in the enhancement of vector 
production and potentially reducing the dosage needed in vivo. 
The LVs used in the clinic are produced transiently by DNA transfection of 
HEK 293T cells with three or four plasmids [229, 424], while a stable producer 
cell line will have the advantages of being cheaper, easily scalable with less 
batch to batch variation. 
The Collins/Takeuchi group developed packaging cell lines that can support 
the continuous production of LV, STAR packaging cells [240] as well as 
WinPac-RD packaging cell line [238]. They initially adopted a non-toxic 
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gammaretroviral envelope, from the feline endogenous virus RD114, with an 
altered cytoplasmic tail to allow LV incorporation, RDpro [240]. This was 
preferred to VSVind.G due to its reported high cytotoxicity and inactivation by 
human serum complement [211, 213]. Due to limited host tropism and reduced 
physical stability, which lead to suboptimal titres and virus recovery, the usage 
of the RDpro packaging cell line is limited.  
In 2010, Trobridge et al. published a paper in which lentiviral vectors were 
pseudotyped with the envelope G protein of Cocal virus (COCV). It has been 
reported that, in transient production systems, G protein of COCV (COCV.G) 
can efficiently pseudotype LVs producing relatively high titres (107 transducing 
units/mL). COCV.G LVs also demonstrated broad tropism as they could 
transduce a variety of cells of different origins including human, primate, and 
dog-hematopoietic progenitor cells. Moreover, compared to VSVind.G-
pseudotyped LVs, COCV.G-pseudotyped LVs showed more resistance to 
inactivation by human and dog serum, which shows promise for in vivo 
applications [243]. Lastly, some preliminary data suggest that COCV.G might 
be less cytotoxic compared to VSVind.G when expressed continuously [244]. 
These favourable characteristics would facilitate affordable large-scale vector 
production if COCV.G also demonstrates high vector stability like VSVind.G. 
This would greatly improve the range of clinical applications of LVs and would 
help propel the field of LV-mediated gene therapy forward [238]. 
Consequently, our laboratory decided to replace the RDpro envelope in 
WinPac-RD packaging cell line with that of Cocal virus to generate WinPac-
COCV.G cell line. The initial results of the test were rather promising, as 
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COCV.G seemed to show similar properties to its close phylogenetic relative 
VSVind.G [244].  
Therefore, well-structured research investigating COCV.G and other members 
of the vesiculovirus genus exploring their ability to pseudotype HIV-1 based 
LVs and the beneficial characteristics they confer upon the vector particles will 







Several vesiculovirus G proteins have been reported to have beneficial 
characteristics over VSVind.G (e.g. reduced toxicity and nonimmune serum 
resistance). Therefore, their adaptation to LV producer cells may lead to the 
generation of promising pseudotypes increasing the therapeutic potential of 
LVs in gene therapy. The work presented in this chapter was aimed towards 
evaluating various vesiculovirus G proteins for their ability to pseudotype HIV-
1 based LVs and the stability of the pseudotyped particles: 
• Investigate whether lentiviral vectors can be pseudotyped with other 
vesiculovirus G proteins including COCV.G, VSVnj.G, PIRYV.G, 
CHAV.G, VSVala.G, and MARAV.G. 
• Inspect whether other vesiculovirus G proteins are as robust as 





3.3 Results  
3.3.1 Development of pMD-2A-VesG constructs 
In order to examine the pseudotyping ability of the vesiculovirus G proteins, 
expression vectors were constructed. To allow for selection of G protein 
expressing cells a selectable marker, the Streptoalloteichus hindustanus 
phleomycin inhibitor (Sh ble) was expressed as a fusion protein with the G 
proteins, separated by a foot-and-mouth disease virus (FMDV) 2A-like self-
cleaving peptide [425, 426] (Figure 3-1A). 2A is an oligopeptide (usually 19–
22 amino acids) with a cleavage site located between the glycine and the last 
proline residues on its C-terminal end (indicated by an arrow in below 
sequence). Successful cleavage during translation results in two cleaved 
proteins: the protein upstream of the 2A which is attached to the complete 2A 
sequence apart from the C-terminal proline, and the protein downstream of the 
2A which is attached to the proline at the N-terminus [427]. The use of such 
peptides allows for expression of two (or more) proteins in a single open 
reading frame controlled by the same promoter. The 2A-like peptide chosen 
for the construct was derived from the insect virus Thosea asigna virus [426] 
and coded for twenty amino acids: RAEGRGSLLTCGDVEENPG↓P. 
Codon-optimised 2A peptide sequence as well as sequences of seven 
different vesiculoviruses, VSVind.G, COCV.G, VSVnj.G, MARAV.G, 
VSVala.G, and PIRYV.G, were subcloned into high expression plasmid 
backbone pMD2. As a control envelope RDpro, derived from the feline 
endogenous gammaretrovirus RD114 with a modifies cytoplasmic tail, was 
utilised [240], which has previously been adopted to two LV packaging cell 
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lines in the Collins/Takeuchi group [238, 240]. The G protein sequences were 
introduced into the C terminal end of the 2A peptide while Sh ble in the N-
terminal end. G proteins were subcloned either from previously constructed 
plasmids or from codon-optimised sequences obtained commercially (see 
section 2.2.2) generating the pMD-2A-VesG plasmids (Figure 3-1A). 
As the first step, pMD-2A-VesG constructs were examined for their 
functionality to ensure that the presence of the 2A peptide had no adverse 
effect on the G protein expression. To investigate this, HEK 293T cells were 
transfected with these constructs. 48 hours later, the cells were stained with 
goat anti-VSVind.G antiserum (VSV-Poly), and the envelope expression was 
determined via flow cytometry (Figure 3-1B). Although this antibody was 
produced against VSVind.G, cross-reaction with other G proteins was 
observed in earlier investigations (accepted manuscript [428]).  Expression of 
all G proteins was detected on the cell surface. The median fluorescence 
intensities of the signals detected, except that of CHAV.G, were at comparable 
levels to that of the saturated signal determined in affinity analyses [428, 429]. 
The fluorescent signal detected from cells expressing CHAV.G were 
comparable to that of mock-transfected HEK293T cells (Figure 3-1B). This 
may be due to lack of cross-reaction of the polyclonal antibody against the 
CHAV.G protein, or lower CHAV.G expression. 
Following detection of expression, the functional LV titres pseudotyped with 
these G proteins were investigated. LVs were generated via transient 3-
plasmid co-transfection. The vector containing media were harvested 48h after 
transfection and were titrated on HEK 293T cells to determine infectious titres.  
Titres indicated that all VesG were able to pseudotype HIV-1-based LVs 
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yielding functional vectors (Figure 3-1C). Moreover, all VesG except for 
CHAV.G (6.1x104), achieved high titres comparable (COCV- 7.5x106; VSVnj- 
4.3x106; PIRYV- 2.0x106; VSVala- 1.0x106; MARAV- 1.5x106) to that of the 







Figure 3-1. Construction of vesiculovirus G protein envelope expression plasmids. 
(A) Vesiculovirus G proteins were sub-cloned into the pMD2 plasmid backbone in which 
the marker gene, Sh ble, and the G protein are linked by the TAV 2A- self-cleaving peptide 
and therefore are controlled by a single CMV promoter. The Sh ble-G-protein fusion protein 
is flanked by an upstream bovine beta-globin intron and a downstream bovine growth 
hormone poly-A site. The restriction endonuclease enzyme sites used for subcloning are 
marked. (B) G proteins were expressed in HEK 293T cells and stained with VSV-Poly and 
analysed via flow cytometry to deduce transient envelope expression levels. (C) Functional 
titres of LVs pseudotyped with pMD-2A-VesG were produced by transient 3-plasmid 
transfection. LV containing media were collected and titrated on HEK 293T cells to 
determine the infectious titres. Data shown represent relative titres +/- SD for three 
experiments performed in duplicates. One-way ANOVA with Dunnett's post-test was 






3.3.2 Development of pMD-2A-Chimerae constructs 
Mapping key determinant dictating the envelope stability may be critical to 
tailor these G proteins to improve G protein-containing advanced therapy 
products as well as improve packaging cell line’s health and LV titres.   
Phylogenetic analysis of amino acid sequences of the G proteins, shows that 
COCV.G is closely related to VSVind.G [335]. The sequence alignment of the 
amino acid sequences of COCV.G and VSVind.G highlights the structural 
similarities between these two G proteins. These include N-terminal signal 
peptide [333] and two N-linked glycosylation sites at amino acids 180 and 337. 
As well as having the similar 4-domain structure, VSVind.G and COCV.G have 
72.5% sequence homology on the amino acid level (see Figure 1-2) [335]. 
Two sets of chimeric G proteins were generated between COCV.G and 
VSVind.G (Figure 3-2A). They were produced, based on amino acid 
alignment, by having the protein junctions in regions where the G proteins are 
conserved. Eight chimeric G proteins were created: series A (COCV.G N-
terminal, VSVind.G C-terminal) and series B (VSVind.G N-terminal, COCV.G 
C-terminal). These chimerae were sub-cloned into the pMD-2A backbone as 
the G proteins. The functionality of these constructs was investigated by 
producing transient LVs pseudotyped with pMD-2A-Chimerae constructs via 
3-plasmid LV production system. The unconcentrated titres were then 
determined by measuring GFP expression 48 post-transduction of HEK 293T 
cells via flow cytometry (Figure 3-2B). While all pMD-2A-Chimerae produced 
reasonable crude titres, 3-A titres were around 100-folds lower. To investigate 
the envelope expression of pMD-2A-Chimerae, HEK 293T cells were 
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transfected with these constructs. 48 post-transfection, the cells were stained 
with VSV-Poly, and the envelope expression was measured using flow 
cytometry. Analysed histograms indicate that all pMD-2A-Chimerae except 3-
A transfected cells express envelope G protein on their surface (Figure 3-2C). 
To further investigate the low envelope expression in 3-A construct, the 
transfected cells were also stained intracellularly using a monoclonal anti 
VSVind.G antibody (P5D4, Sigma). Analysed histograms show higher 
expression of 3-A in intracellular compared to extracellular staining (Figure 3-
2D). This data suggests that the mix-and-match of VSVind.G and COCV.G 
might have introduced some modifications in 3-A construct which might be 

























Figure 3-2. Construction of chimeric G protein envelope expression plasmids. 
(A) The design and the cross-over points of the chimeric G-proteins are represented in 
linear diagrams, in which black bars stand for wild-type (WT) VSVind.G sequences and 
WT COCV.G sequences are represented by white bars. The cross-over points between 
the two WT sequences is indicated by amino acid number above the bar. (B) A- and B-
chimerae were sub-cloned into the pMD-2A backbone. LVs pseudotyped with pMD-2A-
Chimerae were produced using 3-plasmid transient production. The titres of these vectors 
were calculated by measuring GFP percentage via flow cytometry. Data shown represent 
relative titres +/- SD for three experiments performed in duplicates. (C) Extracellular 
staining of A-chimerae (left panel) and B-chimera (right panel) with VSV-Poly 48 hours 
post-transfection. (D) Intracellular staining of A-chimerae (left panel) and B-chimera (right 
panel) with anti-VSVind.G antibody, P5D4, 48 hours post-transfection. These graphs are 
representative of one of two independent experiments performed in duplicates. One-way 




3.3.3 Physical stability of VesG-pseudotyped LVs  
To establish which vesiculovirus G proteins (VesG) are most promising to 
generate a stable packaging cell line, we decided to test the physical stability 
of the VesG-pseudotyped LVs. HEK 293T cells were co-transfected with HIV 
packaging, VesG or RDpro, and transfer vector (GFP) plasmids. Starting at 48 
hours post-transfection, the vector containing supernatant was collected, 
filtered and kept at 4°C. This was repeated for three consecutive days with 24 
hours intervals. On the day of the third collection, the pooled supernatant of 
each vector was concentrated using high-speed (87,119 g) ultracentrifugation 
and resuspended in a 1:300 of the original volume. To check the titres of the 
produced vectors, HEK 293T cells were transduced with both crude and 
concentrated vectors. The titres were determined by measuring GFP 
expression using flow cytometry. Figure 3-3 shows that LV with all 
vesiculovirus envelopes were readily concentrated to around hundred-fold 
higher titres by centrifugation (COCV- from 3.4x106  to 2.1x108; VSVnj- from 
1.9x106  to 2.2x108; PIRYV- from 1.0x106 to 2.2x108; VSVala- from 6.5x105  to 
3.3x107; MARAV- from 1.5x106 to 9.1x107), as was reported for VSVind.G 
(from 3.1x106  to 1.6x108). Moreover, all VesG-pseudotyped LVs could be 
recovered with high efficiency (overall average approximately 75%) following 
concentration indicating minimal envelope shedding due to shearing forces of 
the centrifugation process (Figure 3-3; right Y axis). On the other hand, 
although CHAV.G could also be concentrated to 100-fold higher (3.5x104 to 






Figure 3-3. High physical stability in VesG pseudotyped LVs. 
Transient LVs pseudotyped with VesG were concentrated using high speed 
ultracentrifugation. The titres before and after centrifugation indicate successful 
concentration of these vectors. For all pseudotypes, the percentage of recovery was higher 
than 50%, indicating minimal envelope shedding and robust physical stability. The graph 
represents three repeats from two separate transient LV production; error bars indicate +/- 
SD for three experiments performed in duplicates. One-way ANOVA with Dunnett's post-
test was performed to compare all VesG/RD titres to that of VSVind.G (*** p<0.001; ** 
p<0.01; * p<0.05).# 
127  
 
3.3.4 Thermal stability of VesG-pseudotyped LVs 
To further examine VesG-LVs, the transient vectors were also tested for their 
thermostability by several cycles of freezing-thawing, incubation at 37°C (heat 
block) for 2 and 6 hours, and incubation at 4°C (refrigerator) for 24 and 48 
hours.  
Figure 3-4 demonstrates the crude titres after the vectors went through 
multiple cycles of freeze-thawing. Data show that titres of most LVs remained 
stable throughout freeze-thaw cycles. RDpro LV titres were less stable and 
dropped considerably (~10-fold) after each freeze-thaw cycle compared to 
VesG LVs while CHAV.G-LV significantly lost infectivity after the second cycle. 
Figure 3-5 shows the percentage of recovery of LVs after going through 
freeze-thaw cycles or incubation at 37°C and 4°C. VSVind.G, COCV.G, 
VSVnj.G, and PIRYV.G did not lose infectivity after freeze-thaw cycles, also, 
COCV.G recovery seemed to exceed that of VSVind.G (90% vs 85%, 
respectively (p<0.001). VSVala.G and MARAV.G infection dropped from 
around 80% to approximately 70%, and RDpro infection dropped from around 
60-50% compared to their respective original titres.  
VSVind.G and COCV.G demonstrated similar sensitivity to incubation at 4°C.  
Although a slight decrease in infectivity was observed, 10% after 24 hours and 
a further 10% after 48 hours, overall both pseudotypes were stable. Similarly, 
VSVnj.G and MARAV.G were robust and retained infection levels at more than 
80% for up to 48 hours of incubation. VSVala.G infection dropped slightly from 
around 90-70%. In contrast, PIRYV.G seemed to be less stable at 4°C 
compared to other VesG as the percentage of infectivity dropped from around 
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70% after 24 hours incubation to around 60% at 48 hours. CHAV.G LVs were 
substantially sensitive to incubation at 4°C losing more than half of their 
original titres within 24 hours. However, following this initial loss of titre, the 
infectivity remained constant (around 30-40%). RDpro LVs were also highly 
sensitive to incubation at 4°C; their infectivity dropped from around 60% after 
24 hours to around 20% after 48 hours.  
Furthermore, COCV.G, VSVala.G, and MARAV.G seemed to be following a 
similar pattern of retaining around 90% infectivity for up to 6 hours at 37°C. 
VSVind.G and VSVnj.G LVs infectivity remained stable (around 100%) for up 
to two hours of incubation at 37°C however, infectivity dropped to around 80% 
after additional 4 hours of incubation. RDpro-LVs retained stable infectivity 
(around 70%) for up to 6 hours of incubation while CHAV.G infectivity dropped 
from around 70% after 2 hours of incubation to around 60% up to 6 hours of 









Figure 3-4. Sensitivity of VesG-LV to repeated cycles of freezing and thawing. 
VesG and RDpro LVs went through three cycles of freeze-thawing (x-axis). HEK 293T cells 
were then transduced with these vectors and 48 hours later the titres were measure by 
GFP expression using flow cytometry.  Error bars indicate mean titres +/- SD of three 
repeats performed in duplicates, from two separate batches of transient LV productions. 
One-way ANOVA with Dunnett's post-test was performed comparing 1x, 2x, 3x to the 








Figure 3-5. Thermostability of VesG pseudotyped LVs. 
The relative titres of VesG-LV were calculated after LVs underwent several different 
thermostability assays (i.e. freeze-thaw, incubation at 4ºC and 37ºC). Data represent the 
mean value of three repeats performed in duplicates, from two separate batches of 
transient LV productions. The titres are presented as a percentage of titre before 
commencing the thermostability test. One-way ANOVA with Dunnett's post-test was 
performed to compare all VesG to the gold standard VSVind.G (*** p<0.001; ** p<0.01; * 










































 3.4 Discussion 
Maintaining virus viability over long periods with little or no change of infectivity 
is valuable for research and clinical applications. The manufacture of gene 
therapy products comprises several steps: vector production and purification, 
storage, and application of the vectors for gene transfer. Throughout these 
steps, vectors can get inactivated which can affect the final quality and efficacy 
of the vector preparations as well as vector transduced cells [430].  In addition, 
the efficiency of transduction into primary cells using viral vectors depends on 
the initial viral titres applied and on the stability of vector during the 
transduction period [431, 432]. Moreover, compounds of cellular origin 
released into the medium might affect gene transfer results negatively [433].  
For ex vivo transduction, cells are isolated from a patient and externally 
propagated. In that case, the stability in growth medium is predominant. For in 
vivo applications, vectors are mostly delivered to the bloodstream and 
therefore the stability in the human blood is of interest. Both procedures 
require stable particles. Additionally, in the in vivo approach, the biological 
stability of the vectors in the presence of the immune system is of great 
importance [434]. 
Lentiviral vectors are used commonly for gene transfer protocols while their 
use is expanding rapidly in gene therapy clinical trials. These vectors present 
the main advantage of being able to insert the gene of interest into the host 
cell genome in both dividing and non-dividing cells [435, 436].  Nevertheless, 
the production of lentiviral vectors presents several problems. One of the most 
critical is the low stability of these vectors. For in vitro cell transduction, crude 
(unconcentrated) vector stocks are often sufficient, whereas concentrated 
132  
 
vector stocks are needed for in vivo applications. Concentrating lentiviral 
vector stocks are typically performed using ultracentrifugation approaches 
[437, 438]. This is a rapid and robust method for vector concentration at a 
small scale. However, the low stability of the vectors affects their production, 
storage, and efficacy in preclinical and clinical settings, making high-quality 
clinical preparations a challenging goal to achieve [430]. At 37°C, these 
vectors are less stable, which is a critical issue concerning the efficacy of viral 
preparations in clinical studies. During purification and short-term storage, LVs 
are usually kept at 4°C while for long-term storage; they are kept at -80°C 
however, freeze-thaw has a detrimental effect on viral titres [439].  
Amongst other advantages, to increase the overall vector particle stability, LVs 
are commonly pseudotyped with VSVind.G proteins. Nevertheless, due to 
some drawbacks pertaining to VSVind.G, alternative envelopes have been 
studied for LV pseudotyping. The work presented in this chapter aimed to 
investigate the stability of lentiviral vectors at temperatures relevant for 
production and usage: 37°C and 4°C, in freeze-thaw cycles as well as to check 
the physical stability of the vectors by ultracentrifugation. 
3.4.1 Development of vesiculovirus G protein-pseudotyped 
lentiviral vectors and their physical and thermal stability 
Transient LVs pseudotyped with VSVind.G, COCV.G, VSVnj.G, PIRYV.G, 
CHAV.G, VSVala.G, MARAV.G, and RDpro were produced to establish which 
vesiculovirus are most promising to generate a stable packing cell line with.   
As there are only specific commercial antibodies available against VSVind.G, 
All VesG were stained with goat anti-VSVind.G antiserum, VSV-Poly, which 
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can cross-react with VesG other than VSVind.G (accepted manuscript  [428]) 
in order to examine the expression of the G proteins on the cell surface 
following transfection of HEK 293T cells.  
Figure 3-1 demonstrates that all VesG except CHAV.G were able to 
pseudotype LVs with titres comparable to that of VSVind.G and exceeding that 
of RDpro. Furthermore, they could readily be concentrated by 
ultracentrifugation at 22,000 rpm (87,119) for 2 hours at 4°C. As VSVind.G 
pseudotyped LVs are stable, these vectors were expected to produce high 
titres before and after concentration. All VesG pseudotyped LVs except for 
CHAV.G, produced crude titres of around 106 TU/mL and concentrated titres 
of around 108 TU/mL or higher (Figure 3-2). This shows that these VesG can 
produce LVs with high vector particle stability. CHAV.G produced LVs with 
crude titres of around 104 TU/mL and concentrated titres of around 106 TU/mL, 
which are considered too low titres to be useful for gene delivery purposes. 
VesG vectors were also stable during freeze-thawing achieving recovery 
levels of minimum 80% on average (CHAV.G excluded). Under different 
incubation conditions, the infectivity recovery varied amongst different G 
proteins (Figure 3-4). Overall, COCV.G, VSVnj.G, VSVala.G, and MARAV.G, 
similar to VSVind.G, seemed to be stable under all three conditions. PIRYV.G 
was stable during freeze-thaw cycles and at 37°C, yet the percentage of 
recovery after 48 hours incubation at 4°C dropped to around 60%.  
In contrast, CHAV.G and RDpro vectors were less stable after freeze-thawing 
and incubation at 4°C however, short-term (<6 hours) incubation at 37°C did 
not decrease their infectivity dramatically (p<0.001). Due to CHAV.G 
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pseudotyped LVs demonstrating low titres even after concentration (p<0.001), 
as well as the low performance in thermostability experiments, we decided to 
exclude this G protein from our further experiments.   
In summary, we have compared, by identical technique, the effect of 
temperatures, centrifugation and freeze-thawing upon the viability of HIV-1 
based LVs pseudotyped with VesG. All G proteins except for CHAV.G were 
overall stable in all conditions demonstrating decay rates comparable to that 
of VSVind.G. Their resistance to 37°C incubation is promising as it will allow 
systemic and local delivery of LVs in vivo without the concern of body-
temperature dependent loss of titre. Furthermore, robust vector stability 
demonstrated at 4°C and during freeze-thaw cycles is useful for short and 
long-term storage of the vectors. Taken together, these results support further 
consideration of COCV.G, VSVnj.G, PIRYV.G, VSVala.G and MARAV.G LV 
for their use in stable packaging cell lines for preclinical and clinical 
applications. 
3.4.2 Development of chimeric G proteins and their 
functionality 
To investigate the key elements affecting the envelope stability, based on G 
proteins of VSVind and COCV, I created eight mix-and-match chimeric G 
proteins. Four of these chimerae (A-chimerae) have COCV.G N-terminal and 
VSVind.G C-terminal; while the other four (B-chimerae) have VSVind.G N-
terminal and COCV.G C-terminal. These chimeric G proteins were sub-cloned 
into the pMD-2A backbone as the G proteins.  
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Overall, all chimeric G proteins were successfully produced, except 3-A, 
demonstrated similar transduction ability and protein display characteristics 
compared to their wild-type counterparts (figure 3-1). Although highly 
conserved amino acid sequences were targeted in the generation of the 
chimerae, 3-A’s LV titre was significantly lower than the other seven G proteins 
(p<0.001). Antibody binding assays revealed that 3-A faced membrane 
trafficking issues and was trapped in the intracellular compartments of the cell 
(figure 3-5C/D). The cross-over point of 3A corresponded to the lateral domain 
of VSVind.G and is close to one of the N-linked glycosylation sites of the WT 
protein [2, 332]. Therefore, the switch of this domain with that of COCV.G 
might be hindering post-translational modifications preventing the protein to 
be transported to the cell membrane. In addition, although there were no 
substantial stability differences between the chimerae they were later utilised 
to map serum sensitive determinants on VSVind.G (in press [440]). Thus, 
generation of such chimerae with PIRYV.G or CHAV.G could provide insights 
on other biochemical characteristics of VesG including thermal stability. Partly 
because no substantial difference in stability between VSVind.G and COCV.G 
was observed, these chimeric constructs were not studied for stability. 
Furthermore, understanding the destabilising mechanism enforced on VesG 
pseudotyped vectors in variable conditions will provide valuable insights 
regarding approaches to improve vector stability further. In addition, the effect 
of thermal and physical conditions on HIV-1 capsid and matrix proteins which 
have essential roles in LV structure should also be investigated. Combined, 
this will allow modification of LVs and G protein-containing advanced therapy 
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medicinal products to generate more stable regents with better longevity under 














Investigating the fusogenic 
activity and cytotoxicity of 





Vesicular stomatitis virus (VSV) is a well-studied virus with a small genome 
that can be easily manipulated. In addition to its broad tropism and ability to 
infect target cells with high efficiency, VSV has intrinsic oncolytic properties 
[403]. These characteristics of VSV, as well as its short replication cycle, 
makes it a promising platform for oncolytic virotherapy [441].   
VSV pathogenesis in natural hosts depends on the virus serotype. The two 
major serotypes of VSV, Indiana and New Jersey, are endemic in Central and 
South America and some regions of the USA. Their natural hosts include 
cattle, pigs, horses, and their insect vectors. However, VSVind and VSVnj do 
not have the same pathogenicity; VSVnj causes more frequent and severe 
outbreaks compared to VSVind strain [214, 405].  
The high toxicity of VSV was mainly attributed to its matrix protein (M).  This 
protein promotes viral pathogenesis by inhibiting host gene expression, acting 
on both nuclear transcription and RNA transport, and inducing apoptosis [442]. 
Nevertheless, M-mutant VSVs were found to trigger apoptosis via a distinct 
pathway compared to wild-type VSV. This has been shown to be due to fusion 
caused by the viral G protein. 
It was reported that VSV infection could lead to cell fusion when G protein 
accumulates on the cell surface [443]. Cell fusion was shown to be dependent 
on the interaction between positively charged amino acid residues in G 
proteins and the negatively charged membrane surface [444]. In addition, 
protonation of histidine residues (His) in acidic pH has been reported to 
promote fusion [382]. VSV enters the cells through receptor-mediated 
139  
 
endocytosis. The acidic environment of the endosome induces a fusion-
competent form of the G protein allowing the viral envelope to fuse with the 
endosomal membrane releasing the viral RNA genome into the cytoplasm 
[445]. This fusogenic activity is claimed to be a sign of toxicity for VSV G 
protein [215]. After infection, the adjacent infected cells are fused together to 
form large multinucleated syncytia. A similar syncytia formation mediated by 
viral envelope protein has been reported for other viruses such as Gibbon Ape 
leukaemia virus and respiratory syncytial virus where the resulting syncytia are 
destined to apoptosis [217, 218].  
To improve the vector particle stability as well as to increase its tropism, LVs 
are commonly pseudotyped with vesicular stomatitis virus Indiana strain G 
protein (VSVind.G) [129, 211, 446]. To generate clinically suitable LVs 
however, stable production of these vectors is advantageous as this will aid to 
improve biosafety by standardising the production process and reducing the 
risk of DNA recombination. In addition, a stable producer cell line will reduce 
the cost of producing large batches of vectors required for clinical and some 
preclinical use in large animals [233, 238]. The development of a stable 
packaging cell line for LVs proved to be challenging due to cytotoxicity of some 
viral components such as the Gag-Pol proteins. Moreover, VSVind.G has been 
reported to be toxic to cells when expressed continuously [211, 238] which 
was attributed to its high fusogenic activity causing syncytia formation and 
apoptosis. This affects the integrity of the stable producer cells utilising this G 
protein affecting vector titres. Several cell lines have been developed so far 
either by using alternative G proteins or inducible expression, however; they 
demonstrated either low titres or limited tropism [447-450].   
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To overcome the toxicity issue of VSVind.G, other vesiculovirus G proteins 
have been proposed as alternative proteins. However, no studies have been 
done to investigate whether the cytotoxicity issue is shared amongst these 
family members. Therefore, a detailed analysis of their cytotoxicity and pH-





The work presented in this chapter aimed at investigating the fusogenic activity 
and relative cytotoxicity of the vesiculovirus G proteins.  Initially, the effects of 
pH on VesG mediated syncytium formation and VesG-LV were explored.  The 
difference in G protein-mediated cytotoxicity was also examined, and the 
generation of cell lines stably expressing VesG was attempted for LV 




4.3.1 Fusogenicity in vesiculovirus G protein expressing 
cells 
Cocal virus envelope G protein (COCV.G) has been utilised to generate a 
stable producer cell line for LV production [237]. VSVind.G and COCV.G have 
a high level of homology on the amino acid level (~72%) conferring them some 
shared advantageous characteristics including stability and broad tropism. 
Yet, it has been suggested that COCV.G is less cytotoxic compared to 
VSVind.G [237, 243]. Consequently, the fusogenicity of COCV.G under mildly 
acidic pH in comparison to VSVind.G was investigated, as a reference for 
toxicity. 
First attempts were carried out using HEK 293T cells.  However, they proved 
to be pH sensitive and easily detached from the plate after incubation at acidic 
pH and atmospheric CO2 conditions. Therefore, TE671 cells (human 
rhabdomyosarcoma cell line) were utilised instead as they are less pH 
sensitive compared to HEK 293T cells. TE671 cells were co-transfected 
transiently by a luciferase expressing plasmid, pHV-Luc (as transfection 
efficiency control), and VSVind.G or COCV.G. 72 hours post-transfection, 
media was replaced with fresh Minimum Essential Medium (MEM) adjusted to 
pH 6.0 and 5.0. Cells were incubated at 37ºC in atmospheric CO2 for one hour, 
were washed and fixed in methanol.  The cells were then stained with Wheat 
germ agglutinin (WGA) and SYTO® 61 for cytoplasmic membrane and nucleus 
staining, respectively. The cells were then visualised using a Leica SP8 X 
confocal Laser Scanning Microscope (Figure 4-1).  
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Interestingly, at neutral pH, both VSVind.G and COCV.G formed a few 
syncytia compared to un-transfected cells (approximately 1-2 per field of view). 
When the pH value was reduced to 6.0, an expanded cytoplasm was observed 
in un-transfected, yet no fusion was observed in these cells. This change in 
the shape might be due to the acidic extracellular condition affecting the 
intracellular pH and Ca2+ [451, 452]. On the other hand, both VSVind.G and 
COCV.G expressing cells demonstrated a higher number of syncytia per field 
of view compared to that of neutral pH. While both G proteins induced cell 
fusion at this pH, the syncytia formed by VSVind.G expressing cells were 
visibly larger and contained more nuclei (>10 nuclei) compared to that of 
COCV.G.   
At pH 5.0, while un-transfected cells retained their elongated shape, no fusion 
was observed. In transfected cells, however, cells seemed very unhealthy; 
expanded cytoplasms of cells were fused to generate large syncytia.  
Multinuclear syncytia of at least eight nuclei were observed and in places, 
especially in VSVind.G expressing cells, all remaining cells seem to have 
fused together. The morphology of fused cells in both transfected cells were 
rather different from un-transfected cells.  






Figure 4-1.  Fusogenicity in VSVind.G and COCV.G expressing cells. 
TE671 cells were co-transfected with pHV-Luc and plasmids expressing VesG. (A) 
Luciferase activity was checked with Bright-Glo™ Luciferase Assay system as a reporter 
for transfection efficiency. Data shown is the mean value of one experiment performed in 
duplicates. (B) One-hour post incubation in various pH values, cells were washed, fixed, 
and stained with WGA (green) and SYTO® 61 (red) for cytoplasm and nuclei, respectively.  
Stained samples were visualised using a Leica SP8 X confocal Laser Scanning 






The fusogenic activity has been related to cytotoxicity in VSVind.G [215] while 
COCV.G was reported to be less cytotoxic. Yet, VSVind.G and COCV.G 
displayed similar characteristics regarding fusion and syncytia formation in 
acidic pH. This suggests that COCV.G might be as toxic to cells as VSVind.G. 
To further investigate the syncytia formation of other VesG, in addition to 
VSVind.G and COCV.G, VSVnj.G and PIRYV.G were also incubated in pH 
7.0, 6.0, and 5.0. A similar protocol to above was followed by cell staining with 
Giemsa stain to check for syncytia formation. The cells were then checked 
using bright-field microscopy (Figure 4-2).  
At pH 7.0, 6.0, and 5.0, as expected, cell fusion was observed in both 
VSVind.G and COCV.G expressing cells. For both, the syncytia looked smaller 
in neutral pH while in acidic pH they seemed larger and included a higher 
number of fused cells (i.e. higher numbers of nuclei per syncytia).  At pH 5.0, 
cells seemed to be very unhealthy compared to those of un-transfected cells, 
as they were lifted off the plate in both VSVind.G and COCV.G but looked 
more severe in VSVind.G.   
On the other hand, expression of VSVnj.G and PIRYV.G did not lead to cell 
fusion in neutral pH.  However, upon acidification of the environment, syncytia 
were formed in both G protein-transfected cells. At both pH 6.0 and 5.0, 
VSVnj.G induced smaller syncytia containing less number of cells, and the 
morphology of the cells was similar in both these pH values. PIRYV.G 
however, induced the formation of larger syncytia in both pH 6.0 and 5.0.  
Moreover, the number of syncytia formed seemed higher in PIRYV.G 
compared to VSVnj.G (approximately double). The level of fusogenicity of this 
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G protein seemed to be higher in pH 6.0 compared to pH 5.0 as most cells 
seemed to either be involved in fusion or very unhealthy. 
Overall, VSVind.G and COCV.G demonstrated similar characteristics in terms 
of cell fusion and syncytia formation that was distinct from that of VSVnj.G and 
PIRYV.G infected cells. This might be due to differences in fusogenicity, lower 
pH threshold for fusion, or other characteristics of the G protein such as the 
nature of the conformational changes the VesG go through. Next, we decided 














Figure 4-2.  Fusogenicity vesiculovirus G protein expressing cells. 
TE671 cells were co-transfected with pHV-Luc and VesG. (A) Luciferase activity was 
checked with Bright-Glo™ Luciferase Assay system as a measure of transfection 
efficiency. (B) Envelope expression in transfected cells stained with VSV-Poly antiserum.  
(C)  One hour post incubation in various pH values, cells were washed, fixed, and stained 
with Giemsa stain. Stained samples were visualised using wide-field light microscopy. 






4.3.2 Vesiculovirus infectivity levels in various pH values 
In infections by enveloped viruses, the fusion of the viral membrane with the 
host cell follows the initial step of receptor attachment. In VSV, the G protein 
is the sole viral protein that mediates both attachment and fusion. A three-
stage model has been proposed for VSV.G fusion: first, the G protein 
undergoes pH-dependent conformational changes from the pre-fusion to an 
extended open form. This open conformation results from protonation of each 
G monomer. The extended form of G protein directs the fusion loops 
positioned in the Pleckstrin homology domain (PHD) towards the target 
membrane. The adjacent extended monomers are then trimerised and fold 
back to bring the two membranes together [2, 332, 453].  
While pH-dependent conformational changes of VSVind.G has been well 
studied, no data have been reported for other vesiculovirus G proteins. Hence, 
we planned to investigate the effect of pH changes on VSVind.G, COCV.G, 
VSVnj.G, and PIRYV.G pseudotyped LVs. VesG pseudotyped LVs were 
incubated at 37ºC for 30 minutes in pH values ranging from 2.0 to 10.0. These 
LVs were then plated on HEK 293T cells in neutral pH at MOI 1.0. 48 hours 
post-transduction, the infectivity of VesG-LVs was investigated by measuring 
GFP expression in challenged cells (Figure 4-3).    
Figure 4-3A demonstrates that all LVs remained infectious after incubation at 
pH values between 10.0 and 5.0. In pH ranges lower than 5.0 (i.e. 4.0 and 
2.0), the infectivity of all LVs reduced gradually, then was completely 
abrogated (i.e. dropped to 0% GPF expression) at pH 2.0. These results were 
in line with previous studies reporting that VSV is more sensitive to acidic 
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conditions compared to alkaline conditions [454]. Moreover, all four LVs 
followed a similar pattern of infectivity at various pH values to that of VSVind.G.    
Accordingly, we decided to investigate the effects of lower pH ranges more in-
depth. Therefore, the experiment was repeated where LVs were incubated in 
pH ranges from 7.3 to 2.0, with 0.3-0.4 intervals (Figure 4-4B). The 
normalisation of the GFP expression to that of pH 7.0 revealed that at pH 
between 3.6 and 3.3, the infectivity of VSVind.G, VSVnj.G, and PIRYV.G drop 
drastically. At pH 3.3, while VSVind.G-LV infectivity reduced by more than half, 
GFP expression was almost undetectable in cells challenged with VSVnj.G- 
and PIRYV.G-LV. COCV.G infectivity seemed to reduce by 50% when the pH 
was decreased from 4.0 to 3.6. COCV.G-LV infection was completely blocked 
by reducing the pH further to 3.3. These results may suggest that the pH 
threshold of COCV.G conformational change is slightly higher than the other 
G proteins tested. All VesG infectivity demonstrated similar trends between pH 
6.0 and 5.0, infectivity remaining stable compared to neutral pH.    
Overall, the data show that the inactivation point for all LV’s infectivity lies 
between pH 3.0-3.6 with pH 3.0 being the endpoint of infectivity for all VesG.  
This contradicts previously published data reporting pH 2 as the point of 
deactivation for recombinant VSVind virus [454]. Furthermore, at pH levels 
below 5, VSVind.G and VSVnj.G seem to be more infectious compared to 
COCV.G and PIRYV.G (COCV.G/PIRYV.G infectivity approximately around 
40-50% while NJ/IND around 70-80%). However, until pH 3.6 and below, 
overall infectivity of all VesG was retained at >50%. This implies that all VesG 
tested can go through a wide range of pH changes during which they can 
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remain infective. In addition, no striking difference was observed between 

















Figure 4-3.  pH-dependent inactivation of VesG-LV. 
VSVind.G, COCV.G, VSVnj.G, and PIRYV.G pseudotyped LVs were incubated at 37ºC for 
30 minutes in pH values ranging from 2.0 to 10.0. These LVs were then added on HEK 
293T cells in neutral pH at an MOI of 1 TU per cell. (A) The percentage of GFP expression 
indicative of LV infectivity, was measured by flow cytometry 48 hours post-transduction. 
The percentage of live cells is indicated in dotted lines (right axis). (B) The experiment was 
repeated with more in-depth investigation of pH range 2-7.3. Measured GFP expression 






Following the establishment of pH-dependent VesG-LV inactivation by testing 
the infectivity of VesG-LV pre-treated at different PH, we decided to investigate 
the effects of pH on viral attachment and following steps, by conducting the 
infection while cells are incubated at different pH range. For this, cells were 
challenged with LVs via spinoculation in media adjusted to a range of pH. After 
the spin (2,000 g, for 30 minutes at 4ºC), the LV containing media with different 
pH were removed from the cells and was replaced with media with neutral pH. 
48 hours post-infection, the GFP expression was measured in cells. This 
experiment was based on the hypothesis that at different pH range, G proteins 
go through conformational changes resulting in pre- or post-fusion forms. 
While in the pre-fusion form, the G protein will be able to interact with its 
putative receptor and enter the cells, the change to the post-fusion structure 
will block this interaction.  
LV infectivity was completely abrogated between pH 3.3 to 3.6, while cell 
viability was more than 50% (Figure 4-4A). This profile is similar to that shown 
in Fig 4-3B, suggesting that the observation resulted, at least partly, from pH-
dependent VesG-LV inactivation. A maximum level of infection was observed 
at pH 6.0 to 6.6 implying the highest level of interactions and attachment of G 
proteins to receptors and internalisation at this pH range. In some cases even 
direct fusion might have been achieved as the pH range in early and late 
endosomes, where VSVind.G-LV fuses, are around 6.5 and 5.5, respectively 
[455]. In line with this, Figure 4-4B shows the relative infection rates at different 
pH compared to that of neutral pH. It can be observed that the infectivity levels 
gradually increase as pH decreases from 7.0 to 6.0, reaching a maximum 
around pH 6.0-6.3.    
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Furthermore, compared to VSVind.G and VSVnj.G, COCV.G and PIRYV.G 
lost infectivity much faster, especially for COCV.G where the infectivity 
dropped suddenly when the pH was reduced from 6.0 by only 0.4 points to 
5.6. On the other hand, VSVind.G and VSVnj.G still had higher infectivity at 
pH 5.0-5.3 compared to pH 7.0 suggesting a lower pH threshold for shifting to 



























Figure 4-4.  Effect on LV infection of pH at LV attachment to the cell. 
HEK 293T cells were challenged with VesG LVs via spinoculation in the presence of media 
adjusted to various pH. Following spinoculation the media was removed, cells were 
washed, and complete media in neutral pH was added. GFP expression and live cell 
percentage was measured 48 hours post-challenge via flow cytometry. (A) Measured GFP 
expression was normalised to that off pH7 control. Dotted lines represent the percentage 
of live cells (right axis). (B) The relative infection change compared to neutral pH 7.0. Data 
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4.3.3 Investigating the cytotoxicity of vesiculovirus G 
proteins 
As discussed in section 3.3.1, to allow for the selection of G protein expressing 
cells, the phleomycin resistance gene was linked to the G protein via the 2A 
self-cleaving peptide in the pMD-2A-VesG constructs. The use of 2A peptide 
allows for both the G protein and the marker gene to be controlled by a single 
promoter. This allows the co-expression of both genes at a more similar ratio 
compared to genes expressed under two separate promoters [427]. This 
feature was essential for this assay enabling us to have a more reliable 
comparison of expression of different VesG after phleomycin selection.  
The high fusogenic activity of VSVind.G is linked to high cytotoxicity through 
syncytia formation and apoptosis [201]. On the other hand, COCV.G, a 
phylogenetically close vesiculovirus G, was reported to be less cytotoxic 
compared to VSVind.G [237]. However, the data presented thus far through 
investigating syncytia formation and the effect of pH changes on various VesG, 
demonstrated that the VesG tested do not exhibit major differences. This 
suggested that all VesG might be equally cytotoxic.  
Accordingly, to compare relative toxicity levels amongst different VesG, HEK 
293T cells were co-transfected with pHV-Luc and VesG including VSVind.G, 
COCV.G, VSVnj.G, PIRYV.G, VSVala.G, and MARAV.G. 48 hours later, the 
luciferase activity of the cells was checked to determine relative transfection 
levels (Fig 4-5A) and 2.5x104, 5.0x103, and 1.0x103 of transfected cells per 
well were seeded in 6-well plates. These cells were selected with phleomycin 
for up to one week to ensure the selection of G protein expression. After seven 
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days of selection, G protein expression was measured on cells by staining with 
VSV-Poly antiserum (Figure 4-5B). Cells were then washed with PBS, fixed in 
methanol and stained with Giemsa stain. The number of colonies grown in 
cells transfected with various G proteins was investigated (Figure 4-5C). While 
higher levels of cytotoxicity would lead to reduced numbers of colonies, higher 
numbers of colonies indicate less cytotoxicity. In this assay, VSVind.G was 
used as the positive control for cytotoxicity [215] while RDpro envelope, a non-
toxic feline retrovirus, was used as negative control [238].  
Interestingly, compared to RDpro, the negative control (in LFA backbone 
which was adapted to WinPac-RD cell line [238]), all envelopes yielded a 
similar number of phleomycin resistant colonies, with approximately one 
colony per one hundred transfected cells. Colony numbers in VSVind.G, the 
positive control, seem to be higher in all cell dilutions compared to that of 
COCV.G and RDpro. This data challenges the well-accepted concept of 
VSVind.G being highly toxic to cells [201]. The similar number of colonies 
formed by all VesG in all dilutions were comparable to that of non-toxic RDpro 























Figure 4-5. Colony formation of various vesiculovirus G proteins in the presence of the 
selection marker. 
To compare the cytotoxicity in various VesG, HEK 293T cells were co-transfected with 
pHV-Luc and pMD2-2A-VSVind.G, -COCV.G,-VSVnj.G, -PIRYV.G, and RDpro. 48h post-
transfection; (A) Luciferase expression was checked as a measure of transfection 
efficiency. Data shown mean of two repeats performed in duplicates/triplicates. (B) After 7 
days in selection, cells were stained for G protein expression by VSV-Poly antiserum. (C) 
Cells were seeded in different dilutions (seeding density is indicated) and were selected 
with phleomycin for one week, then fixed and stained with Giemsa. Similar number of 
colonies were formed for each construct suggesting that all these G proteins have similar 






4.3.4 Long-term G protein expression and support for LV 
production 
Based on obtained data highlighting that all VesG share similar level of 
cytotoxicity, comparable to that of non-toxic RDpro, we decided to investigate 
the long-term expression of G proteins and the effect this might have on viral 
titres. For the first attempt, HEK 293T cells were transfected with VSVind.G, 
COCV.G, VSVnj.G, and PIRYV.G plasmids. These cells were kept in 
phleomycin selection as bulk populations for up to 14 weeks. During this 
period, the envelope expression was monitored every two weeks using the 
antiserum VSV-Poly. VSV-Poly binds to VSVind.G with high affinity, while it 
has an intermediate affinity to COCV.G and weak affinity to VSVnj.G and 
PIRYV.G (Figure 4-6A). The flow cytometry histograms indicated that although 
G protein expression gradually decreased over time in all stable VesG 
expressing cells (Figure 4-6B), VSVind.G and COCV.G could still be detected 
for up to 22 weeks (Figure 4-6C). Cells were also transiently transfected with 
gag/pol, rev, and SIN-pHV (coding for GFP transgene) over time to produce 
transient LVs. For all VesG, the transient LV titres were around 106 TU/ml after 
six weeks of phleomycin selection (Figure 4-6D). A ten-fold reduction was 
observed after ten weeks of selection in all VesG. After this time point, while 
VSVind.G and COCV.G still produced LVs, vectors titres were undetectable in 
VSVnj.G, and PIRYV.G so was G protein expression via flow cytometry. 
VSVind.G and COCV.G stable expressing cells were kept in selection for 
further ten weeks. The G protein expression fell gradually in VSVind.G 
expressing cells over this period (Figure 4-6C). Moreover, while transient LV 
titres were stable around 105 TU/ml for up to 14 weeks in selection, they also 
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fell gradually over the next four weeks. The LV titres could not be detected at 
week 22 post-selection. On the other hand, COCV.G envelope expression and 
transient LV titres remained detectable for up to 22 weeks of selection. While 
the titres reduced slowly over time, they were still around 104 TU/ml at week 


































Figure 4-6. Long-term G protein expressing cells and long-term vector production. 
HEK 293T cells were transfected with VSVind.G, COCV.G, VSVnj.G, and PIRYV.G. (A) 
Transient G protein expression was measure by VSV-Poly antiserum 72 hours post-
transfection via flow cytometry. (B) Stable G protein expression in transfected cells kept in 
phleomycin selection was measured for up to 14 weeks. (C) Stable G protein expression 
levels in VSVind.G and COCV.G was measured in cells kept in selection for up to 22 
weeks. (D) Transient VesG-LV titres were measured over the course of selection; Data 



























Achieving stable envelope expression in cells for around 5 months, especially 
for VSVind.G that is considered to be cytotoxic, was a promising result which 
prompted us to try a similar approach with two additional VesG: VSVala.G, 
and MARAV.G. Consequently, HEK 293T cells were co-transfected with pHV-
Luc and VSVind.G, COCV.G, VSVnj.G, PIRYV.G, VSVala.G, and MARAV.G.  
Luciferase activity was measured 48 hours post-transfection (Figure 4-7A).  
Cells were kept in phleomycin selection for up to 14 weeks, during which 
envelope expression and transient LV titres were measured every two weeks.  
Envelope expression was measured by staining with VSV-Poly antiserum. All 
VesG-transfected cells demonstrated G protein expression for up to 14 weeks 
(Figure 4-7B). Although the expression levels decreased gradually over time, 
they were still detectable at week 14, when this experiment was terminated.  
G protein expression levels in these stable cells seemed to be higher 
compared to the ones from the first attempt. 
As per the previous experiment, to investigate LV production, these cells were 
transfected transiently with gag-pol, rev, and SIN-pHV once every two weeks. 
LV titres were then measured in the harvested supernatant. COCV.G 
demonstrated initial titres of 106 TU/ml for up to eight weeks (Figure 4-7C). 
The titres dropped to around 105 TU/ml at week ten where they remained 
stable until week 14. Although VSVala.G initial titres started at around 105 
TU/ml, similar to COCV.G, they remained stable throughout the experiment. 
VSVind.G, VSVnj.G, and PIRYV.G titres started at slightly lower than 106 
TU/ml at week four and six, then fell gradually to around 104 TU/ml over the 
next two months. MARAV.G expressing cells, on the other hand, produced 
titres at around 105 TU/ml at week four and six. These titres then dropped to 
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104 TU/ml at week eight. From week 12 onwards, despite measurable G 
protein expression in these cells, the transient titres were undetectable (Figure 
4-7C, arrows). 
Overall, both experiments highlighted the possibility of expressing VesG, 
including VSVind.G, stably in HEK 293T cells for at least 3-4 months. In 
addition, transient LVs produced by COCV.G and VSVala.G expressing cells 






































Figure 4-7. Establishment of stable VesG expressing cells and long-term vector production. 
HEK 293T cells were transfected with pHV-Luc and VSVind.G, COCV.G, VSVnj.G, and 
PIRYV.G, VSVala.G, and MARAV.G. (A) Luciferase expression was checked as a 
measure of transfection efficiency. (B) Stable G protein expression in transfected cells kept 
in phleomycin selection was measured for up to 14 weeks. (C) Transient VesG-LV titres 































This chapter aimed to investigate the fusogenic activity and relative cytotoxicity 
of the vesiculovirus G proteins. Therefore, the effects of pH on VesG mediated 
syncytium formation and VesG-LV infectivity were explored. Also, the 
differences in pH dependence observed were further studied as a cause of G 
protein-mediated cytotoxicity and the generation of cell lines stably expressing 
VesG was attempted. 
4.4.1 Fusogenic activity amongst various vesiculovirus G 
proteins in a range of pH  
Cocal envelope G protein was reported to be less cytotoxic compared to that 
of VSVind.G [237, 243]. Thus, the first attempt was set to compare the 
fusogenic activity of these two G proteins.  Both G proteins induced cell fusion 
at neutral pH. The formed syncytia were larger and in higher quantities per 
field of view when transfected cells were pre-incubated at pH 6.0 and 5.0 
(Figure 4-1B). This experiment was then repeated to include VSVnj.G and 
PIRYV.G as well to investigate fusogenic activity amongst other vesiculovirus 
family members.  
At mildly acidic pH of 6.0 and 5.0, all four VesG induced cell fusion and 
syncytia formation. However, at neutral pH 7.0, while as expected, both 
VSVind.G and COCV.G induced cell fusion, VSVnj.G and PIRYV.G did not 
trigger syncytia formation (Figure 4-2C). This suggests that VSVnj.G and 
PIRYV.G are not fusion-competent at neutral pH. This may be indicative of 
differences in pH dependence amongst the G proteins. For VSVnj.G and 
PIRYV.G, the population of prefusion trimer at neutral pH might not be enough 
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to trigger fusion at this pH. Another explanation might be that the level of G 
protein expression might be lower compared to that of VSVind.G and 
COCV.G. Due to this the critical number of post-fusion trimers might not be 
reached hence not resulting in cell-cell fusion. It was not possible to control 
the VesG expression level without universal quantitative binding assay for all 
VesG.   
Moreover, based on VSVind.G structure, the acidic residues D268, D274, 
D393 and D395, have been shown to play a role as pH-sensitive switches.  
While the acidic character of D274, D393 and D395 is conserved among 
vesiculovirus genus, D268 is not.  As these pH-sensitive switches are essential 
for the function of G protein, in other VesG they are located in different 
positions (e.g. in CHAV.G in D269-E234-H209 cluster) [456]. It has been 
shown that clustering of protonatable residues can affect the acidification of 
these residues which in turn can affect the conformational changes of the G 
protein [457]. This might affect the stability of the prefusion trimer conformation 
creating the different fusogenic profiles observed (Figure 4-2). 
4.4.2 Effect of pH on the infectivity of vesiculovirus G 
protein-pseudotyped lentiviral vectors 
We further investigated the pH-sensitivity of VesG pseudotyped LVs by pre-
incubating the vectors in media adjusted to a wide range of pH. The data 
revealed that all VesG are more sensitive to acidic than alkaline conditions; 
infection remained stable up to pH 10.0 (Figure 4-3A), in line with previous 
studies which elucidated the stability of the conformational changes up until 
pH 11.0 [454].   
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While all investigated G proteins seem to be more stable at alkaline pH, in 
highly acidic conditions the G protein may undergo irreversible denaturation.  
While other studies reported that VSV inactivation occurred at pH 2, here we 
show that G protein’s infectivity in all VesG was abolished between pH 3.0-3.6 
(Figures 4-3 and 4-4). It has been reported that low pH treatment can induce 
viral aggregation [458]. This can be another reason, besides viral 
denaturation, behind reduced viral infectivity in acidic conditions.  
A maximum level of infection for all VesG was observed at pH 6.0 to 6.6 
(Figure 4-4B). This data is in line with previously published studies reporting a 
high pH threshold of 6.0 for VSV G protein-induced fusion [443]. In addition, 
COCV.G and PIRYV.G seem to have higher pH threshold as they lose 
infectivity at higher pH than VSVind.G and VSVnj.G. VSVind.G and VSVnj.G 
had higher infectivity levels at pH 5.0-5.3, higher than neutral pH, implying a 
lower pH threshold for going to postfusion trimer than the other two. Further 
analyses of pH-dependence of LV infectivity may allow optimisation of 
culturing conditions to improve LV titres. 
4.4.3 Colony formation in the presence of selection marker in 
vesiculovirus G protein-transfected cells  
Overall, pH-induced syncytia formation appeared similar amongst VesG 
investigated, indicating similar cytotoxicity. We tested colony formation of 
these G proteins in the presence of the selectable marker using the pMD-2A-
VesG constructs in which the VesG ORF is linked to the phleomycin resistance 
gene via a 2A peptide, in comparison to RDpro, a non-toxic G protein. These 
results also suggested that there is no major difference in VesG-induced 
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syncytia formation among various VesG as a comparable number of 
phleomycin resistant colonies were produced in all VesG (Figure 4-5).    
4.4.4 Generation of stable vesiculovirus G protein expressing 
cells 
Consequently, we inspected the G protein expression over time in stable VesG 
expressing cells. Surprisingly, we found that VSVind.G could be stably 
expressed in cells for up to at least five months. Moreover, these cells could 
produce transient LVs with titres of more than 104 TU/ml for up to 20 weeks 
post-selection (figure 4-6). These are striking results as it was believed that 
VSVind.G could not be stably expressed in cells due to high toxicity [201]. 
These results were in line with a recently published report by Humbert et al. 
[237]. 
Moreover, we were able to generate stable cell lines with other VesG (Figure 
4-7). While these cell lines performed adequately with regards to G protein 
expression and LV titres, COCV.G and VSVala.G produced transient titres of 
105 TU/ml for at least approximately four months. This performance was 
followed by VSVind.G, VSVnj.G, and PIRYV.G which produced LV titres of 104 
TU/ml for almost four months. 
We have demonstrated that all VesG tested can be stably expressed in 
HEK293T cells without demonstrable cytotoxicity for up to 5 months with 
satisfactory LV titres following transient supply of gag-pol, rev, and the 
transgene. The longevity of the stable cells, when adapted into packaging cell 
lines, will allow for sufficient cell expansion for clinical LV characterisation and 
production. For instance, the best performing VesG constructs can be stably 
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transfected into the WinPac cell line. This may improve the low LV titres 
produced by the WinPac-RD cell line [238]. Furthermore, we have proposed 
an alternative continuous LV production method: admixing. In this method, 
unenveloped bald LVs and G proteins secreted from HEK 293T cells in 
vesicles are produced in trans via their respective stable cell lines and later 
admixed to produce infectious LV particles. This method not only circumvents 
the superinfection problem identified (see chapter 5) but also can support 
continuous LV production. Therefore, these stable G expressing cells can be 
used for such methods as well (in press [440]). 
Taken together, the work presented in this chapter suggest that overall all 
VesG tested demonstrated similar properties with regards to toxicity, pH-
dependent fusion, and infectivity, with modest differences which may be 
dictating key structural and functional changes. However, the most striking 
conclusion is that VSVind.G, as well as other VesG, are not demonstrably 
cytotoxic when expressed constitutively in cells. Furthermore, most G proteins 
could be stably expressed and supported LV production for at least 3-4 months 






   
5 CHAPTER 
Lack of Superinfection 
Interference by 




The cellular entry is the first step in viral infections and involves multiple viral 
and host proteins [459]. Attachment of viruses to the cellular receptor initiates 
endocytosis and fusion resulting in virus genetic material to be delivered to the 
cytoplasm. Several host cell mechanisms have been developed as immune 
mechanisms to interfere with viral infections [460]. However, there is also a 
viral interference mechanism preventing secondary infections called 
superinfection resistance (SIR) [459, 461]. SIR is observed mainly between 
serologically related viruses and usually dependent on differences in time or 
multiplicity of infection [462-466]. SIR can proceed through several different 
mechanisms including attachment and replication hindrance, or competition 
for viral polymerase and host factors [467-469]. Although not exclusive to 
retroviruses, the occurrence of SIR in retroviruses has been extensively 
studied. 
One of the most common types of SIR observed is receptor occupancy via 
virus-encoded envelope proteins on the plasma membrane blocking the 
attachment of other viruses or, in short, receptor interference [459, 470]. This 
was first observed in avian leukosis virus in chicken embryos [471]. Since then 
receptor interference has been widely utilised to characterise and group many 
serotypes of retroviruses including Rous sarcoma virus [472, 473], feline, and 
murine leukaemia viruses [474-476]. It is postulated that the interference 
happens on the cell surface and functions through interactions of the viral 
envelope proteins already expressed on the cell surface with its receptor. This 
theory was later supported as it was demonstrated that when envelope 
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glycoproteins pre-adsorbed on the cell surfaces fully blocked infection and 
fusion by viruses utilising the same receptor [477, 478]. 
As alternative mechanisms, HIV, a lentivirus, achieves SIR via downregulating 
its putative receptor CD4 in infected cells [479-481]. It has been demonstrated 
that HIV proteins Vpu, Env, and Nef are involved in this down-regulation 
process through distinct mechanisms [482, 483]. While Nef down-regulates 
CD4 via direct interactions with its C-terminal end, Env and Vpu mediate this 
process by preventing intracellular transport of the newly synthesised receptor 
molecules. 
SIR can pose an issue with regards to the use of retroviral envelopes to 
pseudotype GRVs and LVs [484]. There have been studies reporting the 
occurrence of superinfection limiting transduction efficacy and levels of 
transgene expression [484, 485].  On the other hand, it becomes an advantage 
in the construction of stable packaging cell lines for clinical grade GRV and LV 
production. Without SIR, produced viral particles can re-enter and re-infect the 
producer cells. This results in accumulation of vector genome and many 
random genome integrations which might lead to loss of titres and possible 
cell death [486]. As retroviruses display a robust SIR against viruses which 
utilise the same receptor [470], several envelopes derived from retroviruses, 
for example, amphotropic MLV [487] and modified RD114 envelope RDpro 
have been successfully adapted to packaging cell lines (PCLs) [238, 240]. 
It has been suggested that VSVind.G’s toxicity occurs through superinfection 
[487]. Vogt and colleagues have reported a lack of superinfection interference 
with VSVind.G pseudotyped LVs (Figure 5-1). They suggest that this might be 
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due to the abundance of the target receptors on the cells which are less likely 
to be saturated with the expressed glycoprotein [486]. VSVind.G’s primary 
receptor for cell entry has been identified as the low-density lipoprotein 
receptor (LDLR) and other LDLR family members [347, 349]. This family of 
proteins are involved in the metabolism and transport of cholesterol and are 
abundantly expressed in several different tissues and cell types [488].  
 
  
Figure 5-1. Receptor interference of expressed G protein.  
Receptor occupancy via virus-encoded RDpro envelope proteins on the plasma membrane 
blocking the attachment of viruses that use the same receptor for cell entry (left panel).  
Lack of superinfection interference in VSVind.G expressing cells allows viruses to enter 
the cells (right panel).   
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Furthermore, it has been found that even virus-like particles which lack 
envelope glycoproteins can efficiently transduce VSVind.G expressing target 
cells. The phenomenon of VSVind.G converting non-infectious unenveloped 
particles into functioning pseudotypes has been previously demonstrated 
[486, 489]. It has been hypothesised that the LDLR expressed on Env negative 
particles act as fusion targets for the VSVind.G expressed on the cell surface 
leading to fusion into the target cells [487]. This may become a substantial 
issue because immortalised cell lines widely utilised in LV production, HEK 
293 or HEK 293T cells, express LDLR on their surface.   
Therefore, lack of superinfection interference has limited the use of VSVind.G 
envelope in generating stable producer cell lines for clinical use and clinical 
trials using VSVind.G pseudotyped LVs thus far. While most trials have 
employed transient production methods, some groups have been 
experimenting with inducible G protein systems [486].  In inducible systems, 
G protein expression is induced by addition of induction/suppression reagents 
to the culture media [233, 246, 490].  Another alternative to overcome the 
superinfection problem is to study alternative G proteins to replace VSVind.G.  
Meanwhile, it is essential not only to investigate these G proteins for 
superinfection but also to explore alternative ways to overcome this issue as 
well.   
Identifying potential solutions to superinfection would help to catapult lentiviral 
gene therapy as not only it will enable the establishment of 
packaging/producer cells with the current gold-standard envelope VSVind.G 
but also possibly lengthen the longevity of vector producer cells and cut down 
on production costs. 
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5.2. Aims  
The primary aim of this chapter was to investigate superinfection in other VesG 
both in stable packaging cells and transient infection, and to explore whether 
VSVind.G ability to superinfect could be curtailed. To achieve this, the 
following points of investigation were utilised:  
• Confirm superinfection in previously established WinPac-COCV.G 
packaging cells and stable VesG expressing cell lines. 
• Examine the main pathway for cell entry utilised by other VesG. 
• Explore the effects of knocking out the LDL receptor to superinfection 




5.3 Results  
5.3.1 Superinfection in WinPac stable packaging cell line 
The Collins/Takeuchi group has previously developed the WinPac (WP) stable 
packaging cell line which stably expresses HIV Gag-Pol and Rev proteins 
[238]. To avoid VSVind.G- related cytotoxicity [215], WP cells were stably 
transfected with RDpro to develop WinPac-RD cell line. These cells can 
continuously produce third generation SIN LV at titres of 106 TU/ml. Moreover, 
vector titres were relatively stable over a period of 4-5 months. Compared to 
inducible packaging cells developed for clinical LV production, stable 
production using WP cells is easier to scale up and avoids the rapid decline in 
titres following induction [238].  
Following this, a phylogenetically close relative of VSVind.G, COCV.G, was 
introduced into WP cells owing to its advantageous characteristics over RDpro 
(higher stability and titres, Chapter 3) and VSVind.G [243]. 
To investigate whether Cocal envelope glycoprotein blocks superinfection, 
WP-RD and WP-COCV.G cell lines were challenged with GFP-LVs 
pseudotyped with VSVind.G, COCV.G, and RDpro at MOIs 0.5 and 3.0. RDpro 
and COCV.G expression levels in WP cells were determined by extracellular 
antibody staining (Figure 5-2A). To detect RDpro, WP-RDpro cells were 
incubated with mouse anti-RDpro polyclonal antibody (Pule group- UCL 
Cancer Institute).  WP-COCV.G cells were stained with VSV-Poly antiserum. 
After being selected for gag-pol, rev and env for 3-4 passages, these cells 
were checked for envelope expression (Figure 5-2A). After infection with GFP-
LVs, GFP expression in the producer cells demonstrated that, as expected, 
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WP-RDpro cells blocked RDpro-LV infection (Figure 5-2B) while they were 
permissive to VSVind.G- and COCV.G-LVs. The level of GFP positive WP-RD 
cells was significantly less than that of WP-COCV following challenge with 
RDpro-LV (p<0.0001). In contrast, WP-COCV.G cells were infected by all LVs, 
including COCV.G-LVs, at similar levels (Figure 5-2B) suggesting that 
























Figure 5-2. WinPac-COCV.G cells lack superinfection resistance through receptor 
interference.  
(A)  Env expression levels for WinPac-RD and WinPac-COCV.G cells of their respective 
envelope glycoproteins. WinPac-RD cells were stained with rat anti-RD antiserum.  
WinPac-COCV.G cells were stained with goat VSV-Poly antiserum (see Table 2-4 and 2-
5 for primary and secondary antibodies, respectively). Data shown represent one of the 
three repeats performed. Envelope negative WinPac cells were utilised as negative control. 
(B) WP-COCV.G and WP-RDpro packaging cell lines were challenged with COCV-G- 
VSVind.G- and RDpro-LV at two MOIs: 0.5 and 3.0.  GFP expression of the cells was 
measured 48h after transduction via flow cytometry.  Data shown represent mean +/- SD 
of three repeats performed in triplicates.  One-way ANOVA analysis with Tukey’s post-test 




5.3.2 Superinfection in stable VesG expressing cells 
The lack of superinfection interference of COCV.G, similar to VSVind.G, led 
us to hypothesise that this may be a shared characteristic amongst VesG.  
Therefore, we decided to test this using the stable envelope expressing cell 
lines generated (section 4-3-4). As a superinfection negative control, stably 
transfected HEK 293T cells with RDpro were used. We tested the bulk cell 
populations for superinfection permissiveness similarly as done in 5.3.1, after 
four weeks of antibiotic selection. The infection rates were determined by 
measuring the GFP expression via flow cytometry while the envelope 
expression was monitored by VSV-Poly antiserum and anti-RDpro. VSV-Poly 
antiserum cross-reacts with all VesG with various levels of affinity. After 
confirming that G proteins were expressed in all stable VesG and RDpro cells 
(Figure 5-3A), they were challenged with VesG- and RDpro-LV.  As previously 
demonstrated RDpro-LV transduced RDpro expressing cells at a significantly 
lower level than that of naïve HEK 293Ts (Figure 5-3) (p<0.001). Furthermore, 
corroborating previously published data and results from section 5.3.1 
VSVind.G and COCV.G-LVs could superinfect their respective Env expressing 
cells (Figure 5-3B).  Interestingly, the same was observed for the other VesG 
tested: no statistically significant differences were observed between the 









































Figure 5-3. All VesG expressing cells are susceptible to superinfection by LVs pseudotyped 
with their relative envelopes.  
(A)  Env expression levels for stable VesG (left) and RDpro (right) expressing cells.  Data 
shown represent one of the three repeats performed. VesG expressing cells were stained 
with goat VSV-Poly and WinPac-RD cells were stained with rat anti-RD antisera (see Table 
2-4 and 2-5 for list of antibodies). (B) Stable Env expressing cells were challenged with 
VesG and RDpro-LV at MOI 1. GFP expression was measured 48h later via flow cytometry. 
Data shown represent mean +/- SD of three repeats performed in triplicates. One-way 
ANOVA analysis with Tukey’s post-test was performed to compare percentage GFP 






5.3.3. Investigating the role of LDLR family members in VesG-
LV entry 
LDLR has been reported to be the primary cellular receptor responsible for 
VSVind.G entry while other LDLR family members have been demonstrated 
as alternative receptors [347, 491]. Soluble LDLR (sLDLR) has been reported 
to bind VSVind.G at high affinity preventing its binding to cells thus inhibiting 
transduction by VSVind.G pseudotyped LVs.  Furthermore, this viral infection 
is successfully inhibited in a dose-dependent manner via soluble LDLR 
molecules and was entirely blocked by the addition of receptor-associated 
protein (RAP). RAP blocks all LDLR family members, except for LDLR itself 
[315]. Similar dose-dependent partial inhibition of COCV infection by soluble 
LDLR has also been demonstrated [243]. 
Combined with this information, the data presented in section 5.3.2 implied 
that the various VesG might be sharing their main path for cell entry and hence 
sharing the apparent lack of superinfection resistance. To test whether LDLR 
is responsible for the VesG-LV infection, an infection assay in the presence 
and absence of sLDLR and RAP proteins was performed. HEK 293T cells 
were challenged with VesG- and RDpro-LV with and without prior treatment 













As expected RDpro-LV infection was unaffected by the presence of both LDLR 
and RAP as it uses ASCT-2, a neutral amino acid transporter, as its primary 
receptor. On the other hand, all VesG-LV infections except that of PIRYV.G-
LV, was inhibited in the presence of sLDLR. The results implied that while 
VSVind.G, COCV.G, VSVnj.G, VSVala.G, and MARAV.G utilised LDLR for 
cell entry, PIRYV.G did not interact with sLDLR and therefore most probably 
does not utilise this protein as a receptor. RAP effect was not observed in this 
study using 293T cells as the infection target, unlike previous studies on WT 
FS-11 fibroblasts and LDLR-deficient GM701 fibroblasts cells [347]. 
  
Figure 5-4. Inhibition of VesG-LV infection by soluble LDLR. 
HEK 293T cells were challenged with GFP expressing VesG and RDpro pseudotyped LV 
at MOI 0.5 in the absence and presence of 0.5 μg/ml sLDLR and 2.5 μg/ml RAP.  The 
infection rates were analysed 48h later via flow cytometry.  Data shown represent relative 
infection +/- SD from three experiments performed in duplicates. One-way ANOVA analysis 
with Dunnett’s post-test was performed to compare percentage GFP positive cells to that 
of virus only samples (*** p<0.001; * p<0.05). 
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5.3.4. Effects of LDLR-Knock Out to VSVind.G infection 
Results from the experiments in section 5.3.3 suggested that all VesG except 
for PIRYV.G use LDLR to infect HEK 293T cells. Consequently, we decided 
to knock out (KO) the LDLR gene on the producer cell lines to obtain further 
evidence that VesG-LVs enter cells via LDLR and to investigate whether 
LDLR-deficient cells are still permissive to superinfection. 
To KO the LDLR gene, the CRISPR-Cas9 genome editing technology was 
utilised. The CRISPR-Cas9 system was initially developed a few years ago 
based on a bacterial defence mechanism against invading phages and 
plasmids. In this system, a guide RNA (gRNA) complementary to the target 
DNA is designed which will guide the nuclease to induce double-strand break 
(DSB) in the target sequence. For this project, the LentiCRISPR system was 
used. This system contains the blasticidin resistance gene as the selectable 
marker as well as the Cas9 enzyme to induce DSB at the target sequence, 
which is encoded into the vector plasmid of an LV. Exploiting LV ability to 
target a broad range of cells and to integrate its genome into the host cell, a 
mammalian codon-optimised Cas9 along with the specific gRNA is delivered 
into the cells, and the genomic cut is carried out (Figure 5-5A).  
For this, I designed three different guide RNAs (gRNA) targeting different parts 
of the gene, checked functionality and proceeded with diagnostic processes 
including sequencing and plasmid digestion with restriction enzymes after 
inserting into the lentiCRISPR construct (section 2-6). One gRNA that targeted 
the LDLR open reading frame was selected to subclone into the LentiCRISPR 
plasmid (Figure 5-5B). LDLR-KO LVs were produced via transient production 
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method.  Briefly, HEK293T cells were transfected with VSVind.G encoding env 
plasmid, p8.91, and LentiCRISPR plasmids to produce transient VSVind.G 
pseudotyped LVs encoding the gRNA and Cas9 protein to KO the LDLR gene 
(αLDLR-LVs). LVs were harvested 48 hours post-transfection while the LV 
producing HEK293T cells were put under blasticidin selection. 
WT HEK 293T cells were transduced with 1.5 mL, 1mL, and 500 µL of αLDLR-
LVs and kept under selection for two weeks before being investigated for 
LDLR expression via immunoblotting. For this 8x106 cells were lysed and 
immunoblotted for LDLR using anti-LDLR mAb, 5E6. After infection with 
αLDLR-LVs, LDLR gene was successfully knocked out from 293T cells at all 





Figure 5-5. KO of LDLR from HEK 293T cells utilising the LentiCRISPRv2 system.  
(A) LV vector backbone encoding the SpCas9 and the selectable marker blasticidin 
resistance gene. The designed gRNAs were subcloned into the backbone utilising the 
BsmBI cloning site. (B) The diagram for the designed gRNA. This oligo was digested using 
BsmBI restriction enzyme, then subcloned into the lentiCRISPR backbone. (C) Western 
blot analysis of LDLR expression in naïve HEK 293Tcells, αLDLR-LV producer cells, and 
αLDLR-LV transduced cells two weeks post-antibiotic selection. GAPDH was used as 
protein input control. Data shown represent one of the three repeats performed. 
Psi packaging signal (psi); rev response element (RRE); central polypurine tract (cPPT); 
elongation factor-1α short promoter (EFS); FLAG octapeptide tag (FLAG); 2A self-cleaving 
peptide (P2A); blasticidin selection marker (Blast); Woodchuck posttranscriptional 







After the LDLR knock out confirmation in the cells, the infection levels of VesG-
LV in WT and KO HEK 293T cells were examined by flow cytometry (Figure 
5-6). RDpro uses ASCT-2, a neutral amino acid transporter, as its primary cell 
entry pathway [492, 493]. Therefore, RDpro-LVs were used as a control where 
no changes in infection were expected. On average, a modest reduction in 
infectivity was detected in KO cells compared to WT when the cells were 
challenged with all VesG-LV except for PIRY (Figure 5-6A). This data 
corroborated our previous findings that sLDLR blocks infection of LV with G 
proteins of VSVind, COCV, VSVnj, VSVala and MARAV and suggest that 
these viruses are sharing LDLR as a cell entry receptor. However, the 
reduction of infection effect was subtler than expected as just the addition of 
0.5 μg/ml sLDLR to the culture media had blocked on average 80% of infection 
(Figure 5-4). These two findings both pointed towards the involvement of other 









































   
Figure 5-6. Investigation of VesG-LV infection of LDLR-KO HEK 293T cells.   
(A) VesG-LV were produced using transient production protocol. LVs were titrated on 
LDLR-KO and naïve HEK 293T (WT) cells using equimolar mounts.  Cells were harvested 
48h later, and GFP expression was measured via flow cytometry. Data presented 
represent mean +/- SD of three experiment performed in duplicates. One-way ANOVA 
analysis with Dunnett’s post-test was performed to compare VesG infection decrease to 
that of RDpro, the negative control with an unrelated primary receptor. (B) LDLR-KO 
HEK293T cells were challenged with GFP expressing VesG and RDpro pseudotyped LV 
at MOI 0.5 in the absence and presence of 0.5 μg/ml sLDLR and 2.5 μg/ml RAP. The 
infection rates were analysed 48h later via flow cytometry. Data shown represent relative 
infection +/- SD from three experiments performed in duplicates. One-way ANOVA analysis 
with Dunnett’s post-test was performed to compare percentage GFP positive cells to that 




One hypothesis behind the lack of infection inhibition observed by RAP and 
the modest reduction of transduction efficiencies in LDLR-KO cells was the 
upregulation of the other family members' expression in order to compensate 
for the lack of LDLR in endogenous lipid/cholesterol pathways. Therefore, 
qPCR analyses on both naïve and LDLR-KO cells were performed to compare 
expression levels of LDLR, and two other LDLR family members: very low-
density lipoprotein receptor (VLDLR) and apolipoprotein E receptor (APOER). 
In addition, we also checked for the Leucine-Rich Repeat Containing G 
Protein-Coupled Receptor 4 (Lgr4) as it has been reported to be essential for 
VSVind.G entry to target cells [494].   
Total RNA from WT and KO cells were extracted, and expression levels of 
different LDLR family members were measured by quantitative PCR. Figure 
5-7A demonstrates the data obtained from the qPCR indicating that LDLR 
gene was still detectable in KO cells. This suggests that complete LDLR KO 
might not have been achieved. As bulk population of LDL-KO cells was used, 
to ensure that LDLR is still absent from the population in use, we decided to 
check the LDLR expression in KO HEK 293T cells from an earlier passage 
(i.e. two weeks in selection) compared to the batch that was currently in use 
that was in culture under blasticidin selection for around 12 weeks (indicated 
here as late passage). qPCR result for LDLR-KO early passage shows that 
LDLR expression, while still detectable, is considerably lower compared to 
LDLR-KO late passage. Moreover, it seems that as well as LDLR, VLDLR 
expression was lower in KO cells compared to WT. When the gRNA was 
aligned against VLDLR sequence to check for any off-target effect, the gRNA 
recognised 5-6 nucleotide long sequences in VLDLR exons 1 and 2 (6 
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determinants in total) suggesting that VLDLR gene might have also been 
knocked out through off-target effect. Also, a slight increase in expression in 
Lgr4 (p<0.05) and APOER genes can be observed in KO cells compared to 
WT suggesting these genes might have been elevated in order to compensate 
for the absence of LDLR.   
To investigate LDLR expression by immunoblotting, cells from LDLR-WT, 
LDLR-KO late passage, and LDLR-KO early passage were lysed and blotted 
using anti-LDLR antibody 5E6. The immunoblotting data indicates that two 
weeks post-selection transduced HEK 293T cells were negative for LDLR 
expression when compared to WT HEK 293T cells, (Figure 5-7B- early pass). 
However, in 12-weeks post knockout cells, an LDLR band was detected, 
similar to the WT control (Figure 5-7B- late pass). These results implied that 
the LDLR expression returned in bulk LDLR-KO population although they were 






































































































Figure 5-7. Exploring the expression Levels of LDLR and other LDLR family members in 
early and late passages of LDLR-KO cells.  
qPCR assay performed on genomic DNAs extracted from WT and LDLR-KO cells: (A) 
Late-passage cells; (B) early passage cells.  Copy numbers measured for each gene was 
normalised to that of WT HEK 293T. Data shown represent means +/- SD of three 
experiment performed in duplicates.  (C) Western blot analysis of LDLR expression in early 
passage KO cells (week 2) and late passage KO cells (week 12).  Data shown represent 
one of the three repeats performed. One-way ANOVA with Tukey's post-test was 
performed to compare each receptor to its wild type expression (*** p<0.001; ** p<0.01; * 








5.3.5 Effect of the LDLR-KO to VesG expression on the cell 
surface and shed in the supernatant 
To investigate whether LDLR-KO influences envelope expression, this 
receptor was knocked out on the stable VesG expressing cells (section 4-3-4) 
and checked the envelope expression in WT compared to KO cells. VSVind.G, 
COCV.G, VSVnj.G, PIRYV.G, VSVala.G, and MARAV.G expressing cells that 
were in phleomycin selection for two weeks were transduced with 500µL of 
αLDLR-LVs and were selected with blasticidin in addition to phleomycin for 
another two weeks. WT and KO Env expressing cells were lysed and blotted 
with VSV-Poly antiserum and P5D4 to detect VesG, and with anti-LDLR 5E6 
to confirm the LDLR KO (Figure 5-8). As expected, the LDLR-KO cells did not 
express the LDLR gene while bands were detected in the WT ones. When 
blotted with anti-VSVind.G mAb P5D4 C-terminally, a modest increase in the 
VSVind.G expression was observed in the KO cells in comparison to the WT 
ones, however, as P5D4 did not cross-react with other VesG on a western blot 
the expression levels of other G proteins could not be deduced. For this, the 
samples were blotted with anti-VSVind.G polyclonal VSV-Poly which was able 
to react with all VesG tested in flow cytometry (section 3-3-1). Although an 
increase in the signal was observed in the KO cell in comparison to WT ones, 
the signals were deemed unspecific, and no conclusive results could be 
deduced with regards to VesG expression.  The data suggest that while VSV-
Poly is suitable for flow cytometry staining and can cross-react with all VesG, 
is not suitable for western blot staining. Moreover, as other available Abs only 
detect VSVind.G and do not cross-react with other VesG, using western blot 








Figure 5-8. Western blot analysis of VesG expression on stable G protein expressing cell 
surface following LDLR KO.   
8x106 cells were lysed, and 50 μg of total protein/ well were loaded.  The samples were 
blotted for LDLR expression (5E6), VSVind.G C-terminal (P5D4), and extracellular domain 
polyclonal VSV-Poly for VesG proteins expression. The data shown represent one of the 
three repeats performed. 
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To observe the VesG expression level differences upon LDLR KO, chimeric 
VesG proteins with the transmembrane and C-terminal domains of VSVind.G, 
produced in our laboratory by Altar Munis, were used; these allowed for G 
protein detection by the mAb P5D4 (Figure 5-9A).  
WT and LDLR-KO cells were seeded at 3x105 cells/well density in 6 well plates 
and transiently transfected with 2.5μg of plasmids expressing VesG-tail 
chimerae. 24 hours later the media was changed with 2 ml of Opti-MEM 
supplemented with L-glutamine and Pen/Strep. 48 hours post-transfection, 
supernatants were harvested, and cells were lysed. Supernatants were 
concentrated via centrifugation at 17,000 g for 2 hours, and total protein 
amounts were normalised using the Pierce BCA Kit.  
The samples were blotted with 5E6 anti-LDLR antibody to confirm LDLR-KO 
and P5D4 to investigate VesG expression and secretion (Figure 5-9B). The 
western blot analysis demonstrated that even by transient transfection a 
modest difference between VesG expression on cells and secretion could be 
observed (depicted by the thickness and density of the bands). All VesG-tail 
chimerae could be detected using P5D4 and comparison of the bands 
between WT and KO cells highlighted that in KO cells the G protein expression 
and secretion were more prominent compared to that of WT indicating that the 
absence of the primary receptor does indeed increase the level of G protein 
expression. However, as this experiment was performed following transient 
transfection all expression levels were relatively high, therefore the preliminary 
results acquired should be further investigated following stable transfection of 






Figure 5-9. Western blot analysis of VesG-tail expression on stable G cell surface following 
LDLR KO.   
(A)  Diagram of VesG-tail chimeric proteins in which the transmembrane and C-terminal 
domains of the G proteins were switched with that of VSVind.G (White Square).  (B)  1x106 
cells were lysed, and 40 μg of total protein/well were loaded on SDS-page gel. The samples 
were blotted for LDLR expression (5E6, Sigma) and C-terminal P5D4 (Sigma) for G 





5.4 Discussion  
Cells infected by retroviruses display resistance to superinfection by viruses 
that utilise the same receptor as the pre-infecting virus. This superinfection 
interference is most likely due to saturation of the virus receptors with the 
retroviral envelope glycoprotein expressed in the infected target cells [486].  
The host range of retroviral vectors including lentiviral vectors can be 
expanded or altered by pseudotyping. VSVind.G is among the first, and still 
one of the most widely, used glycoproteins for pseudotyping LVs, due to its 
advantages including broad tropism and stability [211]. A major issue that has 
been reported in stable VSVind.G pseudotyped LV producer cell lines is that 
these cells are prone to be re-infected by the produced LVs. This might be 
because VSV receptors, i.e. LDLR and LDLR family members, are abundant 
components of plasma membranes and receptor saturation most likely is not 
achieved easily to mediate superinfection resistance [486, 495]. The lack of 
superinfection resistance in the producer cells can lead to the accumulation of 
the vector genome in the cells causing genotoxic effects, cell death, and loss 
of titres [486]. 
5.4.1 Superinfection in stable cell lines 
The work presented in this chapter aimed to investigate whether other VesG 
pseudotyped LVs, superinfect producer cells similarly to VSVind.G-LVs. This 
was explored in two separate sets of cell lines; in WinPac (WP) stable 
packaging cell lines as well as the stable VesG expressing cells (chapter 4). 
Both WP-derived cells lines, WP-RD and WP-COCV.G, and stable VesG 
expressing cells were challenged with VesG pseudotyped LVs expressing 
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GFP. Both sets of cells were checked for envelope expression prior to 
challenge as well as for GFP expression after the challenge (Figures 5-2A and 
5-2B). While stable RDpro expressing cells reduced the superinfection by 
RDpro pseudotyped LVs significantly, complete inhibition like that of WP-RD 
cell line was not observed. This can be explained by that the stable RDpro 
expressing cells were a mixed population and not clonally selected ones. 
Therefore, the bulk population might be made up of cells expressing RDpro at 
low levels and/or not expressing RDpro. This will lead to receptors not being 
saturated permitting RDpro LVs entry to the cells. 
On the other hand, in both approaches, VesG-LV infection was unaffected 
pointing to a lack of superinfection resistance in the genus. This might pose 
some challenges such as genotoxicity and loss of titres of VesG based LV 
producer lines, which need to be addressed. A possible way that has been 
suggested to block superinfection is the use of antiretroviral drugs such as 
azidothymidine (AZT) [486].  AZT is widely used as an antiretroviral medicine 
in patients suffering from HIV-1 infection/AIDS. AZT mechanism of action is by 
inhibiting the HIV-1 reverse transcriptase activity by its triphosphate form 
competing with its natural nucleotide counterpart thymidine triphosphate for 
incorporation into newly synthesised viral DNA. Once incorporated, it leads to 
DNA chain termination stopping further DNA synthesis. However, if used, AZT 
would need to be included in the culture media and later filtered out of the final 
LV preparation, a similar issue currently is present in inducible systems which 
utilise induction/suppression chemicals [233, 496]. This will complicate the 
simple continuous stable production process which currently is an advantage 
of constitutive PCLs over inducible systems. 
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Another approach to block superinfection is the blocking of the primary 
receptor which the pseudotypes use to enter the cells. It has been reported 
that VSVind.G employs the low-density lipoprotein receptor (LDLR) as the 
main receptor for cell entry [347, 377], while other LDLR family members act 
as alternative receptors for this G protein. Furthermore, published studies 
reported that while knockdown of LDLR in a human fibroblast cell line (FS-11) 
reduced VSVind.G infection, overexpression of this gene in LDLR-deficient 
GM701 cells increase VSVind.G infection by 6-fold. It was also shown that 
following stimulation of T cells and haematopoietic stem cells with a cytokine 
cocktail, the surface expression of LDLR was elevated on these cells resulting 
in increased VSVind.G pseudotyped LV transduction efficiency [377].   
However, little is known about the receptor for other vesiculoviruses.  As these 
viruses show some degrees of homology on the amino acid level to VSVind.G, 
from higher levels in MARAV.G and COCV.G to lower homology levels in 
PIRYV.G, we hypothesised that they might be sharing the same receptors for 
cell entry.  Preliminary experiments were performed in our lab investigating the 
putative receptor for COCV.G using sLDLR. These data suggested that 
VSVind.G and COCV.G LVs infectivity was partially blocked in a dose-
dependent manner by sLDLR [244]. Similar results were also reported by 
another research group [237]. When other VesG were investigated for their 
use of LDLR and other family members for infection, a hindrance of infectivity 
by sLDLR was observed for all VesG but PIRYV.G (Figure 5-4). 
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5.4.2 Development LDLR knock out cell line  
Accordingly, we tried to knock-out LDLR on HEK 293T cells in an attempt to 
block superinfection in VesG cells. Although PIRYV.G does not interact with 
LDLR, it still demonstrated a lack of superinfection resistance (Figure 5-3).  
Therefore, LDLR KO was expected not to affect PIRY-LV infection, and it was 
utilised as a negative control in the LDLR KO experiments. Hence, a gRNA 
targeting the LDLR gene was designed and cloned into a LentiCRISPR 
plasmid containing a blasticidin resistance gene. After producing transient 
αLDLR-LVs, HEK 293T cells were transduced and kept in blasticidin selection.  
After confirming LDLR KO via immunoblotting (Figure 5-5C), WT and LDLR-
KO HEK 293T cells were transduced with various volumes of VesG 
pseudotyped LVs to investigate the infectivity levels in LDLR-deficient cells 
compared to WT ones. A slight decrease of infectivity was observed in all 
VesG LVs except for PIRYV.G (Figure 5-6) which was in agreement with our 
previous results suggesting that PIRYV.G LVs likely employ receptors other 
than LDLR (Figure 5-4). While in higher volumes added of LV the infection 
seemed to get saturated, in lower volumes yielding 1-30% GFP expression, 
which is the window utilised to calculate LV titres, statistically significant 
(p<0.001) reduction of infectivity in LDLR-KO cells compared to WT ones 
could be observed.  
However, as LDLR was reported to be the main entry port for VSVind.G, a 
greater effect on infectivity level in the absence of LDLR was expected. We 
hypothesised that a possible explanation could be that other LDLR family 
members are elevated to balance out the lack of LDLR. 
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When investigating the levels of mRNA of the other LDLR family members by 
qPCR analysis, it was revealed that the LDLR-KO cells were not 
homogenously and completely knocked out as LDLR could be detected, albeit 
in substantially lower levels (approximately 103 times less compared to WT) in 
the KO cells. The differences in gene expressions also translated into 
differences in protein expression levels (Figure 5-7B-C). Results from 
immunoblotting analysis demonstrated that while there was no detection of 
LDLR protein in early passages, its expression reappeared in later passages.  
This phenomenon can be explained by the karyotypic phenotype of the initial 
KO population; first, the HEK 293T cells have a complex karyotype of 
hypotriploid DNA, with different mean chromosome numbers in cells from 
different sources. The diversity has been suggested to be due to the long-term 
cultivation of these cells causing different clones of 293 cells to undergo 
karyotype diversification [411, 497]. Having a complex karyotype can make 
having a homologous knock out of genes in all alleles to be challenging. 
Furthermore, as the LDLR-KO cells did not undergo clonal selection, we 
utilised a mixed/bulk population of homologous and heterologous KO cells in 
my experiments. After a few weeks of cultivation and selection, the population 
of cells with heterologous LDLR KO might have dominated the homologous 
one via spontaneous clonal selection.  Having a mixed population of KO cells 
could also be the reason behind the unconvincing results we attained from WT 
vs KO cells' transduction (Figure 5-6). Accordingly, clonal selection and 
isolating single clones with higher performance is of high importance in order 
to achieve a reliable knock out HEK 293T cell line. 
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5.4.3 Investigating other LDLR family members as entry 
receptors for vesiculovirus G proteins 
We then investigated whether the absence of LDLR influenced the expression 
of G protein by checking its levels in the collected supernatant and expressed 
on the cells from WT or KO HEK293T cells. One issue we faced was the lack 
of available antibodies against VesGs other than that of VSVind.G. For flow 
cytometry, we mainly used the VSV-Poly Ab owing to its cross-reacting with 
VesG other than VSVind.G; however, due to it being an antiserum with a 
collection of different immunoglobulins, using it in immunoblotting might result 
in unspecific interactions with lysate proteins. As other available monoclonal 
antibodies do not cross-react with other VesG, comparing G protein 
expression amongst various constructs has proven challenging (Figure 5-8).  
Therefore, we used VesG-tail chimerae which were synthesised by switching 
the endogenous transmembrane and C-terminal tails of VesG with that of 
VSVind.G provided by Altar Munis at NIBSC. This enabled the use of anti-
VSVind.G mAb P5D4 for G protein expression and secretion detection.  
Following transient transfection of these new chimeric G proteins into KO and 
WT HEK 293T cells, western blot analysis was carried out to determine G 
protein expression (Figure 5-9). A modest increase of G protein expression 
was detected for all VesG in LDLR-KO cells in comparison to the WT cells.  
This may be because when expressed on cells, LDLR interacts with VesG and 
other plasma proteins on the secreted vesicles containing VesG to mediate 
their endocytosis. It has been demonstrated that LDLR and LDLR family 
members are continuously recycled at the plasma membrane approximately 
every ten mins [347]. Therefore, when expressed on the cell surface they may 
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interact with the G proteins, incorporate them in the endocytosis cycle and 
reduce their secretion to the supernatant. It is of value to explore the use of 
LDLR-KO cells in the production of LVs hence the preliminary results obtained 
via stable and transient G expressing cells imply that the lack of LDLR on 
producer cells may boost G protein expression and secretion and thus LV 
titres. 
5.4.4 Summary  
Taken together, the work presented in this chapter demonstrates that all VesG 
tested display a lack of superinfection interference (regardless of their primary 
receptor use) and therefore their adaptation to PCLs may lead to instability 
through vector genome accumulation (in press [440]). As a potential approach 
to address this LDLR-KO HEK 293T cells were generated in order to prevent 
produced LVs from re-entering the PCLs. Preliminary data demonstrated a 
modest superinfection block, however, due to incomplete LDLR KO in the cell 
population the results were inconclusive. Therefore, this approach should be 
further investigated following clonal selection of LDLR-KO cells and/or 









LVs are promising gene therapy tools. Their translation to the clinic has proven 
successful considering recent clinical trials have demonstrated curative 
therapies using LVs for several acquired and heritable diseases [300]. 
Maintaining virus viability over several steps of vector manufacture, 
production, purification, storage, and application, is vital for the efficacy of the 
therapies developed as well as the quality of the transduced cells [430]. 
Moreover, the vector titres and cellular contaminants in the vector containing 
medium are also of concern in achieving successful gene therapies [431-433]. 
Vesicular stomatitis virus Indiana strain G protein (VSVind.G) is the most 
widely used glycoprotein to pseudotype LVs for both in vivo and ex vivo 
studies. Despite conferring high stability and titres and broad tropism, 
VSVind.G is claimed to be cytotoxic and cannot be expressed constitutively in 
producer cells [201, 238]. Therefore, recently, G proteins derived from other 
members of the vesiculovirus genus (VesG), namely Cocal [237, 243] and Piry 
virus [498], have been proposed as alternative LV envelopes with possible 
advantages over VSVind.G. Therefore, detailed investigation of VSVind.G and 
other VesGs is of interest for their adaptations of clinical LV production.  
In this work, we investigated VSVind.G and other VesG, namely Cocal virus G 
protein (COCV.G), VSV New Jersey strain G protein (VSVnj.G), VSV Alagoas 
virus G protein (VSVala.G), Maraba virus G protein (MARAV.G), and Piry virus 
G protein (PIRYV.G), for their use in LV producer cell lines. Therefore, in 
chapter 3, we undertook detailed characterisation of these VesG with regards 
to their thermal and physical stability because vector production, storage, and 
efficacy in use, can be affected greatly by the stability of the vector particle. 
Transient LVs pseudotyped with VSVind.G, COCV.G, VSVnj.G, PIRYV.G, 
204  
 
VSVala.G, MARAV.G, and RDpro were produced to establish which 
vesiculovirus are most promising to generate a stable packaging cell line with. 
They were explored for their ability to be readily concentrated via 
ultracentrifugation and resistance to repeated freeze-thaw cycles and 
incubation at 4ºC and 37ºC. While unconcentrated vectors are often sufficient 
for in vitro studies, for in vivo applications higher titres and hence concentrated 
vector preparations are required. LV concentration is usually achieved by 
ultracentrifugation as it is a fast and robust method [437, 438]. LVs are usually 
kept at 4°C during purification and short-term storage. For long-term storage, 
however, they are kept at -80°C, this implies freeze-thaw of the vector 
preparation and has a detrimental effect on viral titres. Also, at 37°C, these 
vectors are less stable, which is a critical issue concerning the efficacy of viral 
preparations in clinical studies. In this project, all tested G proteins were stable 
after cycles of freeze-thaw and incubation at 4 and 37°C exhibiting similar 
characteristics to that of VSVind.G. These G proteins’ stability at 37°C is 
promising as it will allow systemic and local delivery of LVs in vivo without the 
concern of body-temperature dependent loss of titre. Furthermore, robust 
vector stability demonstrated at 4°C and during freeze-thaw cycles is useful 
for short and long-term storage of the vectors. 
Although VSVind.G has often been the choice of the envelope for LVs, 
VSVind.G-based continuous producer cell lines have not been reported. This 
has been believed to be owing to its highly fusogenic characteristic and 
cytotoxicity due to fusogenicity [201]. Therefore, less or non-toxic envelopes 
such as RD114 derived envelope, RDpro, has been used in the generation of 
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stable cell lines [238, 240]. On the other hand, Cocal envelope G protein was 
reported to be less cytotoxic compared to that of VSVind.G [237, 243].   
In chapter 4, we attempted to compare VesG’s fusogenic activity and pH-
dependence through pH-induced syncytia formation and LV inactivation. All 
VesG demonstrated similar pH-dependent fusogenicity overall, implying 
similar toxicity levels. This was later confirmed via a colony formation assay. 
Consequently, all VesG were stably expressed in HEK 293T cells and kept 
under selection for the marker gene. Possibly the most striking finding of this 
study was that VSVind.G could be stably expressed in cells for up to at least 
five months.  Moreover, these cells could produce transient LVs with titres of 
more than 104 TU/ml for up to 20 weeks post-selection. This challenged the 
widely-accepted notion that VSVind.G cannot be stably expressed in cells due 
to high toxicity [201].  Furthermore, all tested VesG could stably be expressed 
in cells for up to 5 months, without any apparent cytotoxicity. In addition, 
following transient supply of gag-pol, rev, and the transgene to these stable 
VesG expressing cells, reasonable LV titres were achieved. This durability of 
the stable cells is of high importance when adapted into packaging cell lines, 
allowing for sufficient cell expansion for clinical LV production. For instance, 
the best performing VesG constructs could replace the RDpro G protein in 
WinPac-RD cell line to improve the produced LV titres and stability (Sanber, 
Knight et al. 2015). These stable VesG expressing cells are also suitable for 
cell-free in trans LV production (in press [440]).  
A major issue in stable VSVind.G pseudotyped LV producer cell lines is the 
lack of superinfection interference which can lead to accumulation of vector 
genome in the cells resulting in genotoxic effects, cell death, and loss of titres 
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[486]. Lack of superinfection interference might be because VSV receptors, 
LDLR and LDLR family members, are not saturated by the expressed G 
protein as these receptors are abundantly expressed on most cell lines where 
they are recycled back to the cell membrane after internalisation every 10 
minutes  [347, 486, 495]. 
Consequently, in chapter 5, we explored the adaptation of VesG, starting with 
COCV.G into WinPac packaging cell line, WinPac-COCV.G, and investigated 
the occurrence of superinfection. Experiments performed demonstrated that 
VesG-LV infection was unaffected by the expression of the G proteins on the 
cell surface indicating a lack of superinfection resistance. This might pose 
some challenges such as genotoxicity and loss of titres of VesG based LV 
producer lines, which needs to be addressed. A possible approach to block 
superinfection can be the use of antiretroviral drugs such as azidothymidine 
(AZT) [486] or Nevirapine (in press [440]). 
We explored an alternative option by knocking out the primary receptor utilised 
by the G proteins to block superinfection. Previously, transient knockdowns of 
LDLR in human cell lines have proven to reduce VSVind infection modestly 
[347]. Preliminary experiments performed previously in our group and later by 
me revealed that all the tested VesG but PIRYV.G, shared the binding ability 
to LDLR suggesting that they use LDLR as the primary cell entry receptor. 
CRISPR-Cas9 mediated knock out of LDLR in HEK 293T cells resulted in a 
modest reduction of VesG-LV infectivity while PIRYV.G transduction was 
unchanged. mRNA analysis of the knock out cells revealed that an initial 
reduction of about 1000 times in LDLR mRNA expression compared to the 
wild-type cells was achieved; however, although the KO cells were kept in 
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selection media, the level of LDLR mRNA increased in time. The differences 
in gene expressions also translated into differences in protein expression 
levels in later passages of LDLR-KO 293T cells.  
6.1 Future Directions 
The work presented in this thesis has provided insights related to VesGs’ use 
in clinical grade LV production. Studies focusing on the stability of VesG may 
help researchers understand the destabilising mechanisms enforced on 
VesG-LV in variable conditions they face during the LV manufacturing 
process. Although most G proteins tested demonstrated both high thermal and 
physical stability, the effect of thermal and physical pressure on HIV-1 capsid 
and matrix proteins which have essential roles in LV structure should also be 
investigated. Combined, this will allow modification of LVs and G protein 
containing advanced therapy medicinal products to generate more stable 
reagents with better longevity under critical manufacturing conditions.   
In addition, our experiments revealed that, against commonly accepted notion, 
all VesG including VSVind.G can be expressed constitutively in cells and 
support LV production up to 5 months following transient supply of gag-pol, 
rev, and the transgene. Taken together, this work revealed that all VesG tested 
demonstrated similar properties with regards to toxicity, pH-dependent fusion, 
and infectivity, with modest differences. These G proteins should be further 
utilised in clinical grade PCL formation and closely monitored for their ability 
to produce functional LVs constitutively.  
Our preliminary work in attempting to adapt COCV.G into the clinical grade 
WinPac LV producer cell line revealed that similar to VSVind.G, COCV.G and 
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the other VesG lack superinfection interference. Although the use of anti-
retroviral drugs in cell culture have been suggested to prevent this, removal of 
these substances from the culture media poses another step in the complex 
manufacture of LVs and may result in further titre losses. Therefore, the option 
of knocking out the putative receptor utilised by VesG was explored. The 
complex karyotype of HEK 293T cells amongst a couple of other issues 
prevented the achievement of a complete LDLR-KO cell line, however, despite 
this, a modest reduction in infection permissiveness and increase in G protein 
expression have been observed. Further work is essential to follow up on 
these promising data. Clonal selection and isolating single clones with higher 
performance or the use of alternative cell lines with more stable karyotypes 
are essential in achieving a true complete LDLR-KO cell line. This cell line may 
later be utilised in the generation of PCLs with less of the problem of 
superinfection and thus vector genome accumulation and genotoxicity. 
Although, the role of other LDLR family members as alternative receptors for 
viral entry has to be investigated. Lastly, we were able to demonstrate that 
PIRYV.G’s, unlike the other VesG, does not bind to LDLR. Therefore, the 
identification of this G protein’s main receptor may reveal vital information on 
vesiculovirus infection, evolution and tropism as well as provide the 
opportunity to tailor and re-target LVs and G protein containing medicinal 
products. 
Overall, generation of stable packaging cell lines is of great importance to both 
basic and clinical research. This method reduces the cost of production and 
batch-to-batch variability resulting from transient plasmid transfection which is 
the method of use for lentiviral vector production.  
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As well as low toxicity, vesiculovirus G proteins exhibited high vector particle 
stability. Implementing a physically stable G protein in stable packaging cell 
lines will aid in achieving high vector titres suitable for clinical use. 
Investigating the receptor usage of these G proteins is of pivotal importance. 
This will aid to develop strategies in order to block superinfection to generate 
a reliable packaging cell line with reduced risk of decline in vector titres as well 
as to produce useful batches of therapeutic LVs.    
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